{ "company_details": [ { "company_id": "0000899866", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000899866.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000899866.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000899866_main_keyfigs.svg", "name": "Alexion Pharmaceuticals INC", "rank": 1, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Alexion Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alexion Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 77% points.The greatest weakness of Alexion Pharmaceuticals INC is the variable Intangible Assets, reducing the Economic Capital Ratio by 8.6% points.

The company's Economic Capital Ratio, given in the ranking table, is 395%, being 108% points above the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000899866_2011_Alexion_Pharmaceuticals_INC.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "3.22", "Assets": "6.70", "Liabilities": "76.8", "Stockholders Equity": "77.1", "ECR before LimitedLiability": "114", "Assets, Current": "12.3", "Property and Equipment": "2.35", "Intangible Assets": "-8.58", "Liabilities, Current": "13.4", "Other Liabilities": "41.1", "Liabilities, Non-Current": "31.4", "Selling, General and Administrative Expense": "-3.74", "Expenses": "4.24", "Revenues": "16.5", "Net Income": "21.2", "Research and Development": "3.25", "Cost of Goods Sold": "5.53", "Other Expenses": "-0.833", "Other Revenues": "16.5", "Comprehensive Net Income": "21.2", "Economic Capital Ratio": "108" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000899866_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "646,556", "Cost of Goods Sold": "0", "Intangible Assets": "44,100", "Liabilities, Current": "138,515", "Liabilities, Non-Current": "9,324", "Other Assets": "159,141", "Other Compr. Net Income": "0", "Other Expenses": "117,122", "Other Liabilities": "4,462", "Other Net Income": "-923", "Other Revenues": "540,957", "Property and Equipment": "162,240", "Research and Development": "98,394", "Selling, General and Administrative Expense": "227,488" }, "output_variables": { "Assets": "1,012,037", "Liabilities": "152,301", "Expenses": "443,004", "Revenues": "540,957", "Stockholders Equity": "859,736", "Net Income": "97,030", "Comprehensive Net Income": "97,030", "BaseVar": "1,074,611", "ECR before LimitedLiability": "339%", "Economic Capital Ratio": "395%" } } }, "top_rated": true, "trend": null, "value": 3.949713085976848, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000899866.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000899866.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000899866.svg" }, { "company_id": "0000038074", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000038074.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000038074.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000038074_main_keyfigs.svg", "name": "Forest Laboratories LLC", "rank": 2, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Forest Laboratories LLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Forest Laboratories LLC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 89% points.The greatest weakness of Forest Laboratories LLC is the variable Intangible Assets, reducing the Economic Capital Ratio by 8.4% points.

The company's Economic Capital Ratio, given in the ranking table, is 394%, being 106% points above the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000038074_2011_Forest_Laboratories_LLC.pdf", "shrinked_graph_json": { "2009": { "Assets, Current": "20.4", "Assets": "-5.80", "Liabilities": "71.7", "Stockholders Equity": "19.0", "ECR before LimitedLiability": "59.3", "Other Assets": "1.41", "Intangible Assets": "-14.1", "Property and Equipment": "-5.31", "Liabilities, Current": "16.9", "Other Liabilities": "26.7", "Liabilities, Non-Current": "36.4", "Cost of Goods Sold": "0.794", "Expenses": "-15.5", "Revenues": "19.4", "Net Income": "4.15", "Selling, General and Administrative Expense": "-11.0", "Research and Development": "-4.46", "Other Revenues": "19.4", "Comprehensive Net Income": "3.18", "Other Compr. Net Income": "-0.977", "Economic Capital Ratio": "60.2" }, "2010": { "Other Assets": "0.970", "Assets": "-0.813", "Liabilities": "88.6", "Stockholders Equity": "57.1", "ECR before LimitedLiability": "113", "Assets, Current": "15.5", "Property and Equipment": "-4.75", "Intangible Assets": "-8.36", "Liabilities, Current": "13.9", "Other Liabilities": "47.4", "Liabilities, Non-Current": "38.9", "Selling, General and Administrative Expense": "1.95", "Expenses": "-3.46", "Revenues": "26.5", "Net Income": "23.9", "Research and Development": "-3.45", "Cost of Goods Sold": "6.21", "Other Expenses": "-8.26", "Other Revenues": "26.5", "Comprehensive Net Income": "24.4", "Economic Capital Ratio": "106" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000038074_strength_weakness.svg", "table_records": { "2009": { "input_variables": { "Assets, Current": "3,785,954", "Cost of Goods Sold": "0", "Intangible Assets": "512,862", "Liabilities, Current": "817,828", "Liabilities, Non-Current": "0", "Other Assets": "552,057", "Other Compr. Net Income": "-81,737", "Other Expenses": "1,019,471", "Other Liabilities": "0", "Other Net Income": "0", "Other Revenues": "3,922,782", "Property and Equipment": "345,935", "Research and Development": "661,294", "Selling, General and Administrative Expense": "1,474,274" }, "output_variables": { "Assets": "5,196,808", "Liabilities": "817,828", "Expenses": "3,155,039", "Revenues": "3,922,782", "Stockholders Equity": "4,378,980", "Net Income": "767,743", "Comprehensive Net Income": "726,874", "BaseVar": "6,587,097", "ECR before LimitedLiability": "342%", "Economic Capital Ratio": "397%" } }, "2010": { "input_variables": { "Assets, Current": "4,579,191", "Cost of Goods Sold": "0", "Intangible Assets": "481,707", "Liabilities, Current": "979,646", "Liabilities, Non-Current": "0", "Other Assets": "839,349", "Other Compr. Net Income": "50,840", "Other Expenses": "1,192,649", "Other Liabilities": "0", "Other Net Income": "0", "Other Revenues": "4,192,862", "Property and Equipment": "323,284", "Research and Development": "1,053,561", "Selling, General and Administrative Expense": "1,264,269" }, "output_variables": { "Assets": "6,223,531", "Liabilities": "979,646", "Expenses": "3,510,479", "Revenues": "4,192,862", "Stockholders Equity": "5,243,885", "Net Income": "682,383", "Comprehensive Net Income": "707,803", "BaseVar": "7,478,679", "ECR before LimitedLiability": "337%", "Economic Capital Ratio": "394%" } } }, "top_rated": true, "trend": 1.0, "value": 3.9389806346811387, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000038074.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000038074.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000038074.svg" }, { "company_id": "0001274057", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0001274057.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0001274057.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001274057_main_keyfigs.svg", "name": "Hospira INC", "rank": 3, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Hospira INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Hospira INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 88% points.The greatest weakness of Hospira INC is the variable Other Expenses, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 389%, being 101% points above the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0001274057_2011_Hospira_INC.pdf", "shrinked_graph_json": { "2009": { "Assets, Current": "0.926", "Assets": "-5.61", "Liabilities": "67.3", "Stockholders Equity": "20.9", "ECR before LimitedLiability": "50.0", "Other Assets": "-2.95", "Intangible Assets": "-6.13", "Property and Equipment": "2.87", "Liabilities, Current": "14.0", "Other Liabilities": "25.5", "Liabilities, Non-Current": "34.9", "Cost of Goods Sold": "0.769", "Expenses": "-18.8", "Revenues": "14.4", "Net Income": "-4.52", "Selling, General and Administrative Expense": "9.16", "Other Expenses": "-34.8", "Research and Development": "5.34", "Other Revenues": "14.4", "Comprehensive Net Income": "-4.55", "Economic Capital Ratio": "50.9" }, "2010": { "Other Assets": "-4.19", "Assets": "-0.537", "Liabilities": "88.2", "Stockholders Equity": "58.7", "ECR before LimitedLiability": "108", "Assets, Current": "-6.29", "Property and Equipment": "5.03", "Intangible Assets": "6.52", "Liabilities, Current": "14.7", "Other Liabilities": "46.6", "Liabilities, Non-Current": "38.2", "Selling, General and Administrative Expense": "12.6", "Expenses": "-6.22", "Revenues": "23.7", "Net Income": "17.9", "Research and Development": "10.7", "Cost of Goods Sold": "6.15", "Other Expenses": "-36.9", "Other Revenues": "23.7", "Comprehensive Net Income": "17.9", "Economic Capital Ratio": "101" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001274057_strength_weakness.svg", "table_records": { "2009": { "input_variables": { "Assets, Current": "2,526,200", "Cost of Goods Sold": "0", "Intangible Assets": "1,649,900", "Liabilities, Current": "881,900", "Liabilities, Non-Current": "0", "Other Assets": "179,000", "Other Compr. Net Income": "0", "Other Expenses": "2,604,300", "Other Liabilities": "0", "Other Net Income": "-11,800", "Other Revenues": "3,879,300", "Property and Equipment": "1,147,800", "Research and Development": "240,500", "Selling, General and Administrative Expense": "618,800" }, "output_variables": { "Assets": "5,502,900", "Liabilities": "881,900", "Expenses": "3,463,600", "Revenues": "3,879,300", "Stockholders Equity": "4,621,000", "Net Income": "403,900", "Comprehensive Net Income": "403,900", "BaseVar": "6,869,750", "ECR before LimitedLiability": "328%", "Economic Capital Ratio": "388%" } }, "2010": { "input_variables": { "Assets, Current": "2,477,500", "Cost of Goods Sold": "0", "Intangible Assets": "1,998,900", "Liabilities, Current": "931,600", "Liabilities, Non-Current": "0", "Other Assets": "290,700", "Other Compr. Net Income": "0", "Other Expenses": "2,557,900", "Other Liabilities": "0", "Other Net Income": "-26,600", "Other Revenues": "3,917,200", "Property and Equipment": "1,279,200", "Research and Development": "300,500", "Selling, General and Administrative Expense": "675,000" }, "output_variables": { "Assets": "6,046,300", "Liabilities": "931,600", "Expenses": "3,533,400", "Revenues": "3,917,200", "Stockholders Equity": "5,114,700", "Net Income": "357,200", "Comprehensive Net Income": "357,200", "BaseVar": "7,227,550", "ECR before LimitedLiability": "330%", "Economic Capital Ratio": "389%" } } }, "top_rated": true, "trend": 1.0, "value": 3.8889708681531716, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0001274057.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0001274057.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0001274057.svg" }, { "company_id": "0000310158", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000310158.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000310158.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000310158.svg", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000310158_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000310158_main_keyfigs.svg", "name": "Merck Co Inc", "rank": 4, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Merck Co Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merck Co Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 85% points.The greatest weakness of Merck Co Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 386%, being 98% points above the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000310158_2011_Merck_Co_Inc.pdf", "shrinked_graph_json": { "2009": { "Assets, Current": "-0.847", "Assets": "25.1", "Liabilities": "28.6", "Stockholders Equity": "102", "ECR before LimitedLiability": "64.5", "Intangible Assets": "20.2", "Property and Equipment": "3.56", "Liabilities, Current": "-12.0", "Other Liabilities": "16.9", "Liabilities, Non-Current": "23.3", "Cost of Goods Sold": "0.485", "Expenses": "19.2", "Revenues": "-13.5", "Net Income": "5.96", "Selling, General and Administrative Expense": "4.80", "Other Expenses": "13.8", "Research and Development": "0.222", "Other Revenues": "-13.5", "Comprehensive Net Income": "5.94", "Other Net Income": "-0.165", "Economic Capital Ratio": "65.3" }, "2010": { "Other Assets": "-1.65", "Assets": "11.6", "Liabilities": "70.0", "Stockholders Equity": "85.2", "ECR before LimitedLiability": "105", "Assets, Current": "-9.35", "Property and Equipment": "3.19", "Intangible Assets": "25.5", "Liabilities, Current": "4.33", "Other Liabilities": "39.7", "Liabilities, Non-Current": "32.4", "Selling, General and Administrative Expense": "6.91", "Expenses": "2.59", "Revenues": "7.15", "Net Income": "10.3", "Research and Development": "1.62", "Cost of Goods Sold": "5.18", "Other Expenses": "-11.2", "Other Revenues": "7.15", "Comprehensive Net Income": "10.3", "Economic Capital Ratio": "98.4" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000310158_strength_weakness.svg", "table_records": { "2009": { "input_variables": { "Assets, Current": "28,428,600", "Cost of Goods Sold": "0", "Intangible Assets": "59,578,900", "Liabilities, Current": "15,750,700", "Liabilities, Non-Current": "0", "Other Assets": "5,808,700", "Other Compr. Net Income": "0", "Other Expenses": "15,900", "Other Liabilities": "0", "Other Net Income": "0", "Other Revenues": "27,428,300", "Property and Equipment": "18,273,500", "Research and Development": "5,845,000", "Selling, General and Administrative Expense": "8,543,200" }, "output_variables": { "Assets": "112,089,700", "Liabilities": "15,750,700", "Expenses": "14,404,100", "Revenues": "27,428,300", "Stockholders Equity": "96,339,000", "Net Income": "13,024,200", "Comprehensive Net Income": "13,024,200", "BaseVar": "84,836,400", "ECR before LimitedLiability": "349%", "Economic Capital Ratio": "402%" } }, "2010": { "input_variables": { "Assets, Current": "29,064,000", "Cost of Goods Sold": "0", "Intangible Assets": "51,834,000", "Liabilities, Current": "15,641,000", "Liabilities, Non-Current": "0", "Other Assets": "7,801,000", "Other Compr. Net Income": "0", "Other Expenses": "20,769,000", "Other Liabilities": "0", "Other Net Income": "0", "Other Revenues": "45,987,000", "Property and Equipment": "17,082,000", "Research and Development": "10,991,000", "Selling, General and Administrative Expense": "13,245,000" }, "output_variables": { "Assets": "105,781,000", "Liabilities": "15,641,000", "Expenses": "45,005,000", "Revenues": "45,987,000", "Stockholders Equity": "90,140,000", "Net Income": "982,000", "Comprehensive Net Income": "982,000", "BaseVar": "106,207,000", "ECR before LimitedLiability": "325%", "Economic Capital Ratio": "386%" } } }, "top_rated": true, "trend": -2.0, "value": 3.857870462691586, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000310158.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000310158.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000310158.svg" }, { "company_id": "0001100962", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0001100962.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0001100962.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001100962_main_keyfigs.svg", "name": "ENDO Health Solutions INC", "rank": 5, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of ENDO Health Solutions INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENDO Health Solutions INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 73% points.The greatest weakness of ENDO Health Solutions INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 376%, being 88% points above the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0001100962_2011_ENDO_Health_Solutions_INC.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "-5.07", "Assets": "13.1", "Liabilities": "52.6", "Stockholders Equity": "73.2", "ECR before LimitedLiability": "94.5", "Assets, Current": "-5.63", "Property and Equipment": "-4.03", "Intangible Assets": "38.9", "Liabilities, Current": "-14.0", "Other Liabilities": "37.1", "Liabilities, Non-Current": "30.3", "Selling, General and Administrative Expense": "4.76", "Expenses": "10.2", "Revenues": "7.59", "Net Income": "17.0", "Research and Development": "9.01", "Cost of Goods Sold": "-9.83", "Other Expenses": "6.14", "Other Revenues": "7.59", "Comprehensive Net Income": "17.0", "Economic Capital Ratio": "88.2" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001100962_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "1,359,534", "Cost of Goods Sold": "504,757", "Intangible Assets": "2,246,765", "Liabilities, Current": "735,828", "Liabilities, Non-Current": "0", "Other Assets": "90,795", "Other Compr. Net Income": "720", "Other Expenses": "187,654", "Other Liabilities": "0", "Other Net Income": "-44,668", "Other Revenues": "1,716,229", "Property and Equipment": "215,295", "Research and Development": "144,525", "Selling, General and Administrative Expense": "547,605" }, "output_variables": { "Assets": "3,912,389", "Liabilities": "735,828", "Expenses": "1,384,541", "Revenues": "1,716,229", "Stockholders Equity": "3,176,561", "Net Income": "287,020", "Comprehensive Net Income": "287,380", "BaseVar": "3,897,188", "ECR before LimitedLiability": "310%", "Economic Capital Ratio": "376%" } } }, "top_rated": true, "trend": null, "value": 3.7560463603070096, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0001100962.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0001100962.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0001100962.svg" }, { "company_id": "0000850693", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000850693.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000850693.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000850693_main_keyfigs.svg", "name": "Allergan INC", "rank": 6, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Allergan INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Allergan INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 73% points.The greatest weakness of Allergan INC is the variable Other Expenses, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 369%, being 82% points above the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000850693_2011_Allergan_INC.pdf", "shrinked_graph_json": { "2009": { "Assets, Current": "0.767", "Assets": "1.24", "Liabilities": "80.4", "Stockholders Equity": "59.0", "ECR before LimitedLiability": "76.7", "Other Assets": "-1.59", "Intangible Assets": "4.20", "Property and Equipment": "-1.73", "Liabilities, Current": "30.3", "Other Liabilities": "26.0", "Liabilities, Non-Current": "35.5", "Expenses": "-11.0", "Revenues": "10.3", "Net Income": "-2.12", "Selling, General and Administrative Expense": "-11.2", "Other Expenses": "1.40", "Research and Development": "-1.89", "Other Revenues": "10.3", "Comprehensive Net Income": "-2.15", "Other Net Income": "-1.62", "Economic Capital Ratio": "77.5" }, "2010": { "Liabilities, Current": "0.718", "Liabilities": "72.9", "Stockholders Equity": "50.8", "ECR before LimitedLiability": "88.0", "Other Liabilities": "42.8", "Liabilities, Non-Current": "35.0", "Selling, General and Administrative Expense": "-3.03", "Expenses": "-6.10", "Net Income": "10.4", "Research and Development": "4.71", "Cost of Goods Sold": "5.80", "Other Expenses": "-13.7", "Other Revenues": "16.9", "Revenues": "16.9", "Other Assets": "-4.34", "Assets, Current": "-2.40", "Property and Equipment": "-2.92", "Intangible Assets": "11.3", "Comprehensive Net Income": "10.4", "Other Net Income": "-0.506", "Economic Capital Ratio": "81.6" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000850693_strength_weakness.svg", "table_records": { "2009": { "input_variables": { "Assets, Current": "3,106,300", "Cost of Goods Sold": "0", "Intangible Assets": "3,355,500", "Liabilities, Current": "811,600", "Liabilities, Non-Current": "0", "Other Assets": "266,700", "Other Compr. Net Income": "0", "Other Expenses": "1,172,800", "Other Liabilities": "0", "Other Net Income": "-79,500", "Other Revenues": "4,503,600", "Property and Equipment": "808,100", "Research and Development": "706,000", "Selling, General and Administrative Expense": "1,921,500" }, "output_variables": { "Assets": "7,536,600", "Liabilities": "811,600", "Expenses": "3,800,300", "Revenues": "4,503,600", "Stockholders Equity": "6,725,000", "Net Income": "623,800", "Comprehensive Net Income": "623,800", "BaseVar": "8,365,800", "ECR before LimitedLiability": "366%", "Economic Capital Ratio": "414%" } }, "2010": { "input_variables": { "Assets, Current": "3,993,700", "Cost of Goods Sold": "0", "Intangible Assets": "3,034,600", "Liabilities, Current": "1,528,400", "Liabilities, Non-Current": "0", "Other Assets": "479,200", "Other Compr. Net Income": "0", "Other Expenses": "2,004,500", "Other Liabilities": "0", "Other Net Income": "-87,800", "Other Revenues": "4,919,400", "Property and Equipment": "800,600", "Research and Development": "804,600", "Selling, General and Administrative Expense": "2,017,600" }, "output_variables": { "Assets": "8,308,100", "Liabilities": "1,528,400", "Expenses": "4,826,700", "Revenues": "4,919,400", "Stockholders Equity": "6,779,700", "Net Income": "4,900", "Comprehensive Net Income": "4,900", "BaseVar": "9,835,200", "ECR before LimitedLiability": "301%", "Economic Capital Ratio": "369%" } } }, "top_rated": true, "trend": -5.0, "value": 3.690627697126529, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000850693.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000850693.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000850693.svg" }, { "company_id": "0001113481", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0001113481.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0001113481.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001113481_main_keyfigs.svg", "name": "Medicines CO DE", "rank": 7, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Medicines CO DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Medicines CO DE compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 76% points.The greatest weakness of Medicines CO DE is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 368%, being 81% points above the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0001113481_2011_Medicines_CO_DE.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "-5.27", "Assets": "-13.3", "Liabilities": "75.8", "Stockholders Equity": "4.21", "ECR before LimitedLiability": "87.2", "Assets, Current": "4.86", "Property and Equipment": "-8.13", "Intangible Assets": "-5.35", "Liabilities, Current": "17.1", "Other Liabilities": "31.0", "Liabilities, Non-Current": "35.8", "Selling, General and Administrative Expense": "-7.85", "Expenses": "-6.76", "Revenues": "41.1", "Net Income": "35.3", "Research and Development": "-1.28", "Cost of Goods Sold": "-23.0", "Other Expenses": "24.8", "Other Revenues": "41.1", "Comprehensive Net Income": "35.3", "Economic Capital Ratio": "80.8" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001113481_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "324,621", "Cost of Goods Sold": "129,299", "Intangible Assets": "97,596", "Liabilities, Current": "85,370", "Liabilities, Non-Current": "5,769", "Other Assets": "31,245", "Other Compr. Net Income": "0", "Other Expenses": "-40,487", "Other Liabilities": "25,387", "Other Net Income": "0", "Other Revenues": "437,378", "Property and Equipment": "20,662", "Research and Development": "85,241", "Selling, General and Administrative Expense": "158,690" }, "output_variables": { "Assets": "474,124", "Liabilities": "116,526", "Expenses": "332,743", "Revenues": "437,378", "Stockholders Equity": "357,598", "Net Income": "104,635", "Comprehensive Net Income": "104,635", "BaseVar": "680,386", "ECR before LimitedLiability": "299%", "Economic Capital Ratio": "368%" } } }, "top_rated": true, "trend": null, "value": 3.6825195090688307, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0001113481.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0001113481.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0001113481.svg" }, { "company_id": "0000859368", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000859368.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000859368.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000859368_main_keyfigs.svg", "name": "Medicis Pharmaceutical CORP", "rank": 8, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Medicis Pharmaceutical CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Medicis Pharmaceutical CORP compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 41% points.The greatest weakness of Medicis Pharmaceutical CORP is the variable Liabilities, Current, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 352%, being 64% points above the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000859368_2011_Medicis_Pharmaceutical_CORP.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "-5.09", "Assets": "6.07", "Liabilities": "38.5", "Stockholders Equity": "41.2", "ECR before LimitedLiability": "70.6", "Assets, Current": "25.5", "Property and Equipment": "-8.52", "Liabilities, Current": "-32.5", "Other Liabilities": "36.7", "Liabilities, Non-Current": "29.9", "Selling, General and Administrative Expense": "-4.11", "Expenses": "6.29", "Revenues": "11.5", "Net Income": "18.7", "Research and Development": "9.04", "Cost of Goods Sold": "5.05", "Other Expenses": "-3.71", "Other Revenues": "11.5", "Comprehensive Net Income": "18.7", "Other Net Income": "0.904", "Economic Capital Ratio": "64.2" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000859368_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "967,074", "Cost of Goods Sold": "0", "Intangible Assets": "287,707", "Liabilities, Current": "339,892", "Liabilities, Non-Current": "0", "Other Assets": "62,491", "Other Compr. Net Income": "0", "Other Expenses": "199,137", "Other Liabilities": "0", "Other Net Income": "3,860", "Other Revenues": "699,968", "Property and Equipment": "24,552", "Research and Development": "58,282", "Selling, General and Administrative Expense": "323,074" }, "output_variables": { "Assets": "1,341,824", "Liabilities": "339,892", "Expenses": "580,493", "Revenues": "699,968", "Stockholders Equity": "1,001,932", "Net Income": "123,335", "Comprehensive Net Income": "123,335", "BaseVar": "1,483,018", "ECR before LimitedLiability": "274%", "Economic Capital Ratio": "352%" } } }, "top_rated": false, "trend": null, "value": 3.516440294385919, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000859368.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000859368.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000859368.svg" }, { "company_id": "0000001800", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000001800.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000001800.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000001800.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000001800_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000001800_main_keyfigs.svg", "name": "Abbott Laboratories", "rank": 9, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Abbott Laboratories are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Abbott Laboratories compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 38% points.The greatest weakness of Abbott Laboratories is the variable Liabilities, Current, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 337%, being 49% points above the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000001800_2011_Abbott_Laboratories.pdf", "shrinked_graph_json": { "2009": { "Assets, Current": "1.92", "Assets": "-3.13", "Liabilities": "25.3", "Stockholders Equity": "7.40", "ECR before LimitedLiability": "17.4", "Other Assets": "-3.10", "Intangible Assets": "-0.953", "Property and Equipment": "-0.937", "Liabilities, Current": "-27.0", "Other Liabilities": "20.7", "Liabilities, Non-Current": "28.4", "Cost of Goods Sold": "0.654", "Expenses": "-6.03", "Revenues": "3.65", "Net Income": "0.406", "Selling, General and Administrative Expense": "2.14", "Other Expenses": "-12.3", "Research and Development": "3.40", "Other Revenues": "3.65", "Other Net Income": "2.77", "Economic Capital Ratio": "18.3" }, "2010": { "Other Assets": "-8.74", "Assets": "-1.21", "Liabilities": "34.8", "Stockholders Equity": "20.9", "ECR before LimitedLiability": "55.7", "Assets, Current": "-12.2", "Intangible Assets": "27.2", "Liabilities, Current": "-39.2", "Other Liabilities": "37.6", "Liabilities, Non-Current": "30.6", "Selling, General and Administrative Expense": "4.56", "Expenses": "1.86", "Revenues": "14.6", "Net Income": "17.5", "Research and Development": "7.94", "Cost of Goods Sold": "5.31", "Other Expenses": "-16.0", "Other Revenues": "14.6", "Comprehensive Net Income": "17.5", "Other Net Income": "0.937", "Economic Capital Ratio": "49.3" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000001800_strength_weakness.svg", "table_records": { "2009": { "input_variables": { "Assets, Current": "23,313,891", "Cost of Goods Sold": "0", "Intangible Assets": "19,492,163", "Liabilities, Current": "13,049,489", "Liabilities, Non-Current": "0", "Other Assets": "1,991,080", "Other Compr. Net Income": "0", "Other Expenses": "15,346,921", "Other Liabilities": "0", "Other Net Income": "1,477,689", "Other Revenues": "30,764,707", "Property and Equipment": "7,619,489", "Research and Development": "2,743,733", "Selling, General and Administrative Expense": "8,405,904" }, "output_variables": { "Assets": "52,416,623", "Liabilities": "13,049,489", "Expenses": "26,496,558", "Revenues": "30,764,707", "Stockholders Equity": "39,367,134", "Net Income": "5,745,838", "Comprehensive Net Income": "5,745,838", "BaseVar": "62,102,533", "ECR before LimitedLiability": "280%", "Economic Capital Ratio": "355%" } }, "2010": { "input_variables": { "Assets, Current": "22,317,529", "Cost of Goods Sold": "0", "Intangible Assets": "28,081,705", "Liabilities, Current": "17,262,434", "Liabilities, Non-Current": "0", "Other Assets": "1,092,076", "Other Compr. Net Income": "0", "Other Expenses": "16,618,189", "Other Liabilities": "0", "Other Net Income": "178,388", "Other Revenues": "35,166,721", "Property and Equipment": "7,970,956", "Research and Development": "3,724,424", "Selling, General and Administrative Expense": "10,376,324" }, "output_variables": { "Assets": "59,462,266", "Liabilities": "17,262,434", "Expenses": "30,718,937", "Revenues": "35,166,721", "Stockholders Equity": "42,199,832", "Net Income": "4,626,172", "Comprehensive Net Income": "4,626,172", "BaseVar": "71,394,373", "ECR before LimitedLiability": "252%", "Economic Capital Ratio": "337%" } } }, "top_rated": false, "trend": -4.0, "value": 3.3677719306591936, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000001800.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000001800.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000001800.svg" }, { "company_id": "0000881464", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000881464.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000881464.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000881464_main_keyfigs.svg", "name": "Amylin Pharmaceuticals INC", "rank": 10, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Amylin Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amylin Pharmaceuticals INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 63% points.The greatest weakness of Amylin Pharmaceuticals INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 328%, being 41% points above the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000881464_2011_Amylin_Pharmaceuticals_INC.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "-7.93", "Assets": "5.98", "Liabilities": "35.5", "Stockholders Equity": "37.7", "ECR before LimitedLiability": "47.3", "Assets, Current": "-4.29", "Property and Equipment": "62.6", "Intangible Assets": "-19.3", "Liabilities, Current": "-32.8", "Other Liabilities": "35.5", "Liabilities, Non-Current": "28.8", "Selling, General and Administrative Expense": "1.66", "Expenses": "-4.10", "Revenues": "2.18", "Net Income": "-1.32", "Research and Development": "1.99", "Cost of Goods Sold": "5.07", "Other Expenses": "-12.8", "Other Revenues": "2.18", "Comprehensive Net Income": "-1.31", "Economic Capital Ratio": "40.9" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000881464_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "676,395", "Cost of Goods Sold": "0", "Intangible Assets": "0", "Liabilities, Current": "401,595", "Liabilities, Non-Current": "0", "Other Assets": "43,289", "Other Compr. Net Income": "0", "Other Expenses": "363,862", "Other Liabilities": "0", "Other Net Income": "0", "Other Revenues": "671,511", "Property and Equipment": "811,745", "Research and Development": "171,312", "Selling, General and Administrative Expense": "288,650" }, "output_variables": { "Assets": "1,531,429", "Liabilities": "401,595", "Expenses": "823,824", "Revenues": "671,511", "Stockholders Equity": "1,129,834", "Net Income": "-152,313", "Comprehensive Net Income": "-152,313", "BaseVar": "1,714,180", "ECR before LimitedLiability": "239%", "Economic Capital Ratio": "328%" } } }, "top_rated": false, "trend": null, "value": 3.283631716665732, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000881464.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000881464.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000881464.svg" }, { "company_id": "0001130591", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0001130591.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0001130591.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001130591_main_keyfigs.svg", "name": "Xenoport INC", "rank": 11, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Xenoport INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenoport INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 131% points.The greatest weakness of Xenoport INC is the variable Net Income, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 326%, being 39% points above the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0001130591_2011_Xenoport_INC.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "-7.28", "Assets": "34.6", "Liabilities": "74.3", "Stockholders Equity": "127", "ECR before LimitedLiability": "45.4", "Assets, Current": "131", "Property and Equipment": "-5.27", "Intangible Assets": "-18.6", "Liabilities, Current": "19.2", "Other Liabilities": "33.6", "Liabilities, Non-Current": "27.3", "Selling, General and Administrative Expense": "-7.94", "Expenses": "-36.4", "Revenues": "-37.7", "Net Income": "-74.7", "Research and Development": "-39.4", "Cost of Goods Sold": "4.79", "Other Expenses": "6.09", "Other Revenues": "-37.7", "Comprehensive Net Income": "-74.7", "Economic Capital Ratio": "39.1" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001130591_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "110,801", "Cost of Goods Sold": "0", "Intangible Assets": "0", "Liabilities, Current": "11,487", "Liabilities, Non-Current": "0", "Other Assets": "3,219", "Other Compr. Net Income": "0", "Other Expenses": "5,275", "Other Liabilities": "0", "Other Net Income": "0", "Other Revenues": "3,675", "Property and Equipment": "7,209", "Research and Development": "52,546", "Selling, General and Administrative Expense": "28,323" }, "output_variables": { "Assets": "121,229", "Liabilities": "11,487", "Expenses": "86,144", "Revenues": "3,675", "Stockholders Equity": "109,742", "Net Income": "-82,469", "Comprehensive Net Income": "-82,469", "BaseVar": "111,268", "ECR before LimitedLiability": "236%", "Economic Capital Ratio": "326%" } } }, "top_rated": false, "trend": null, "value": 3.2649778973547807, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0001130591.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0001130591.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0001130591.svg" }, { "company_id": "0001107332", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0001107332.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0001107332.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001107332_main_keyfigs.svg", "name": "Dendreon CORP", "rank": 12, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Dendreon CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dendreon CORP compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 121% points.The greatest weakness of Dendreon CORP is the variable Net Income, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is 326%, being 38% points above the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0001107332_2011_Dendreon_CORP.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "-6.20", "Assets": "24.7", "Liabilities": "86.0", "Stockholders Equity": "121", "ECR before LimitedLiability": "44.5", "Assets, Current": "16.7", "Property and Equipment": "51.2", "Intangible Assets": "-20.1", "Liabilities, Current": "27.7", "Other Liabilities": "36.2", "Liabilities, Non-Current": "29.4", "Selling, General and Administrative Expense": "-25.6", "Expenses": "-44.3", "Revenues": "-35.1", "Net Income": "-81.0", "Research and Development": "-1.28", "Cost of Goods Sold": "-0.553", "Other Expenses": "-16.7", "Other Revenues": "-35.1", "Comprehensive Net Income": "-81.0", "Economic Capital Ratio": "38.1" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001107332_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "330,394", "Cost of Goods Sold": "28,520", "Intangible Assets": "0", "Liabilities, Current": "50,079", "Liabilities, Non-Current": "0", "Other Assets": "26,670", "Other Compr. Net Income": "0", "Other Expenses": "143,744", "Other Liabilities": "0", "Other Net Income": "-3,572", "Other Revenues": "48,057", "Property and Equipment": "246,889", "Research and Development": "75,941", "Selling, General and Administrative Expense": "235,760" }, "output_variables": { "Assets": "603,953", "Liabilities": "50,079", "Expenses": "483,965", "Revenues": "48,057", "Stockholders Equity": "553,874", "Net Income": "-439,480", "Comprehensive Net Income": "-439,480", "BaseVar": "594,813", "ECR before LimitedLiability": "235%", "Economic Capital Ratio": "326%" } } }, "top_rated": false, "trend": null, "value": 3.2557103500496374, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0001107332.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0001107332.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0001107332.svg" }, { "company_id": "0001182129", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0001182129.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0001182129.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001182129_main_keyfigs.svg", "name": "Auxilium Pharmaceuticals INC", "rank": 13, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Auxilium Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Auxilium Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 81% points.The greatest weakness of Auxilium Pharmaceuticals INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 316%, being 29% points above the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0001182129_2011_Auxilium_Pharmaceuticals_INC.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "-11.7", "Assets": "-31.0", "Liabilities": "81.3", "Stockholders Equity": "-19.6", "ECR before LimitedLiability": "35.4", "Assets, Current": "17.5", "Property and Equipment": "-6.55", "Intangible Assets": "-28.4", "Liabilities, Current": "-3.99", "Other Liabilities": "49.1", "Liabilities, Non-Current": "39.9", "Selling, General and Administrative Expense": "-39.9", "Expenses": "-37.9", "Revenues": "28.6", "Net Income": "-8.96", "Research and Development": "-0.958", "Cost of Goods Sold": "7.32", "Other Expenses": "-4.31", "Other Revenues": "28.6", "Comprehensive Net Income": "-8.94", "Economic Capital Ratio": "29.1" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001182129_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "202,912", "Cost of Goods Sold": "0", "Intangible Assets": "0", "Liabilities, Current": "64,173", "Liabilities, Non-Current": "0", "Other Assets": "11,056", "Other Compr. Net Income": "0", "Other Expenses": "50,147", "Other Liabilities": "0", "Other Net Income": "167", "Other Revenues": "211,429", "Property and Equipment": "29,936", "Research and Development": "48,005", "Selling, General and Administrative Expense": "164,675" }, "output_variables": { "Assets": "243,904", "Liabilities": "64,173", "Expenses": "262,827", "Revenues": "211,429", "Stockholders Equity": "179,731", "Net Income": "-51,231", "Comprehensive Net Income": "-51,231", "BaseVar": "391,250", "ECR before LimitedLiability": "221%", "Economic Capital Ratio": "316%" } } }, "top_rated": false, "trend": null, "value": 3.1649535422323627, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0001182129.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0001182129.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0001182129.svg" }, { "company_id": "0000792977", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000792977.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000792977.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000792977_main_keyfigs.svg", "name": "AMAG Pharmaceuticals INC", "rank": 14, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of AMAG Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AMAG Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 89% points.The greatest weakness of AMAG Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 311%, being 23% points above the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000792977_2011_AMAG_Pharmaceuticals_INC.pdf", "shrinked_graph_json": { "2010": { "Assets": "27.1", "Liabilities": "15.3", "Stockholders Equity": "57.2", "ECR before LimitedLiability": "29.7", "Assets, Current": "88.9", "Property and Equipment": "-8.39", "Intangible Assets": "-19.1", "Liabilities, Current": "13.6", "Other Liabilities": "-24.5", "Liabilities, Non-Current": "24.2", "Selling, General and Administrative Expense": "-8.15", "Expenses": "-1.71", "Revenues": "-16.7", "Net Income": "-17.4", "Research and Development": "-5.24", "Cost of Goods Sold": "4.36", "Other Expenses": "7.39", "Other Revenues": "-16.7", "Comprehensive Net Income": "-17.4", "Other Net Income": "0.942", "Economic Capital Ratio": "23.4" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000792977_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "290,784", "Cost of Goods Sold": "0", "Intangible Assets": "0", "Liabilities, Current": "36,711", "Liabilities, Non-Current": "0", "Other Assets": "34,057", "Other Compr. Net Income": "0", "Other Expenses": "9,358", "Other Liabilities": "54,079", "Other Net Income": "1,361", "Other Revenues": "66,245", "Property and Equipment": "11,235", "Research and Development": "54,462", "Selling, General and Administrative Expense": "84,939" }, "output_variables": { "Assets": "336,076", "Liabilities": "90,790", "Expenses": "148,759", "Revenues": "66,245", "Stockholders Equity": "245,286", "Net Income": "-81,153", "Comprehensive Net Income": "-81,153", "BaseVar": "321,616", "ECR before LimitedLiability": "213%", "Economic Capital Ratio": "311%" } } }, "top_rated": false, "trend": null, "value": 3.107904089056334, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000792977.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000792977.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000792977.svg" }, { "company_id": "0001082554", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0001082554.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0001082554.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001082554.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001082554_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001082554_main_keyfigs.svg", "name": "United Therapeutics Corp", "rank": 15, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of United Therapeutics Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of United Therapeutics Corp compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 18% points.The greatest weakness of United Therapeutics Corp is the variable Liabilities, Current, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 308%, being 21% points above the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0001082554_2011_United_Therapeutics_Corp.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "18.3", "Assets": "11.4", "Liabilities": "-6.47", "Stockholders Equity": "16.0", "ECR before LimitedLiability": "27.3", "Assets, Current": "8.10", "Property and Equipment": "10.8", "Intangible Assets": "-20.0", "Liabilities, Current": "-44.9", "Other Liabilities": "16.8", "Liabilities, Non-Current": "16.9", "Selling, General and Administrative Expense": "5.49", "Expenses": "13.8", "Revenues": "2.11", "Net Income": "15.4", "Research and Development": "0.872", "Cost of Goods Sold": "4.52", "Other Expenses": "2.85", "Other Revenues": "2.11", "Comprehensive Net Income": "15.4", "Economic Capital Ratio": "21.0" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001082554_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "764,487", "Cost of Goods Sold": "0", "Intangible Assets": "0", "Liabilities, Current": "428,686", "Liabilities, Non-Current": "39,252", "Other Assets": "361,104", "Other Compr. Net Income": "0", "Other Expenses": "115,388", "Other Liabilities": "68,929", "Other Net Income": "-16,166", "Other Revenues": "603,831", "Property and Equipment": "306,044", "Research and Development": "166,761", "Selling, General and Administrative Expense": "199,600" }, "output_variables": { "Assets": "1,431,635", "Liabilities": "536,867", "Expenses": "481,749", "Revenues": "603,831", "Stockholders Equity": "894,768", "Net Income": "105,916", "Comprehensive Net Income": "105,916", "BaseVar": "1,535,124", "ECR before LimitedLiability": "209%", "Economic Capital Ratio": "308%" } } }, "top_rated": false, "trend": null, "value": 3.0841035212163543, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0001082554.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0001082554.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0001082554.svg" }, { "company_id": "0001048477", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0001048477.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0001048477.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001048477.svg", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001048477_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001048477_main_keyfigs.svg", "name": "Biomarin Pharmaceutical INC", "rank": 16, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Biomarin Pharmaceutical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biomarin Pharmaceutical INC compared to the market average is the variable Assets, increasing the Economic Capital Ratio by 29% points.The greatest weakness of Biomarin Pharmaceutical INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is 300%, being 12% points above the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0001048477_2011_Biomarin_Pharmaceutical_INC.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "28.3", "Assets": "28.9", "Liabilities": "-39.4", "Stockholders Equity": "18.5", "ECR before LimitedLiability": "18.5", "Property and Equipment": "8.23", "Intangible Assets": "-6.47", "Liabilities, Current": "23.0", "Other Liabilities": "-71.6", "Liabilities, Non-Current": "1.71", "Selling, General and Administrative Expense": "4.77", "Expenses": "27.0", "Revenues": "-4.74", "Net Income": "22.6", "Research and Development": "-0.696", "Cost of Goods Sold": "-1.43", "Other Expenses": "24.2", "Other Revenues": "-4.74", "Comprehensive Net Income": "22.6", "Other Net Income": "0.605", "Economic Capital Ratio": "12.1" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001048477_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "504,260", "Cost of Goods Sold": "70,285", "Intangible Assets": "157,012", "Liabilities, Current": "83,844", "Liabilities, Non-Current": "84,001", "Other Assets": "379,485", "Other Compr. Net Income": "0", "Other Expenses": "-196,846", "Other Liabilities": "377,521", "Other Net Income": "2,023", "Other Revenues": "376,267", "Property and Equipment": "221,866", "Research and Development": "147,309", "Selling, General and Administrative Expense": "151,723" }, "output_variables": { "Assets": "1,262,623", "Liabilities": "545,366", "Expenses": "172,471", "Revenues": "376,267", "Stockholders Equity": "717,257", "Net Income": "205,819", "Comprehensive Net Income": "205,819", "BaseVar": "1,179,375", "ECR before LimitedLiability": "196%", "Economic Capital Ratio": "300%" } } }, "top_rated": false, "trend": null, "value": 2.995491725526233, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0001048477.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0001048477.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0001048477.svg" }, { "company_id": "0000200406", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000200406.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000200406.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000200406.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000200406_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000200406_main_keyfigs.svg", "name": "Johnson Johnson", "rank": 17, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Johnson Johnson are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Johnson Johnson compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 22% points.The greatest weakness of Johnson Johnson is the variable Stockholders Equity, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 287%, being 0.92% points below the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000200406_2011_Johnson_Johnson.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "-4.05", "Assets": "-13.5", "Liabilities": "-7.71", "Stockholders Equity": "-29.5", "ECR before LimitedLiability": "5.42", "Assets, Current": "-17.1", "Intangible Assets": "8.71", "Liabilities, Current": "-6.15", "Other Liabilities": "11.8", "Liabilities, Non-Current": "-13.8", "Selling, General and Administrative Expense": "3.15", "Expenses": "5.77", "Revenues": "15.1", "Net Income": "22.4", "Research and Development": "7.74", "Cost of Goods Sold": "5.44", "Other Expenses": "-10.4", "Other Revenues": "15.1", "Comprehensive Net Income": "22.4", "Other Net Income": "1.26", "Economic Capital Ratio": "-0.917" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000200406_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "39,541,000", "Cost of Goods Sold": "0", "Intangible Assets": "31,185,000", "Liabilities, Current": "21,731,000", "Liabilities, Non-Current": "14,170,000", "Other Assets": "9,197,000", "Other Compr. Net Income": "0", "Other Expenses": "23,460,000", "Other Liabilities": "8,193,000", "Other Net Income": "616,000", "Other Revenues": "61,897,000", "Property and Equipment": "14,759,000", "Research and Development": "6,986,000", "Selling, General and Administrative Expense": "19,801,000" }, "output_variables": { "Assets": "94,682,000", "Liabilities": "44,094,000", "Expenses": "50,247,000", "Revenues": "61,897,000", "Stockholders Equity": "50,588,000", "Net Income": "12,266,000", "Comprehensive Net Income": "12,266,000", "BaseVar": "125,768,000", "ECR before LimitedLiability": "177%", "Economic Capital Ratio": "287%" } } }, "top_rated": false, "trend": null, "value": 2.86511284190702, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000200406.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000200406.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000200406.svg" }, { "company_id": "0000884629", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000884629.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000884629.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000884629_main_keyfigs.svg", "name": "Allergan Finance LLC", "rank": 18, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Allergan Finance LLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Allergan Finance LLC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 47% points.The greatest weakness of Allergan Finance LLC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 286%, being 1.8% points below the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000884629_2011_Allergan_Finance_LLC.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "-10.6", "Assets": "-12.6", "Liabilities": "-0.571", "Stockholders Equity": "-22.9", "ECR before LimitedLiability": "4.54", "Assets, Current": "-27.1", "Property and Equipment": "-4.90", "Intangible Assets": "46.5", "Liabilities, Current": "18.7", "Other Liabilities": "10.6", "Liabilities, Non-Current": "-32.2", "Selling, General and Administrative Expense": "16.1", "Expenses": "1.38", "Revenues": "11.8", "Net Income": "13.0", "Research and Development": "10.0", "Cost of Goods Sold": "5.51", "Other Expenses": "-29.2", "Other Revenues": "11.8", "Comprehensive Net Income": "13.0", "Economic Capital Ratio": "-1.80" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000884629_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "1,799,400", "Cost of Goods Sold": "0", "Intangible Assets": "3,160,100", "Liabilities, Current": "820,700", "Liabilities, Non-Current": "1,199,200", "Other Assets": "225,500", "Other Compr. Net Income": "0", "Other Expenses": "2,596,600", "Other Liabilities": "524,800", "Other Net Income": "-54,800", "Other Revenues": "3,566,900", "Property and Equipment": "642,300", "Research and Development": "296,100", "Selling, General and Administrative Expense": "436,100" }, "output_variables": { "Assets": "5,827,300", "Liabilities": "2,544,700", "Expenses": "3,328,800", "Revenues": "3,566,900", "Stockholders Equity": "3,282,600", "Net Income": "183,300", "Comprehensive Net Income": "183,300", "BaseVar": "7,661,250", "ECR before LimitedLiability": "175%", "Economic Capital Ratio": "286%" } } }, "top_rated": false, "trend": null, "value": 2.856272739021308, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000884629.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000884629.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000884629.svg" }, { "company_id": "0000912183", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000912183.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000912183.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000912183_main_keyfigs.svg", "name": "Cubist Pharmaceuticals INC", "rank": 19, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Cubist Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cubist Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 35% points.The greatest weakness of Cubist Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 98% points.

The company's Economic Capital Ratio, given in the ranking table, is 262%, being 25% points below the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000912183_2011_Cubist_Pharmaceuticals_INC.pdf", "shrinked_graph_json": { "2010": { "Liabilities, Current": "21.2", "Liabilities": "-40.6", "Stockholders Equity": "-27.6", "ECR before LimitedLiability": "-18.9", "Other Liabilities": "-97.6", "Liabilities, Non-Current": "23.3", "Selling, General and Administrative Expense": "17.0", "Expenses": "16.3", "Net Income": "15.3", "Research and Development": "2.55", "Cost of Goods Sold": "-4.56", "Other Expenses": "1.42", "Other Revenues": "0.833", "Revenues": "0.833", "Other Assets": "7.83", "Assets, Current": "34.7", "Property and Equipment": "-10.1", "Intangible Assets": "-21.9", "Comprehensive Net Income": "15.3", "Other Net Income": "-1.79", "Economic Capital Ratio": "-25.3" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000912183_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "1,016,243", "Cost of Goods Sold": "140,765", "Intangible Assets": "75,304", "Liabilities, Current": "150,644", "Liabilities, Non-Current": "6,370", "Other Assets": "241,176", "Other Compr. Net Income": "0", "Other Expenses": "150,383", "Other Liabilities": "594,720", "Other Net Income": "-35,290", "Other Revenues": "636,458", "Property and Equipment": "82,434", "Research and Development": "157,854", "Selling, General and Administrative Expense": "57,841" }, "output_variables": { "Assets": "1,415,157", "Liabilities": "751,734", "Expenses": "506,843", "Revenues": "636,458", "Stockholders Equity": "663,423", "Net Income": "94,325", "Comprehensive Net Income": "94,325", "BaseVar": "1,672,741", "ECR before LimitedLiability": "142%", "Economic Capital Ratio": "262%" } } }, "top_rated": false, "trend": null, "value": 2.621756474007777, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000912183.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000912183.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000912183.svg" }, { "company_id": "0000936402", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000936402.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000936402.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000936402_main_keyfigs.svg", "name": "Shire plc", "rank": 20, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Shire plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Shire plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 28% points.The greatest weakness of Shire plc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 262%, being 26% points below the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000936402_2011_Shire_plc.pdf", "shrinked_graph_json": { "2009": { "Assets, Current": "-20.3", "Assets": "-27.8", "Liabilities": "-59.5", "Stockholders Equity": "-82.2", "ECR before LimitedLiability": "-86.0", "Other Assets": "-6.71", "Intangible Assets": "2.70", "Property and Equipment": "-5.41", "Liabilities, Current": "-1.45", "Other Liabilities": "-67.9", "Liabilities, Non-Current": "8.33", "Cost of Goods Sold": "0.686", "Expenses": "-1.61", "Revenues": "-0.0897", "Net Income": "-1.74", "Selling, General and Administrative Expense": "-7.24", "Other Expenses": "8.73", "Research and Development": "-3.61", "Other Revenues": "-0.0897", "Comprehensive Net Income": "-1.23", "Other Compr. Net Income": "0.508", "Economic Capital Ratio": "-85.2" }, "2010": { "Other Assets": "-11.0", "Assets": "-19.0", "Liabilities": "-26.0", "Stockholders Equity": "-48.2", "ECR before LimitedLiability": "-19.2", "Assets, Current": "-28.2", "Intangible Assets": "27.9", "Liabilities, Current": "-6.98", "Other Liabilities": "-39.8", "Liabilities, Non-Current": "19.2", "Selling, General and Administrative Expense": "-3.14", "Expenses": "7.47", "Revenues": "12.8", "Net Income": "20.8", "Research and Development": "3.53", "Cost of Goods Sold": "5.62", "Other Expenses": "1.46", "Other Revenues": "12.8", "Comprehensive Net Income": "20.2", "Other Compr. Net Income": "-0.539", "Economic Capital Ratio": "-25.6" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000936402_strength_weakness.svg", "table_records": { "2009": { "input_variables": { "Assets, Current": "1,570,200", "Cost of Goods Sold": "0", "Intangible Assets": "2,175,400", "Liabilities, Current": "1,020,000", "Liabilities, Non-Current": "290,700", "Other Assets": "195,100", "Other Compr. Net Income": "52,300", "Other Expenses": "545,100", "Other Liabilities": "1,394,300", "Other Net Income": "9,700", "Other Revenues": "3,007,700", "Property and Equipment": "676,800", "Research and Development": "638,300", "Selling, General and Administrative Expense": "1,342,600" }, "output_variables": { "Assets": "4,617,500", "Liabilities": "2,705,000", "Expenses": "2,526,000", "Revenues": "3,007,700", "Stockholders Equity": "1,912,500", "Net Income": "491,400", "Comprehensive Net Income": "517,550", "BaseVar": "6,459,100", "ECR before LimitedLiability": "128%", "Economic Capital Ratio": "252%" } }, "2010": { "input_variables": { "Assets, Current": "1,880,300", "Cost of Goods Sold": "0", "Intangible Assets": "2,381,400", "Liabilities, Current": "1,293,300", "Liabilities, Non-Current": "182,900", "Other Assets": "272,500", "Other Compr. Net Income": "-63,400", "Other Expenses": "671,900", "Other Liabilities": "1,460,000", "Other Net Income": "-23,400", "Other Revenues": "3,471,100", "Property and Equipment": "853,400", "Research and Development": "661,500", "Selling, General and Administrative Expense": "1,526,300" }, "output_variables": { "Assets": "5,387,600", "Liabilities": "2,936,200", "Expenses": "2,859,700", "Revenues": "3,471,100", "Stockholders Equity": "2,451,400", "Net Income": "588,000", "Comprehensive Net Income": "556,300", "BaseVar": "7,370,700", "ECR before LimitedLiability": "142%", "Economic Capital Ratio": "262%" } } }, "top_rated": false, "trend": -14.0, "value": 2.618682250751209, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000936402.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000936402.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000936402.svg" }, { "company_id": "0000078003", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000078003.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000078003.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000078003.svg", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000078003_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000078003_main_keyfigs.svg", "name": "Pfizer INC", "rank": 21, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Pfizer INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pfizer INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 59% points.The greatest weakness of Pfizer INC is the variable Liabilities, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is 255%, being 32% points below the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000078003_2011_Pfizer_INC.pdf", "shrinked_graph_json": { "2009": { "Assets, Current": "-9.58", "Assets": "20.3", "Liabilities": "-92.2", "Stockholders Equity": "-36.6", "ECR before LimitedLiability": "-90.0", "Other Assets": "3.10", "Intangible Assets": "34.8", "Property and Equipment": "-3.77", "Liabilities, Current": "-5.50", "Other Liabilities": "-34.2", "Liabilities, Non-Current": "-45.5", "Cost of Goods Sold": "-3.48", "Expenses": "18.2", "Revenues": "-21.7", "Net Income": "-4.66", "Selling, General and Administrative Expense": "8.03", "Other Expenses": "10.1", "Research and Development": "3.33", "Other Revenues": "-21.7", "Comprehensive Net Income": "-4.67", "Economic Capital Ratio": "-89.1" }, "2010": { "Other Assets": "-5.24", "Assets": "11.1", "Liabilities": "-53.4", "Stockholders Equity": "-22.7", "ECR before LimitedLiability": "-25.6", "Assets, Current": "-21.2", "Property and Equipment": "-3.96", "Intangible Assets": "59.2", "Liabilities, Current": "6.98", "Other Liabilities": "-19.2", "Liabilities, Non-Current": "-40.1", "Selling, General and Administrative Expense": "9.71", "Expenses": "18.1", "Revenues": "-5.95", "Net Income": "12.4", "Research and Development": "7.77", "Cost of Goods Sold": "-3.41", "Other Expenses": "3.83", "Other Revenues": "-5.95", "Comprehensive Net Income": "12.4", "Economic Capital Ratio": "-32.0" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000078003_strength_weakness.svg", "table_records": { "2009": { "input_variables": { "Assets, Current": "61,670,000", "Cost of Goods Sold": "8,888,000", "Intangible Assets": "110,391,000", "Liabilities, Current": "37,225,000", "Liabilities, Non-Current": "48,804,000", "Other Assets": "18,108,000", "Other Compr. Net Income": "0", "Other Expenses": "9,771,000", "Other Liabilities": "36,474,000", "Other Net Income": "14,000", "Other Revenues": "50,009,000", "Property and Equipment": "22,780,000", "Research and Development": "7,845,000", "Selling, General and Administrative Expense": "14,875,000" }, "output_variables": { "Assets": "212,949,000", "Liabilities": "122,503,000", "Expenses": "41,379,000", "Revenues": "50,009,000", "Stockholders Equity": "90,446,000", "Net Income": "8,644,000", "Comprehensive Net Income": "8,644,000", "BaseVar": "213,427,000", "ECR before LimitedLiability": "123%", "Economic Capital Ratio": "248%" } }, "2010": { "input_variables": { "Assets, Current": "60,468,000", "Cost of Goods Sold": "16,279,000", "Intangible Assets": "101,505,000", "Liabilities, Current": "28,609,000", "Liabilities, Non-Current": "44,011,000", "Other Assets": "13,918,000", "Other Compr. Net Income": "0", "Other Expenses": "14,205,000", "Other Liabilities": "34,129,000", "Other Net Income": "-9,000", "Other Revenues": "67,809,000", "Property and Equipment": "19,123,000", "Research and Development": "9,413,000", "Selling, General and Administrative Expense": "19,614,000" }, "output_variables": { "Assets": "195,014,000", "Liabilities": "106,749,000", "Expenses": "59,511,000", "Revenues": "67,809,000", "Stockholders Equity": "88,265,000", "Net Income": "8,289,000", "Comprehensive Net Income": "8,289,000", "BaseVar": "214,546,000", "ECR before LimitedLiability": "133%", "Economic Capital Ratio": "255%" } } }, "top_rated": false, "trend": -14.0, "value": 2.5545226499293965, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000078003.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000078003.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000078003.svg" }, { "company_id": "0000059478", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000059478.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000059478.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000059478.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000059478_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000059478_main_keyfigs.svg", "name": "ELI Lilly Co", "rank": 22, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of ELI Lilly Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI Lilly Co compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 36% points.The greatest weakness of ELI Lilly Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 253%, being 35% points below the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000059478_2011_ELI_Lilly_Co.pdf", "shrinked_graph_json": { "2009": { "Assets, Current": "-13.7", "Assets": "-42.3", "Liabilities": "-64.7", "Stockholders Equity": "-108", "ECR before LimitedLiability": "-98.7", "Other Assets": "25.3", "Intangible Assets": "-54.5", "Property and Equipment": "15.4", "Other Liabilities": "18.8", "Liabilities, Non-Current": "-88.1", "Cost of Goods Sold": "0.754", "Expenses": "-4.73", "Revenues": "6.89", "Net Income": "1.81", "Selling, General and Administrative Expense": "-1.40", "Other Expenses": "0.299", "Research and Development": "-4.38", "Other Revenues": "6.89", "Comprehensive Net Income": "2.32", "Other Compr. Net Income": "0.508", "Economic Capital Ratio": "-97.9" }, "2010": { "Other Assets": "19.1", "Assets": "-28.4", "Liabilities": "-31.4", "Stockholders Equity": "-66.5", "ECR before LimitedLiability": "-28.5", "Assets, Current": "-19.8", "Property and Equipment": "13.6", "Intangible Assets": "-33.6", "Other Liabilities": "35.9", "Liabilities, Non-Current": "-74.7", "Selling, General and Administrative Expense": "3.75", "Expenses": "6.77", "Revenues": "18.9", "Net Income": "26.8", "Research and Development": "1.30", "Cost of Goods Sold": "5.96", "Other Expenses": "-4.22", "Other Revenues": "18.9", "Comprehensive Net Income": "26.5", "Other Net Income": "0.704", "Economic Capital Ratio": "-34.8" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000059478_strength_weakness.svg", "table_records": { "2009": { "input_variables": { "Assets, Current": "12,486,500", "Cost of Goods Sold": "0", "Intangible Assets": "0", "Liabilities, Current": "6,568,100", "Liabilities, Non-Current": "11,367,500", "Other Assets": "6,777,000", "Other Compr. Net Income": "314,900", "Other Expenses": "6,288,200", "Other Liabilities": "0", "Other Net Income": "0", "Other Revenues": "21,836,000", "Property and Equipment": "8,197,400", "Research and Development": "4,326,500", "Selling, General and Administrative Expense": "6,892,500" }, "output_variables": { "Assets": "27,460,900", "Liabilities": "17,935,600", "Expenses": "17,507,200", "Revenues": "21,836,000", "Stockholders Equity": "9,525,300", "Net Income": "4,328,800", "Comprehensive Net Income": "4,486,250", "BaseVar": "42,527,300", "ECR before LimitedLiability": "111%", "Economic Capital Ratio": "239%" } }, "2010": { "input_variables": { "Assets, Current": "14,840,000", "Cost of Goods Sold": "0", "Intangible Assets": "0", "Liabilities, Current": "7,101,400", "Liabilities, Non-Current": "11,487,200", "Other Assets": "8,220,700", "Other Compr. Net Income": "-198,200", "Other Expenses": "6,068,900", "Other Liabilities": "0", "Other Net Income": "0", "Other Revenues": "23,076,000", "Property and Equipment": "7,940,700", "Research and Development": "4,884,200", "Selling, General and Administrative Expense": "7,053,400" }, "output_variables": { "Assets": "31,001,400", "Liabilities": "18,588,600", "Expenses": "18,006,500", "Revenues": "23,076,000", "Stockholders Equity": "12,412,800", "Net Income": "5,069,500", "Comprehensive Net Income": "4,970,400", "BaseVar": "45,435,350", "ECR before LimitedLiability": "129%", "Economic Capital Ratio": "253%" } } }, "top_rated": false, "trend": -14.0, "value": 2.5260074260317094, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000059478.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000059478.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000059478.svg" }, { "company_id": "0000872589", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000872589.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000872589.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000872589.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000872589_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000872589_main_keyfigs.svg", "name": "Regeneron Pharmaceuticals INC", "rank": 23, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Regeneron Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regeneron Pharmaceuticals INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 44% points.The greatest weakness of Regeneron Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is 251%, being 37% points below the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000872589_2011_Regeneron_Pharmaceuticals_INC.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "44.3", "Assets": "-5.23", "Liabilities": "-31.6", "Stockholders Equity": "-30.1", "ECR before LimitedLiability": "-30.3", "Assets, Current": "-26.5", "Property and Equipment": "32.3", "Intangible Assets": "-30.7", "Liabilities, Current": "25.0", "Other Liabilities": "-91.4", "Liabilities, Non-Current": "23.9", "Selling, General and Administrative Expense": "16.6", "Expenses": "3.55", "Revenues": "-3.58", "Net Income": "-0.0762", "Research and Development": "-29.1", "Cost of Goods Sold": "5.29", "Other Expenses": "12.4", "Other Revenues": "-3.58", "Comprehensive Net Income": "-0.0618", "Economic Capital Ratio": "-36.7" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000872589_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "357,622", "Cost of Goods Sold": "0", "Intangible Assets": "0", "Liabilities, Current": "109,056", "Liabilities, Non-Current": "7,350", "Other Assets": "384,360", "Other Compr. Net Income": "0", "Other Expenses": "2,093", "Other Liabilities": "445,211", "Other Net Income": "-6,996", "Other Revenues": "459,074", "Property and Equipment": "347,450", "Research and Development": "489,252", "Selling, General and Administrative Expense": "65,201" }, "output_variables": { "Assets": "1,089,432", "Liabilities": "561,617", "Expenses": "556,546", "Revenues": "459,074", "Stockholders Equity": "527,815", "Net Income": "-104,468", "Comprehensive Net Income": "-104,468", "BaseVar": "1,336,832", "ECR before LimitedLiability": "127%", "Economic Capital Ratio": "251%" } } }, "top_rated": false, "trend": null, "value": 2.5076930731906115, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000872589.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000872589.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000872589.svg" }, { "company_id": "0000885590", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000885590.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000885590.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000885590.svg", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000885590_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000885590_main_keyfigs.svg", "name": "Bausch Health Companies Inc", "rank": 24, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Bausch Health Companies Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bausch Health Companies Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 126% points.The greatest weakness of Bausch Health Companies Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 80% points.

The company's Economic Capital Ratio, given in the ranking table, is 250%, being 37% points below the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000885590_2011_Bausch_Health_Companies_Inc.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "-10.9", "Assets": "47.4", "Liabilities": "-75.2", "Stockholders Equity": "-0.525", "ECR before LimitedLiability": "-31.0", "Assets, Current": "-35.4", "Property and Equipment": "-10.8", "Intangible Assets": "126", "Liabilities, Current": "20.2", "Other Liabilities": "-16.8", "Liabilities, Non-Current": "-80.4", "Selling, General and Administrative Expense": "13.6", "Expenses": "27.4", "Revenues": "-21.1", "Net Income": "4.87", "Research and Development": "8.81", "Cost of Goods Sold": "3.77", "Other Expenses": "0.605", "Other Revenues": "-21.1", "Comprehensive Net Income": "4.88", "Economic Capital Ratio": "-37.3" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000885590_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "1,020,166", "Cost of Goods Sold": "0", "Intangible Assets": "9,374,156", "Liabilities, Current": "692,456", "Liabilities, Non-Current": "3,608,699", "Other Assets": "119,043", "Other Compr. Net Income": "0", "Other Expenses": "919,231", "Other Liabilities": "1,582,866", "Other Net Income": "-36,097", "Other Revenues": "1,181,237", "Property and Equipment": "281,752", "Research and Development": "157,556", "Selling, General and Administrative Expense": "276,546" }, "output_variables": { "Assets": "10,795,117", "Liabilities": "5,884,021", "Expenses": "1,353,333", "Revenues": "1,181,237", "Stockholders Equity": "4,911,096", "Net Income": "-208,193", "Comprehensive Net Income": "-208,193", "BaseVar": "9,624,902", "ECR before LimitedLiability": "126%", "Economic Capital Ratio": "250%" } } }, "top_rated": false, "trend": null, "value": 2.5013555879200813, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000885590.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000885590.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000885590.svg" }, { "company_id": "0000874015", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000874015.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000874015.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000874015.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000874015_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000874015_main_keyfigs.svg", "name": "Ionis Pharmaceuticals INC", "rank": 25, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Ionis Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ionis Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 97% points.The greatest weakness of Ionis Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 238%, being 49% points below the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000874015_2011_Ionis_Pharmaceuticals_INC.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "-6.94", "Assets": "23.7", "Liabilities": "-62.7", "Stockholders Equity": "-18.0", "ECR before LimitedLiability": "-42.9", "Assets, Current": "97.4", "Property and Equipment": "-8.26", "Intangible Assets": "-28.1", "Liabilities, Current": "-8.38", "Other Liabilities": "-78.8", "Liabilities, Non-Current": "21.3", "Selling, General and Administrative Expense": "17.0", "Expenses": "15.3", "Revenues": "-18.2", "Net Income": "-3.10", "Research and Development": "-14.0", "Cost of Goods Sold": "4.48", "Other Expenses": "8.21", "Other Revenues": "-18.2", "Comprehensive Net Income": "-3.09", "Economic Capital Ratio": "-49.2" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000874015_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "483,137", "Cost of Goods Sold": "0", "Intangible Assets": "0", "Liabilities, Current": "105,890", "Liabilities, Non-Current": "0", "Other Assets": "31,637", "Other Compr. Net Income": "0", "Other Expenses": "13,324", "Other Liabilities": "200,045", "Other Net Income": "429", "Other Revenues": "108,473", "Property and Equipment": "35,703", "Research and Development": "145,160", "Selling, General and Administrative Expense": "11,669" }, "output_variables": { "Assets": "550,477", "Liabilities": "305,935", "Expenses": "170,153", "Revenues": "108,473", "Stockholders Equity": "244,542", "Net Income": "-61,251", "Comprehensive Net Income": "-61,251", "BaseVar": "567,734", "ECR before LimitedLiability": "110%", "Economic Capital Ratio": "238%" } } }, "top_rated": false, "trend": null, "value": 2.3818304614964347, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000874015.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000874015.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000874015.svg" }, { "company_id": "0000820096", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000820096.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000820096.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000820096_main_keyfigs.svg", "name": "Perrigo CO", "rank": 26, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Perrigo CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Perrigo CO compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 36% points.The greatest weakness of Perrigo CO is the variable Stockholders Equity, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is 232%, being 56% points below the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000820096_2011_Perrigo_CO.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "11.1", "Assets": "-36.5", "Liabilities": "-39.2", "Stockholders Equity": "-80.6", "ECR before LimitedLiability": "-49.4", "Assets, Current": "-28.2", "Property and Equipment": "-4.62", "Intangible Assets": "-16.2", "Liabilities, Current": "-15.3", "Other Liabilities": "36.4", "Liabilities, Non-Current": "-64.6", "Selling, General and Administrative Expense": "18.7", "Expenses": "1.76", "Revenues": "16.0", "Net Income": "18.6", "Research and Development": "14.1", "Cost of Goods Sold": "-38.5", "Other Expenses": "10.4", "Other Revenues": "16.0", "Comprehensive Net Income": "18.6", "Economic Capital Ratio": "-55.8" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000820096_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "1,402,701", "Cost of Goods Sold": "1,521,917", "Intangible Assets": "587,000", "Liabilities, Current": "922,509", "Liabilities, Non-Current": "1,092,554", "Other Assets": "670,719", "Other Compr. Net Income": "0", "Other Expenses": "150,475", "Other Liabilities": "0", "Other Net Income": "530", "Other Revenues": "2,268,150", "Property and Equipment": "448,583", "Research and Development": "102,515", "Selling, General and Administrative Expense": "269,974" }, "output_variables": { "Assets": "3,109,003", "Liabilities": "2,015,063", "Expenses": "2,044,881", "Revenues": "2,268,150", "Stockholders Equity": "1,093,940", "Net Income": "223,799", "Comprehensive Net Income": "223,799", "BaseVar": "4,718,814", "ECR before LimitedLiability": "102%", "Economic Capital Ratio": "232%" } } }, "top_rated": false, "trend": null, "value": 2.316388451376101, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000820096.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000820096.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000820096.svg" }, { "company_id": "0001178670", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0001178670.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0001178670.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001178670.svg", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001178670_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001178670_main_keyfigs.svg", "name": "Alnylam Pharmaceuticals INC", "rank": 27, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Alnylam Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alnylam Pharmaceuticals INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 40% points.The greatest weakness of Alnylam Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is 227%, being 60% points below the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0001178670_2011_Alnylam_Pharmaceuticals_INC.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "40.2", "Assets": "11.2", "Liabilities": "-65.6", "Stockholders Equity": "-34.9", "ECR before LimitedLiability": "-54.1", "Assets, Current": "32.7", "Property and Equipment": "-12.8", "Intangible Assets": "-31.2", "Liabilities, Current": "-23.2", "Other Liabilities": "-65.8", "Liabilities, Non-Current": "22.3", "Selling, General and Administrative Expense": "10.9", "Expenses": "13.0", "Revenues": "-15.7", "Net Income": "-2.44", "Research and Development": "-13.8", "Cost of Goods Sold": "4.85", "Other Expenses": "11.4", "Other Revenues": "-15.7", "Comprehensive Net Income": "-2.43", "Economic Capital Ratio": "-60.4" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001178670_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "254,139", "Cost of Goods Sold": "0", "Intangible Assets": "448", "Liabilities, Current": "102,046", "Liabilities, Non-Current": "143", "Other Assets": "120,389", "Other Compr. Net Income": "-2.0", "Other Expenses": "514", "Other Liabilities": "132,843", "Other Net Income": "1,069", "Other Revenues": "100,041", "Property and Equipment": "18,289", "Research and Development": "106,384", "Selling, General and Administrative Expense": "37,727" }, "output_variables": { "Assets": "393,265", "Liabilities": "235,032", "Expenses": "144,625", "Revenues": "100,041", "Stockholders Equity": "158,233", "Net Income": "-43,515", "Comprehensive Net Income": "-43,516", "BaseVar": "437,017", "ECR before LimitedLiability": "96%", "Economic Capital Ratio": "227%" } } }, "top_rated": false, "trend": null, "value": 2.2698405879645227, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0001178670.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0001178670.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0001178670.svg" }, { "company_id": "0000069499", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000069499.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000069499.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000069499_main_keyfigs.svg", "name": "Mylan INC", "rank": 28, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Mylan INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mylan INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 60% points.The greatest weakness of Mylan INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is 218%, being 70% points below the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000069499_2011_Mylan_INC.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "-11.4", "Assets": "-15.4", "Liabilities": "-69.6", "Stockholders Equity": "-68.4", "ECR before LimitedLiability": "-63.3", "Assets, Current": "-36.0", "Property and Equipment": "-7.28", "Intangible Assets": "60.2", "Liabilities, Current": "11.8", "Other Liabilities": "20.8", "Liabilities, Non-Current": "-111", "Selling, General and Administrative Expense": "14.2", "Expenses": "13.9", "Revenues": "-1.25", "Net Income": "12.9", "Research and Development": "12.6", "Cost of Goods Sold": "-21.1", "Other Expenses": "9.13", "Other Revenues": "-1.25", "Comprehensive Net Income": "13.0", "Economic Capital Ratio": "-69.7" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000069499_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "3,559,443", "Cost of Goods Sold": "3,233,125", "Intangible Assets": "6,100,484", "Liabilities, Current": "1,809,612", "Liabilities, Non-Current": "5,633,697", "Other Assets": "667,535", "Other Compr. Net Income": "0", "Other Expenses": "468,922", "Other Liabilities": "478,094", "Other Net Income": "-34,178", "Other Revenues": "5,450,522", "Property and Equipment": "1,209,342", "Research and Development": "282,146", "Selling, General and Administrative Expense": "1,086,609" }, "output_variables": { "Assets": "11,536,804", "Liabilities": "7,921,403", "Expenses": "5,070,802", "Revenues": "5,450,522", "Stockholders Equity": "3,615,401", "Net Income": "345,542", "Comprehensive Net Income": "345,542", "BaseVar": "15,006,854", "ECR before LimitedLiability": "85%", "Economic Capital Ratio": "218%" } } }, "top_rated": false, "trend": null, "value": 2.17767039808547, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000069499.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000069499.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000069499.svg" }, { "company_id": "0000875320", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0000875320.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0000875320.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000875320.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000875320_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000875320_main_keyfigs.svg", "name": "Vertex Pharmaceuticals INC MA", "rank": 29, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Vertex Pharmaceuticals INC MA are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vertex Pharmaceuticals INC MA compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 24% points.The greatest weakness of Vertex Pharmaceuticals INC MA is the variable Liabilities, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is 164%, being 124% points below the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0000875320_2011_Vertex_Pharmaceuticals_INC_MA.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "24.2", "Assets": "5.83", "Liabilities": "-90.6", "Stockholders Equity": "-66.5", "ECR before LimitedLiability": "-117", "Assets, Current": "22.8", "Property and Equipment": "-19.2", "Intangible Assets": "-41.0", "Liabilities, Current": "-24.5", "Other Liabilities": "-89.3", "Liabilities, Non-Current": "22.2", "Selling, General and Administrative Expense": "11.5", "Expenses": "1.90", "Revenues": "-36.8", "Net Income": "-36.8", "Research and Development": "-25.2", "Cost of Goods Sold": "5.60", "Other Expenses": "11.1", "Other Revenues": "-36.8", "Comprehensive Net Income": "-36.8", "Economic Capital Ratio": "-124" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0000875320_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "1,057,039", "Cost of Goods Sold": "0", "Intangible Assets": "26,102", "Liabilities, Current": "474,783", "Liabilities, Non-Current": "0", "Other Assets": "569,972", "Other Compr. Net Income": "0", "Other Expenses": "33,506", "Other Liabilities": "746,690", "Other Net Income": "-39,274", "Other Revenues": "143,370", "Property and Equipment": "72,333", "Research and Development": "637,416", "Selling, General and Administrative Expense": "187,800" }, "output_variables": { "Assets": "1,725,446", "Liabilities": "1,221,473", "Expenses": "858,722", "Revenues": "143,370", "Stockholders Equity": "503,973", "Net Income": "-754,626", "Comprehensive Net Income": "-754,626", "BaseVar": "1,994,142", "ECR before LimitedLiability": "23%", "Economic Capital Ratio": "164%" } } }, "top_rated": false, "trend": null, "value": 1.6378238272514196, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0000875320.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0000875320.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0000875320.svg" }, { "company_id": "0001323854", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0001323854.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0001323854.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001323854_main_keyfigs.svg", "name": "Warner Chilcott plc", "rank": 30, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Warner Chilcott plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Warner Chilcott plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 14% points.The greatest weakness of Warner Chilcott plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 177% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 146% points below the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0001323854_2011_Warner_Chilcott_plc.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "-23.0", "Assets": "-50.1", "Liabilities": "-125", "Stockholders Equity": "-142", "Assets, Current": "-72.5", "Property and Equipment": "-26.0", "Intangible Assets": "14.2", "Liabilities, Current": "0.459", "Other Liabilities": "1.20", "Liabilities, Non-Current": "-177", "Selling, General and Administrative Expense": "0.459", "Expenses": "0.733", "Revenues": "-3.96", "Net Income": "0.618", "Research and Development": "0.630", "Cost of Goods Sold": "-2.12", "Other Expenses": "-3.40", "Other Revenues": "-3.96", "ECR before LimitedLiability": "-140", "Comprehensive Net Income": "0.615", "Economic Capital Ratio": "-146" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001323854_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "1,177,040", "Cost of Goods Sold": "492,801", "Intangible Assets": "4,045,291", "Liabilities, Current": "1,123,442", "Liabilities, Non-Current": "4,523,854", "Other Assets": "193,949", "Other Compr. Net Income": "-11,738", "Other Expenses": "1,073,852", "Other Liabilities": "70,335", "Other Net Income": "0", "Other Revenues": "2,974,482", "Property and Equipment": "235,709", "Research and Development": "146,506", "Selling, General and Administrative Expense": "1,090,351" }, "output_variables": { "Assets": "5,651,989", "Liabilities": "5,717,631", "Expenses": "2,803,510", "Revenues": "2,974,482", "Stockholders Equity": "-65,642", "Net Income": "170,972", "Comprehensive Net Income": "165,103", "BaseVar": "8,579,675", "ECR before LimitedLiability": "0.39%", "Economic Capital Ratio": "141%" } } }, "top_rated": false, "trend": null, "value": 1.4143428357667194, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0001323854.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0001323854.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0001323854.svg" }, { "company_id": "0001415684", "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution_0001415684.svg", "graph_url": "https://www.realrate-archive.com/us_pharma/2010/graphs/IME_0001415684.svg", "logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001415684.svg", "logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001415684_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001415684_main_keyfigs.svg", "name": "Musclepharm Corp", "rank": 31, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Musclepharm Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Musclepharm Corp compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 2.2% points.The greatest weakness of Musclepharm Corp is the variable Assets, reducing the Economic Capital Ratio by 164% points.

The company's Economic Capital Ratio, given in the ranking table, is 4.8%, being 283% points below the market average of 287%.", "report_url": "https://www.realrate-archive.com/us_pharma/2010/report/0001415684_2011_Musclepharm_Corp.pdf", "shrinked_graph_json": { "2010": { "Other Assets": "-5.35", "Assets": "-164", "Liabilities": "-1.89", "Stockholders Equity": "-136", "ECR before LimitedLiability": "-276", "Assets, Current": "-113", "Property and Equipment": "-28.0", "Intangible Assets": "-64.2", "Liabilities, Current": "2.17", "Other Liabilities": "-2.42", "Selling, General and Administrative Expense": "-98.8", "Expenses": "-82.2", "Revenues": "-4.59", "Net Income": "-115", "Research and Development": "2.20", "Cost of Goods Sold": "-3.65", "Other Expenses": "1.99", "Other Revenues": "-4.59", "Comprehensive Net Income": "-115", "Other Net Income": "-1.98", "Economic Capital Ratio": "-283" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2010/plot_over_time/0001415684_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "1,406", "Cost of Goods Sold": "2,804", "Intangible Assets": "0", "Liabilities, Current": "4,216", "Liabilities, Non-Current": "250", "Other Assets": "1,176", "Other Compr. Net Income": "0", "Other Expenses": "0", "Other Liabilities": "0", "Other Net Income": "-1,318", "Other Revenues": "4,047", "Property and Equipment": "139", "Research and Development": "0", "Selling, General and Administrative Expense": "19,495" }, "output_variables": { "Assets": "2,721", "Liabilities": "4,466", "Expenses": "22,299", "Revenues": "4,047", "Stockholders Equity": "-1,745", "Net Income": "-19,569", "Comprehensive Net Income": "-19,569", "BaseVar": "17,425", "ECR before LimitedLiability": "-650%", "Economic Capital Ratio": "4.8%" } } }, "top_rated": false, "trend": null, "value": 0.047798819735838945, "company_index": "https://www.realrate-archive.com/us_pharma/2010/industry_indexes/0001415684.svg", "analysing_equity": "https://www.realrate-archive.com/us_pharma/2010/analytics/equity/0001415684.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2010/analytics/profit_loss/0001415684.svg" } ], "feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2010/feature_distribution/feature_distribution.svg", "final_var_label": "Economic Capital Ratio", "industry_box": [ [ "Revenues", "273 B" ], [ "Assets", "566 B" ], [ "Expenses", "240 B" ], [ "Stockholders Equity", "327 B" ] ], "industry_id": "us_pharma", "industry_label": "Pharmaceutical", "num_companies": 31, "num_top_companies": 7, "ecr_records": { "2009": { "0000850693": { "rank": 1, "ecr": "414" }, "0000310158": { "rank": 2, "ecr": "402" }, "0000038074": { "rank": 3, "ecr": "397" }, "0001274057": { "rank": 4, "ecr": "388" }, "0000001800": { "rank": 5, "ecr": "355" }, "0000936402": { "rank": 6, "ecr": "252" }, "0000078003": { "rank": 7, "ecr": "248" }, "0000059478": { "rank": 8, "ecr": "239" } }, "2010": { "0000899866": { "rank": 1, "ecr": "395" }, "0000038074": { "rank": 2, "ecr": "394" }, "0001274057": { "rank": 3, "ecr": "389" }, "0000310158": { "rank": 4, "ecr": "386" }, "0001100962": { "rank": 5, "ecr": "376" }, "0000850693": { "rank": 6, "ecr": "369" }, "0001113481": { "rank": 7, "ecr": "368" }, "0000859368": { "rank": 8, "ecr": "352" }, "0000001800": { "rank": 9, "ecr": "337" }, "0000881464": { "rank": 10, "ecr": "328" }, "0001130591": { "rank": 11, "ecr": "326" }, "0001107332": { "rank": 12, "ecr": "326" }, "0001182129": { "rank": 13, "ecr": "316" }, "0000792977": { "rank": 14, "ecr": "311" }, "0001082554": { "rank": 15, "ecr": "308" }, "0001048477": { "rank": 16, "ecr": "300" }, "0000200406": { "rank": 17, "ecr": "287" }, "0000884629": { "rank": 18, "ecr": "286" }, "0000912183": { "rank": 19, "ecr": "262" }, "0000936402": { "rank": 20, "ecr": "262" }, "0000078003": { "rank": 21, "ecr": "255" }, "0000059478": { "rank": 22, "ecr": "253" }, "0000872589": { "rank": 23, "ecr": "251" }, "0000885590": { "rank": 24, "ecr": "250" }, "0000874015": { "rank": 25, "ecr": "238" }, "0000820096": { "rank": 26, "ecr": "232" }, "0001178670": { "rank": 27, "ecr": "227" }, "0000069499": { "rank": 28, "ecr": "218" }, "0000875320": { "rank": 29, "ecr": "164" }, "0001323854": { "rank": 30, "ecr": "141" }, "0001415684": { "rank": 31, "ecr": "4.8" } } }, "rating_box": [ [ "Top rated", "7 of 31" ], [ "Best, worst rating", "395 %, 4.78 %" ], [ "New companies", "23" ] ], "regression_plot": null, "scentences": [ "Forest Laboratories LLC climbed 1 positions from 3 to 2 due to its excellent Liabilities.", "ELI Lilly Co lost 14 positions from 8 to 22 due to its bad Liabilities, Non-Current.", "Alexion Pharmaceuticals INC entered the 2011 ranking at rank 1, making it the best newcomer." ], "url_segment": "2011-us-pharma", "year": 2011, "feature_importance": "https://www.realrate-archive.com/us_pharma/2010/feature_importance/feature_importance.svg", "obs_ecr": { "0000001800": { "2011": { "obs_EconomicCapitalRatio": 1.713107979288017 }, "2012": { "obs_EconomicCapitalRatio": 1.9818897856107043 }, "2013": { "obs_EconomicCapitalRatio": 1.769123933983911 }, "2014": { "obs_EconomicCapitalRatio": 2.1310058713021722 }, "2015": { "obs_EconomicCapitalRatio": 2.183359905306885 }, "2016": { "obs_EconomicCapitalRatio": 1.5961090407785672 }, "2017": { "obs_EconomicCapitalRatio": 2.000468071061702 }, "2018": { "obs_EconomicCapitalRatio": 2.810827504766453 }, "2019": { "obs_EconomicCapitalRatio": 3.481865615110975 }, "2020": { "obs_EconomicCapitalRatio": 4.107812733572192 }, "2021": { "obs_EconomicCapitalRatio": 5.136856213515629 }, "2022": { "obs_EconomicCapitalRatio": 3.9093024416771485 }, "2023": { "obs_EconomicCapitalRatio": 4.126727193145108 }, "2024": { "obs_EconomicCapitalRatio": 4.006765354897495 }, "2025": { "obs_EconomicCapitalRatio": 4.169990837258094 } }, "0000059478": { "2011": { "obs_EconomicCapitalRatio": 1.3011542204549682 }, "2012": { "obs_EconomicCapitalRatio": 1.6073698634051163 }, "2013": { "obs_EconomicCapitalRatio": 1.7086734027999013 }, "2014": { "obs_EconomicCapitalRatio": 2.168132783245762 }, "2015": { "obs_EconomicCapitalRatio": 2.828430576978719 }, "2016": { "obs_EconomicCapitalRatio": 2.1987283790775205 }, "2017": { "obs_EconomicCapitalRatio": 2.123950765224203 }, "2018": { "obs_EconomicCapitalRatio": 2.731455167628783 }, "2019": { "obs_EconomicCapitalRatio": 3.077422071844895 }, "2020": { "obs_EconomicCapitalRatio": 3.4529271354729705 }, "2021": { "obs_EconomicCapitalRatio": 5.70344420672454 }, "2022": { "obs_EconomicCapitalRatio": 7.6589144018063715 }, "2023": { "obs_EconomicCapitalRatio": 9.17322017661815 }, "2024": { "obs_EconomicCapitalRatio": 10.183951826657761 }, "2025": { "obs_EconomicCapitalRatio": 10.21482121245407 } }, "0000078003": { "2011": { "obs_EconomicCapitalRatio": 0.6204658798489293 }, "2012": { "obs_EconomicCapitalRatio": 0.7275629998959219 }, "2013": { "obs_EconomicCapitalRatio": 0.8708003565331511 }, "2014": { "obs_EconomicCapitalRatio": 0.9027716576964234 }, "2015": { "obs_EconomicCapitalRatio": 0.9342018064245718 }, "2016": { "obs_EconomicCapitalRatio": 0.907660993640416 }, "2019": { "obs_EconomicCapitalRatio": 1.1640232368871106 }, "2020": { "obs_EconomicCapitalRatio": 1.2783936545298629 }, "2021": { "obs_EconomicCapitalRatio": 1.8276579049294321 }, "2022": { "obs_EconomicCapitalRatio": 1.570764514575865 }, "2023": { "obs_EconomicCapitalRatio": 0.7485848149955884 }, "2024": { "obs_EconomicCapitalRatio": 0.8004626854205364 }, "2025": { "obs_EconomicCapitalRatio": 0.8358387669038688 } }, "0000310158": { "2011": { "obs_EconomicCapitalRatio": 1.1838108948285708 }, "2012": { "obs_EconomicCapitalRatio": 1.3266057959183948 }, "2013": { "obs_EconomicCapitalRatio": 1.5875598350732738 }, "2014": { "obs_EconomicCapitalRatio": 1.9668047289520008 }, "2015": { "obs_EconomicCapitalRatio": 1.765264109808397 }, "2016": { "obs_EconomicCapitalRatio": 2.179324674206441 }, "2017": { "obs_EconomicCapitalRatio": 2.2179160781193725 }, "2018": { "obs_EconomicCapitalRatio": 2.918914539340223 }, "2019": { "obs_EconomicCapitalRatio": 3.5493653686617934 }, "2020": { "obs_EconomicCapitalRatio": 2.861832807217268 }, "2021": { "obs_EconomicCapitalRatio": 2.598974464066237 }, "2022": { "obs_EconomicCapitalRatio": 3.7956011713029745 }, "2024": { "obs_EconomicCapitalRatio": 3.2845310383661435 }, "2025": { "obs_EconomicCapitalRatio": 3.1141288688122706 } }, "0000200406": { "2011": { "obs_EconomicCapitalRatio": 1.585118624542793 }, "2012": { "obs_EconomicCapitalRatio": 1.504690567647153 }, "2013": { "obs_EconomicCapitalRatio": 1.9242798191550312 }, "2014": { "obs_EconomicCapitalRatio": 2.2278890509924185 }, "2016": { "obs_EconomicCapitalRatio": 2.4777357391297277 }, "2017": { "obs_EconomicCapitalRatio": 2.3520652022077133 }, "2018": { "obs_EconomicCapitalRatio": 2.2634671786176646 }, "2019": { "obs_EconomicCapitalRatio": 2.5042625665138107 }, "2021": { "obs_EconomicCapitalRatio": 2.7314212375357267 }, "2022": { "obs_EconomicCapitalRatio": 2.878621220487235 }, "2023": { "obs_EconomicCapitalRatio": 2.6197519723699583 }, "2024": { "obs_EconomicCapitalRatio": 2.3191305413843795 }, "2025": { "obs_EconomicCapitalRatio": 3.119823423001993 } }, "0000872589": { "2011": { "obs_EconomicCapitalRatio": 4.582076910345481 }, "2012": { "obs_EconomicCapitalRatio": 0.24585036111793895 }, "2013": { "obs_EconomicCapitalRatio": 0.2815811600194353 }, "2014": { "obs_EconomicCapitalRatio": 0.3100470608736094 }, "2015": { "obs_EconomicCapitalRatio": 0.27182465887451096 }, "2016": { "obs_EconomicCapitalRatio": 0.14892623314075953 }, "2017": { "obs_EconomicCapitalRatio": 0.12780427752058388 }, "2018": { "obs_EconomicCapitalRatio": 0.09353815222614291 }, "2019": { "obs_EconomicCapitalRatio": 0.07405318854905384 }, "2020": { "obs_EconomicCapitalRatio": 0.07704699466107758 }, "2021": { "obs_EconomicCapitalRatio": 0.0708054489047348 }, "2022": { "obs_EconomicCapitalRatio": 0.0728389877336521 }, "2023": { "obs_EconomicCapitalRatio": 0.0762989818667771 }, "2024": { "obs_EconomicCapitalRatio": 0.05570410882668733 }, "2025": { "obs_EconomicCapitalRatio": 0.056457061472648826 } }, "0000874015": { "2011": { "obs_EconomicCapitalRatio": 1.7488613998301505 }, "2012": { "obs_EconomicCapitalRatio": 2.270155255658294 }, "2013": { "obs_EconomicCapitalRatio": 7.062785583504883 }, "2014": { "obs_EconomicCapitalRatio": 8.820019473688006 }, "2015": { "obs_EconomicCapitalRatio": 8.300195128294876 }, "2016": { "obs_EconomicCapitalRatio": 7.244631215797163 }, "2017": { "obs_EconomicCapitalRatio": 5.7055360292456125 }, "2018": { "obs_EconomicCapitalRatio": 3.4034656712267033 }, "2019": { "obs_EconomicCapitalRatio": 3.6247798271585627 }, "2020": { "obs_EconomicCapitalRatio": 4.057757935086542 }, "2021": { "obs_EconomicCapitalRatio": 2.0111035177647114 }, "2022": { "obs_EconomicCapitalRatio": 2.405605379604031 }, "2023": { "obs_EconomicCapitalRatio": 2.5857751168273673 }, "2025": { "obs_EconomicCapitalRatio": 3.8706342956245274 } }, "0000875320": { "2011": { "obs_EconomicCapitalRatio": 4.011950728873362 }, "2012": { "obs_EconomicCapitalRatio": 4.271057005011649 }, "2013": { "obs_EconomicCapitalRatio": 10.465959059153883 }, "2014": { "obs_EconomicCapitalRatio": 15.896010008565815 }, "2015": { "obs_EconomicCapitalRatio": 15.592867642583915 }, "2016": { "obs_EconomicCapitalRatio": 8.296574202463598 }, "2017": { "obs_EconomicCapitalRatio": 14.958650129119075 }, "2018": { "obs_EconomicCapitalRatio": 10.253923586592718 }, "2019": { "obs_EconomicCapitalRatio": 10.706680332118959 }, "2020": { "obs_EconomicCapitalRatio": 8.238943652191004 }, "2021": { "obs_EconomicCapitalRatio": 6.737638276287789 }, "2022": { "obs_EconomicCapitalRatio": 6.652462385791637 }, "2023": { "obs_EconomicCapitalRatio": 7.506270617948925 }, "2024": { "obs_EconomicCapitalRatio": 7.310208963840968 }, "2025": { "obs_EconomicCapitalRatio": 7.120028571708822 } }, "0000885590": { "2011": { "obs_EconomicCapitalRatio": 1.2666859338583747 }, "2012": { "obs_EconomicCapitalRatio": 1.133546210262225 }, "2013": { "obs_EconomicCapitalRatio": 1.4857321204621172 }, "2014": { "obs_EconomicCapitalRatio": 2.022848068353309 }, "2015": { "obs_EconomicCapitalRatio": 0.8112057344714052 }, "2017": { "obs_EconomicCapitalRatio": 0.2138501706421959 }, "2018": { "obs_EconomicCapitalRatio": 0.21104827651258354 }, "2019": { "obs_EconomicCapitalRatio": 0.31527749153545165 }, "2020": { "obs_EconomicCapitalRatio": 0.23248358716778134 }, "2021": { "obs_EconomicCapitalRatio": 0.339482039945958 }, "2022": { "obs_EconomicCapitalRatio": 0.09104758594800844 }, "2023": { "obs_EconomicCapitalRatio": 0.09992833157007878 }, "2024": { "obs_EconomicCapitalRatio": 0.10434237028585064 }, "2025": { "obs_EconomicCapitalRatio": 0.09893661457111663 } }, "0001048477": { "2011": { "obs_EconomicCapitalRatio": 4.191088034178572 }, "2012": { "obs_EconomicCapitalRatio": 5.537160403950625 }, "2013": { "obs_EconomicCapitalRatio": 6.234147377653601 }, "2014": { "obs_EconomicCapitalRatio": 7.769566635963881 }, "2015": { "obs_EconomicCapitalRatio": 6.696971026740999 }, "2016": { "obs_EconomicCapitalRatio": 5.5154730752925385 }, "2017": { "obs_EconomicCapitalRatio": 4.9407181151439135 }, "2018": { "obs_EconomicCapitalRatio": 5.116817632896571 }, "2019": { "obs_EconomicCapitalRatio": 4.872335389121422 }, "2020": { "obs_EconomicCapitalRatio": 4.209123471121257 }, "2021": { "obs_EconomicCapitalRatio": 4.250038133443851 }, "2022": { "obs_EconomicCapitalRatio": 4.766788663625819 }, "2023": { "obs_EconomicCapitalRatio": 4.161003152678966 }, "2024": { "obs_EconomicCapitalRatio": 3.023712826972472 }, "2025": { "obs_EconomicCapitalRatio": 2.5199974939053984 } }, "0001082554": { "2011": { "obs_EconomicCapitalRatio": 2.5911979399197222 }, "2012": { "obs_EconomicCapitalRatio": 2.465978801573956 }, "2013": { "obs_EconomicCapitalRatio": 3.924599868968605 }, "2014": { "obs_EconomicCapitalRatio": 4.970769469753602 }, "2015": { "obs_EconomicCapitalRatio": 5.218004291411121 }, "2016": { "obs_EconomicCapitalRatio": 4.35971495180887 }, "2017": { "obs_EconomicCapitalRatio": 3.262507002920337 }, "2018": { "obs_EconomicCapitalRatio": 2.2953600704628623 }, "2019": { "obs_EconomicCapitalRatio": 1.5558122744235194 }, "2020": { "obs_EconomicCapitalRatio": 2.270010361107863 }, "2021": { "obs_EconomicCapitalRatio": 3.0205299234286707 }, "2022": { "obs_EconomicCapitalRatio": 3.437755821443613 }, "2023": { "obs_EconomicCapitalRatio": 2.471650006778008 }, "2024": { "obs_EconomicCapitalRatio": 3.880904249672765 }, "2025": { "obs_EconomicCapitalRatio": 5.057179921650618 } }, "0001178670": { "2011": { "obs_EconomicCapitalRatio": 1.5487006572365678 }, "2012": { "obs_EconomicCapitalRatio": 4.348978489565005 }, "2013": { "obs_EconomicCapitalRatio": 14.4117591901869 }, "2014": { "obs_EconomicCapitalRatio": 12.210984605617043 }, "2015": { "obs_EconomicCapitalRatio": 10.225771894885957 }, "2016": { "obs_EconomicCapitalRatio": 4.357512767955176 }, "2017": { "obs_EconomicCapitalRatio": 10.37169962203894 }, "2018": { "obs_EconomicCapitalRatio": 7.48962729612636 }, "2019": { "obs_EconomicCapitalRatio": 7.779988241681978 }, "2020": { "obs_EconomicCapitalRatio": 5.528023267295534 }, "2021": { "obs_EconomicCapitalRatio": 6.399472454496644 }, "2022": { "obs_EconomicCapitalRatio": 8.062817835829533 }, "2023": { "obs_EconomicCapitalRatio": 6.027810663540046 }, "2024": { "obs_EconomicCapitalRatio": 7.376380265814746 }, "2025": { "obs_EconomicCapitalRatio": 11.523330894989943 } }, "0000025743": { "2011": { "obs_EconomicCapitalRatio": 60.20949105963872 }, "2012": { "obs_EconomicCapitalRatio": 44.69064821898129 }, "2013": { "obs_EconomicCapitalRatio": 21.201251272186344 }, "2014": { "obs_EconomicCapitalRatio": 19.322141949843708 }, "2015": { "obs_EconomicCapitalRatio": 44.10663573129477 }, "2016": { "obs_EconomicCapitalRatio": 14.66973471892876 }, "2017": { "obs_EconomicCapitalRatio": 16.58982671505257 }, "2018": { "obs_EconomicCapitalRatio": 5.458000746358346 }, "2019": { "obs_EconomicCapitalRatio": 2.484721409784232 }, "2020": { "obs_EconomicCapitalRatio": 1.3438452828795873 }, "2021": { "obs_EconomicCapitalRatio": 0.7957005830337637 }, "2022": { "obs_EconomicCapitalRatio": 0.7475072146889215 }, "2023": { "obs_EconomicCapitalRatio": 0.8688035841356281 } }, "0000275053": { "2011": { "obs_EconomicCapitalRatio": 1.2531988908057246 }, "2012": { "obs_EconomicCapitalRatio": 1.1558901920083584 }, "2013": { "obs_EconomicCapitalRatio": 1.4698845321423835 }, "2014": { "obs_EconomicCapitalRatio": 1.8506510041043027 }, "2015": { "obs_EconomicCapitalRatio": 1.3828122477889726 }, "2016": { "obs_EconomicCapitalRatio": 1.8800614803325786 }, "2017": { "obs_EconomicCapitalRatio": 1.5906624242068597 }, "2018": { "obs_EconomicCapitalRatio": 1.0639683885140225 }, "2019": { "obs_EconomicCapitalRatio": 1.1261240844321403 }, "2020": { "obs_EconomicCapitalRatio": 1.614631166398386 }, "2021": { "obs_EconomicCapitalRatio": 2.041252601886645 }, "2022": { "obs_EconomicCapitalRatio": 1.0248487934144268 }, "2023": { "obs_EconomicCapitalRatio": 1.9759150347492755 }, "2024": { "obs_EconomicCapitalRatio": 1.733962234691023 }, "2025": { "obs_EconomicCapitalRatio": 2.1266911651471774 } }, "0000315545": { "2011": { "obs_EconomicCapitalRatio": 9.728230006085877 }, "2012": { "obs_EconomicCapitalRatio": 15.887423730276764 }, "2016": { "obs_EconomicCapitalRatio": 1.0066834133413627 }, "2021": { "obs_EconomicCapitalRatio": 3.8900064558665526 }, "2022": { "obs_EconomicCapitalRatio": 8.87714792904606 }, "2023": { "obs_EconomicCapitalRatio": 7.797781413794207 }, "2024": { "obs_EconomicCapitalRatio": 12.847856868898074 }, "2025": { "obs_EconomicCapitalRatio": 6.551754447968051 } }, "0000318306": { "2011": { "obs_EconomicCapitalRatio": 3.1752133102955193 }, "2015": { "obs_EconomicCapitalRatio": 2.5013091166697334 }, "2016": { "obs_EconomicCapitalRatio": 3.069615158757255 }, "2017": { "obs_EconomicCapitalRatio": 7.910921427809256 }, "2018": { "obs_EconomicCapitalRatio": 3.0094651589500496 }, "2019": { "obs_EconomicCapitalRatio": 1.3725865674867888 }, "2020": { "obs_EconomicCapitalRatio": 1.5776662593509971 }, "2021": { "obs_EconomicCapitalRatio": 0.605095364063935 }, "2022": { "obs_EconomicCapitalRatio": 0.878496970737568 }, "2023": { "obs_EconomicCapitalRatio": 2.1538587998309753 }, "2024": { "obs_EconomicCapitalRatio": 2.8283640249010116 }, "2025": { "obs_EconomicCapitalRatio": 2.046279329648632 } }, "0000715446": { "2012": { "obs_EconomicCapitalRatio": 8.892991148763185 }, "2014": { "obs_EconomicCapitalRatio": 3.6906327637788694 }, "2015": { "obs_EconomicCapitalRatio": 3.876288621898964 }, "2017": { "obs_EconomicCapitalRatio": 7.917082397538187 }, "2018": { "obs_EconomicCapitalRatio": 18.202537277953734 }, "2019": { "obs_EconomicCapitalRatio": 15.15218182490549 }, "2020": { "obs_EconomicCapitalRatio": 12.697740921912375 }, "2021": { "obs_EconomicCapitalRatio": 4.776368566800651 }, "2022": { "obs_EconomicCapitalRatio": 7.387227293212897 }, "2023": { "obs_EconomicCapitalRatio": 8.690130111527727 }, "2024": { "obs_EconomicCapitalRatio": 6.821617650312289 }, "2025": { "obs_EconomicCapitalRatio": 11.76766152312355 } }, "0000748592": { "2011": { "obs_EconomicCapitalRatio": 0.0 }, "2012": { "obs_EconomicCapitalRatio": 0.0 }, "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 0.0 }, "2020": { "obs_EconomicCapitalRatio": 0.0 }, "2021": { "obs_EconomicCapitalRatio": 0.0 }, "2022": { "obs_EconomicCapitalRatio": 0.6925555190903209 }, "2023": { "obs_EconomicCapitalRatio": 0.22247029122106401 }, "2024": { "obs_EconomicCapitalRatio": 3.3355484422032364 }, "2025": { "obs_EconomicCapitalRatio": 2.100490419769073 } }, "0000749647": { "2011": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 1.2119887459957592 }, "2018": { "obs_EconomicCapitalRatio": 0.7571314740855524 }, "2019": { "obs_EconomicCapitalRatio": 1.1777291102712146 }, "2020": { "obs_EconomicCapitalRatio": 0.9468259412544934 }, "2022": { "obs_EconomicCapitalRatio": 0.3413380313211731 }, "2023": { "obs_EconomicCapitalRatio": 0.46505525070218745 }, "2024": { "obs_EconomicCapitalRatio": 1.5915148096808187 }, "2025": { "obs_EconomicCapitalRatio": 1.2902447483616575 } }, "0000791908": { "2011": { "obs_EconomicCapitalRatio": 0.5583856749916702 }, "2012": { "obs_EconomicCapitalRatio": 2.1709958491689902 }, "2013": { "obs_EconomicCapitalRatio": 4.620702296336393 }, "2014": { "obs_EconomicCapitalRatio": 4.499100115951777 }, "2015": { "obs_EconomicCapitalRatio": 2.1564470760800925 }, "2016": { "obs_EconomicCapitalRatio": 0.6280492703738663 }, "2017": { "obs_EconomicCapitalRatio": 6.4554819522962195 }, "2018": { "obs_EconomicCapitalRatio": 1.9052029000318187 }, "2019": { "obs_EconomicCapitalRatio": 3.265630189155313 }, "2020": { "obs_EconomicCapitalRatio": 5.954049697671537 }, "2021": { "obs_EconomicCapitalRatio": 2.601758183620559 }, "2022": { "obs_EconomicCapitalRatio": 2.5787179787158876 }, "2023": { "obs_EconomicCapitalRatio": 1.1152712280926076 } }, "0000812796": { "2011": { "obs_EconomicCapitalRatio": 0.0 }, "2012": { "obs_EconomicCapitalRatio": 0.0 }, "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 1.3457726017492695 }, "2017": { "obs_EconomicCapitalRatio": 2.662725746021708 }, "2018": { "obs_EconomicCapitalRatio": 1.0112986820465009 }, "2019": { "obs_EconomicCapitalRatio": 3.9109096857646555 }, "2020": { "obs_EconomicCapitalRatio": 2.1465813648935557 }, "2021": { "obs_EconomicCapitalRatio": 1.4351857012915932 }, "2022": { "obs_EconomicCapitalRatio": 1.6716849128061206 }, "2023": { "obs_EconomicCapitalRatio": 0.7417373755183468 }, "2024": { "obs_EconomicCapitalRatio": 1.0535798266037453 } }, "0000832489": { "2020": { "obs_EconomicCapitalRatio": 2.533577843676224 }, "2022": { "obs_EconomicCapitalRatio": 0.9397960609714056 }, "2023": { "obs_EconomicCapitalRatio": 1.6326053628418118 }, "2024": { "obs_EconomicCapitalRatio": 3.8621601278642066 }, "2025": { "obs_EconomicCapitalRatio": 1.1837070965076288 } }, "0000849146": { "2011": { "obs_EconomicCapitalRatio": 5.133799114691684 }, "2012": { "obs_EconomicCapitalRatio": 7.0759325639561705 }, "2013": { "obs_EconomicCapitalRatio": 3.8064085468765803 }, "2014": { "obs_EconomicCapitalRatio": 2.169949711761878 }, "2015": { "obs_EconomicCapitalRatio": 2.73458678948633 }, "2016": { "obs_EconomicCapitalRatio": 2.270039911669275 }, "2017": { "obs_EconomicCapitalRatio": 1.5925782016539693 }, "2018": { "obs_EconomicCapitalRatio": 3.884682222330364 }, "2019": { "obs_EconomicCapitalRatio": 4.525643174601984 }, "2020": { "obs_EconomicCapitalRatio": 2.824684450107507 }, "2021": { "obs_EconomicCapitalRatio": 1.2348824711451079 }, "2022": { "obs_EconomicCapitalRatio": 0.7537315251607775 }, "2023": { "obs_EconomicCapitalRatio": 1.5398212604493489 }, "2024": { "obs_EconomicCapitalRatio": 4.544921489881177 } }, "0000863894": { "2011": { "obs_EconomicCapitalRatio": 10.700068515838652 }, "2015": { "obs_EconomicCapitalRatio": 2.006174387707465 }, "2016": { "obs_EconomicCapitalRatio": 1.4325559018195881 }, "2017": { "obs_EconomicCapitalRatio": 2.1228772969992913 }, "2018": { "obs_EconomicCapitalRatio": 2.4982538018636133 }, "2019": { "obs_EconomicCapitalRatio": 5.21705955273325 }, "2020": { "obs_EconomicCapitalRatio": 16.967671288010344 }, "2021": { "obs_EconomicCapitalRatio": 4.876334264454306 }, "2022": { "obs_EconomicCapitalRatio": 4.237261674743829 }, "2023": { "obs_EconomicCapitalRatio": 1.6059750284116059 }, "2024": { "obs_EconomicCapitalRatio": 2.149766238076027 }, "2025": { "obs_EconomicCapitalRatio": 1.7665972830796772 } }, "0000879407": { "2011": { "obs_EconomicCapitalRatio": 4.558164646367193 }, "2012": { "obs_EconomicCapitalRatio": 2.7337420538024295 }, "2013": { "obs_EconomicCapitalRatio": 16.935793379415518 }, "2014": { "obs_EconomicCapitalRatio": 3.5359828982433434 }, "2015": { "obs_EconomicCapitalRatio": 4.70934763569825 }, "2016": { "obs_EconomicCapitalRatio": 1.3333215592276315 }, "2017": { "obs_EconomicCapitalRatio": 4.183361895725003 }, "2018": { "obs_EconomicCapitalRatio": 17.57601912062697 }, "2019": { "obs_EconomicCapitalRatio": 27.19874135672785 }, "2020": { "obs_EconomicCapitalRatio": 28.20740718699276 }, "2021": { "obs_EconomicCapitalRatio": 14.158611567248395 }, "2022": { "obs_EconomicCapitalRatio": 8.308844151619333 }, "2023": { "obs_EconomicCapitalRatio": 5.212086989973918 }, "2024": { "obs_EconomicCapitalRatio": 2.325391915553657 }, "2025": { "obs_EconomicCapitalRatio": 8.216237250704822 } }, "0000886163": { "2011": { "obs_EconomicCapitalRatio": 2.0528169474592 }, "2012": { "obs_EconomicCapitalRatio": 4.688551600471962 }, "2016": { "obs_EconomicCapitalRatio": 5.191668762826494 }, "2017": { "obs_EconomicCapitalRatio": 6.247336815338922 }, "2018": { "obs_EconomicCapitalRatio": 2.9187542937303745 }, "2019": { "obs_EconomicCapitalRatio": 1.6909103782381305 }, "2020": { "obs_EconomicCapitalRatio": 1.6235498567426718 }, "2021": { "obs_EconomicCapitalRatio": 2.9450386595365905 }, "2022": { "obs_EconomicCapitalRatio": 2.3986179476784764 }, "2025": { "obs_EconomicCapitalRatio": 3.675901913739014 } }, "0000886744": { "2011": { "obs_EconomicCapitalRatio": 2.1521859391249407 }, "2012": { "obs_EconomicCapitalRatio": 3.557226129775963 }, "2013": { "obs_EconomicCapitalRatio": 16.540241022155513 }, "2014": { "obs_EconomicCapitalRatio": 4.731529553667248 }, "2015": { "obs_EconomicCapitalRatio": 9.876524947988056 }, "2016": { "obs_EconomicCapitalRatio": 4.793318515735717 }, "2017": { "obs_EconomicCapitalRatio": 5.111053783735203 }, "2018": { "obs_EconomicCapitalRatio": 1.9713747376326156 }, "2019": { "obs_EconomicCapitalRatio": 2.9500565017262677 }, "2020": { "obs_EconomicCapitalRatio": 3.0435783432248256 }, "2021": { "obs_EconomicCapitalRatio": 2.6099809060401853 }, "2022": { "obs_EconomicCapitalRatio": 5.278895972838991 }, "2025": { "obs_EconomicCapitalRatio": 1.876268265003127 } }, "0000890821": { "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 0.0 }, "2023": { "obs_EconomicCapitalRatio": 0.0 }, "2024": { "obs_EconomicCapitalRatio": 0.0 } }, "0000897448": { "2011": { "obs_EconomicCapitalRatio": 7.060017923283657 } }, "0000899460": { "2011": { "obs_EconomicCapitalRatio": 0.987680321189219 }, "2012": { "obs_EconomicCapitalRatio": 1.7592520406979646 }, "2013": { "obs_EconomicCapitalRatio": 6.741934446075487 }, "2014": { "obs_EconomicCapitalRatio": 5.074493209423393 }, "2015": { "obs_EconomicCapitalRatio": 2.0503086064890024 }, "2016": { "obs_EconomicCapitalRatio": 1.6718936044598256 }, "2017": { "obs_EconomicCapitalRatio": 1.4830988576198576 }, "2018": { "obs_EconomicCapitalRatio": 0.9114209531413758 }, "2019": { "obs_EconomicCapitalRatio": 1.4635164586620224 }, "2020": { "obs_EconomicCapitalRatio": 3.966029438015374 }, "2021": { "obs_EconomicCapitalRatio": 2.5902381462411137 }, "2022": { "obs_EconomicCapitalRatio": 3.198017637267306 } }, "0000906709": { "2011": { "obs_EconomicCapitalRatio": 1.2198840615029938 }, "2012": { "obs_EconomicCapitalRatio": 1.7021961631875409 }, "2013": { "obs_EconomicCapitalRatio": 2.7465545409505356 }, "2014": { "obs_EconomicCapitalRatio": 4.680730778508984 }, "2015": { "obs_EconomicCapitalRatio": 4.5531019930727235 }, "2016": { "obs_EconomicCapitalRatio": 3.6584647178446996 }, "2017": { "obs_EconomicCapitalRatio": 19.71925223631124 }, "2018": { "obs_EconomicCapitalRatio": 4.447823678924978 }, "2019": { "obs_EconomicCapitalRatio": 2.9932544199314077 }, "2020": { "obs_EconomicCapitalRatio": 3.349493049250769 }, "2021": { "obs_EconomicCapitalRatio": 3.5440957945153957 }, "2022": { "obs_EconomicCapitalRatio": 0.8167920134851411 } }, "0000908259": { "2011": { "obs_EconomicCapitalRatio": 2.2928948216517826 }, "2012": { "obs_EconomicCapitalRatio": 29.962434305066648 }, "2013": { "obs_EconomicCapitalRatio": 1.8595490030165929 }, "2014": { "obs_EconomicCapitalRatio": 2.0938306536143934 }, "2018": { "obs_EconomicCapitalRatio": 3.38121902646468 }, "2019": { "obs_EconomicCapitalRatio": 0.9813033712527973 }, "2021": { "obs_EconomicCapitalRatio": 3.0536485439404255 }, "2022": { "obs_EconomicCapitalRatio": 0.7373792125771812 }, "2023": { "obs_EconomicCapitalRatio": 0.6595581698615146 }, "2024": { "obs_EconomicCapitalRatio": 0.5326676859160112 }, "2025": { "obs_EconomicCapitalRatio": 0.15128398062521595 } }, "0000944809": { "2011": { "obs_EconomicCapitalRatio": 10.212715569467793 }, "2012": { "obs_EconomicCapitalRatio": 7.462920051834949 }, "2013": { "obs_EconomicCapitalRatio": 3.7615161019547734 }, "2014": { "obs_EconomicCapitalRatio": 4.924906406362779 }, "2015": { "obs_EconomicCapitalRatio": 3.049230320818117 }, "2016": { "obs_EconomicCapitalRatio": 3.790950737489276 }, "2017": { "obs_EconomicCapitalRatio": 1.6797136409187279 }, "2018": { "obs_EconomicCapitalRatio": 1.000574746336909 }, "2019": { "obs_EconomicCapitalRatio": 0.6714096811879043 }, "2020": { "obs_EconomicCapitalRatio": 1.7371110357496995 }, "2021": { "obs_EconomicCapitalRatio": 2.095893547803228 }, "2022": { "obs_EconomicCapitalRatio": 0.6548492146984649 }, "2023": { "obs_EconomicCapitalRatio": 0.9273707539895665 }, "2024": { "obs_EconomicCapitalRatio": 0.6813640563694751 } }, "0001001316": { "2011": { "obs_EconomicCapitalRatio": 0.02094069371323602 }, "2014": { "obs_EconomicCapitalRatio": 15.082869869678678 }, "2016": { "obs_EconomicCapitalRatio": 7.018209109082157 }, "2017": { "obs_EconomicCapitalRatio": 9.289800999999851 }, "2018": { "obs_EconomicCapitalRatio": 4.428644142234769 }, "2019": { "obs_EconomicCapitalRatio": 7.527390932886038 }, "2020": { "obs_EconomicCapitalRatio": 19.08396570545782 }, "2021": { "obs_EconomicCapitalRatio": 10.30790574467113 } }, "0001016504": { "2011": { "obs_EconomicCapitalRatio": 0.035945261091117155 }, "2012": { "obs_EconomicCapitalRatio": 0.18525507371166935 }, "2013": { "obs_EconomicCapitalRatio": 0.22557068088200882 }, "2014": { "obs_EconomicCapitalRatio": 0.11401012787599316 }, "2015": { "obs_EconomicCapitalRatio": 0.1231491667258505 }, "2016": { "obs_EconomicCapitalRatio": 0.2446976706070115 }, "2017": { "obs_EconomicCapitalRatio": 0.20948385072936013 }, "2018": { "obs_EconomicCapitalRatio": 0.2563069722468672 }, "2019": { "obs_EconomicCapitalRatio": 0.37656625156663687 }, "2020": { "obs_EconomicCapitalRatio": 1.1464993618718018 }, "2021": { "obs_EconomicCapitalRatio": 1.697303158889242 }, "2022": { "obs_EconomicCapitalRatio": 0.7974054290207178 }, "2023": { "obs_EconomicCapitalRatio": 0.47029170963407396 }, "2024": { "obs_EconomicCapitalRatio": 0.580653182102171 } }, "0001023024": { "2025": { "obs_EconomicCapitalRatio": 1.5697482097453828 } }, "0001034842": { "2011": { "obs_EconomicCapitalRatio": 4.184973940587285 }, "2018": { "obs_EconomicCapitalRatio": 4.53448892985124 }, "2019": { "obs_EconomicCapitalRatio": 3.4290834421731513 }, "2020": { "obs_EconomicCapitalRatio": 8.246867354558892 }, "2021": { "obs_EconomicCapitalRatio": 4.014400705411107 }, "2022": { "obs_EconomicCapitalRatio": 1.531292181419975 }, "2023": { "obs_EconomicCapitalRatio": 1.782837907433584 }, "2024": { "obs_EconomicCapitalRatio": 1.8533923185575185 } }, "0001041024": { "2011": { "obs_EconomicCapitalRatio": 6.864401419926169 }, "2012": { "obs_EconomicCapitalRatio": 7.665477298235786 }, "2013": { "obs_EconomicCapitalRatio": 16.200961448783545 }, "2014": { "obs_EconomicCapitalRatio": 6.823227479640062 }, "2015": { "obs_EconomicCapitalRatio": 10.781551495937341 }, "2016": { "obs_EconomicCapitalRatio": 7.080561630250149 }, "2017": { "obs_EconomicCapitalRatio": 9.204121624289595 }, "2018": { "obs_EconomicCapitalRatio": 3.7248376391274483 }, "2019": { "obs_EconomicCapitalRatio": 4.411810117408765 }, "2020": { "obs_EconomicCapitalRatio": 1.534718360025618 }, "2021": { "obs_EconomicCapitalRatio": 0.7865871894137169 }, "2022": { "obs_EconomicCapitalRatio": 0.2909490633684185 }, "2023": { "obs_EconomicCapitalRatio": 1.2794707220084427 }, "2024": { "obs_EconomicCapitalRatio": 1.5814864872422232 } }, "0001061983": { "2011": { "obs_EconomicCapitalRatio": 2.499653747304144 }, "2012": { "obs_EconomicCapitalRatio": 2.265925122836351 }, "2013": { "obs_EconomicCapitalRatio": 3.4818397980547005 }, "2014": { "obs_EconomicCapitalRatio": 2.398166528838458 }, "2015": { "obs_EconomicCapitalRatio": 5.132953958619455 }, "2016": { "obs_EconomicCapitalRatio": 4.003531368306603 }, "2017": { "obs_EconomicCapitalRatio": 1.886835990998462 }, "2018": { "obs_EconomicCapitalRatio": 1.7279073639824796 }, "2019": { "obs_EconomicCapitalRatio": 2.0578846433493947 }, "2020": { "obs_EconomicCapitalRatio": 3.0945606278198854 }, "2021": { "obs_EconomicCapitalRatio": 5.258808656390064 }, "2022": { "obs_EconomicCapitalRatio": 4.01908917413911 } }, "0001062822": { "2011": { "obs_EconomicCapitalRatio": 1.3677650735673388 }, "2012": { "obs_EconomicCapitalRatio": 4.183731183292958 }, "2013": { "obs_EconomicCapitalRatio": 4.9070900906027735 }, "2014": { "obs_EconomicCapitalRatio": 1.4003761344938945 }, "2015": { "obs_EconomicCapitalRatio": 2.704397422234801 }, "2017": { "obs_EconomicCapitalRatio": 2.617264752541097 }, "2018": { "obs_EconomicCapitalRatio": 2.3298433436614046 }, "2019": { "obs_EconomicCapitalRatio": 1.2634354219312478 }, "2020": { "obs_EconomicCapitalRatio": 3.9708097565733844 }, "2021": { "obs_EconomicCapitalRatio": 7.685335401596773 }, "2022": { "obs_EconomicCapitalRatio": 2.688334739503511 }, "2023": { "obs_EconomicCapitalRatio": 1.727707860094187 }, "2024": { "obs_EconomicCapitalRatio": 1.1785439552715242 }, "2025": { "obs_EconomicCapitalRatio": 3.254076663809848 } }, "0001069530": { "2011": { "obs_EconomicCapitalRatio": 1.6920367721878569 }, "2012": { "obs_EconomicCapitalRatio": 2.353113921576425 }, "2013": { "obs_EconomicCapitalRatio": 8.035629301696703 }, "2014": { "obs_EconomicCapitalRatio": 4.453386467914091 }, "2015": { "obs_EconomicCapitalRatio": 4.863351449111631 }, "2016": { "obs_EconomicCapitalRatio": 2.8915258260504832 }, "2017": { "obs_EconomicCapitalRatio": 4.636648807456758 }, "2018": { "obs_EconomicCapitalRatio": 1.4092308454695395 }, "2019": { "obs_EconomicCapitalRatio": 5.275240949415371 }, "2020": { "obs_EconomicCapitalRatio": 3.988044196645427 }, "2021": { "obs_EconomicCapitalRatio": 12.502340699582172 }, "2022": { "obs_EconomicCapitalRatio": 10.744987341161343 }, "2023": { "obs_EconomicCapitalRatio": 12.416401043316418 }, "2024": { "obs_EconomicCapitalRatio": 1.3663714024841915 }, "2025": { "obs_EconomicCapitalRatio": 1.3036319444534121 } }, "0001070494": { "2011": { "obs_EconomicCapitalRatio": 2.932953680881476 }, "2012": { "obs_EconomicCapitalRatio": 4.5529405778863055 }, "2013": { "obs_EconomicCapitalRatio": 23.302183453643206 }, "2014": { "obs_EconomicCapitalRatio": 18.54984696092805 }, "2015": { "obs_EconomicCapitalRatio": 28.934092219944826 }, "2016": { "obs_EconomicCapitalRatio": 11.449655133128285 }, "2017": { "obs_EconomicCapitalRatio": 16.67808614739591 }, "2018": { "obs_EconomicCapitalRatio": 6.5373853496850005 }, "2019": { "obs_EconomicCapitalRatio": 15.725238773169458 }, "2020": { "obs_EconomicCapitalRatio": 18.655998772273424 }, "2021": { "obs_EconomicCapitalRatio": 9.02784999201308 }, "2022": { "obs_EconomicCapitalRatio": 6.442054975572726 } }, "0001087294": { "2011": { "obs_EconomicCapitalRatio": 2.133325711370675 }, "2012": { "obs_EconomicCapitalRatio": 1.4741118648312574 }, "2013": { "obs_EconomicCapitalRatio": 1.9420121698610198 }, "2014": { "obs_EconomicCapitalRatio": 1.8405724060005366 }, "2016": { "obs_EconomicCapitalRatio": 1.5541808322415878 }, "2017": { "obs_EconomicCapitalRatio": 1.889112943592727 }, "2018": { "obs_EconomicCapitalRatio": 1.1292501763391123 }, "2019": { "obs_EconomicCapitalRatio": 0.9859121896587316 }, "2021": { "obs_EconomicCapitalRatio": 1.0973775649988797 }, "2022": { "obs_EconomicCapitalRatio": 0.4333168488598409 }, "2023": { "obs_EconomicCapitalRatio": 0.3715399695981037 }, "2024": { "obs_EconomicCapitalRatio": 0.5087599565594081 }, "2025": { "obs_EconomicCapitalRatio": 0.963869140200575 } }, "0001088856": { "2011": { "obs_EconomicCapitalRatio": 12.880945590095282 }, "2012": { "obs_EconomicCapitalRatio": 2.840563583246527 }, "2013": { "obs_EconomicCapitalRatio": 7.846638973918242 }, "2014": { "obs_EconomicCapitalRatio": 12.810210834279417 }, "2015": { "obs_EconomicCapitalRatio": 14.759813082944229 }, "2016": { "obs_EconomicCapitalRatio": 18.296036223725203 }, "2017": { "obs_EconomicCapitalRatio": 16.029930900609163 }, "2018": { "obs_EconomicCapitalRatio": 8.65608179405391 }, "2019": { "obs_EconomicCapitalRatio": 6.358701486657653 }, "2020": { "obs_EconomicCapitalRatio": 9.972013421558033 }, "2021": { "obs_EconomicCapitalRatio": 9.64819974668179 }, "2022": { "obs_EconomicCapitalRatio": 6.602885091667568 }, "2023": { "obs_EconomicCapitalRatio": 8.970790437540055 }, "2024": { "obs_EconomicCapitalRatio": 10.835124023970803 }, "2025": { "obs_EconomicCapitalRatio": 16.849652464590477 } }, "0001094038": { "2017": { "obs_EconomicCapitalRatio": 12.248591009591806 }, "2022": { "obs_EconomicCapitalRatio": 0.9337214180332358 }, "2023": { "obs_EconomicCapitalRatio": 3.7356145408172226 } }, "0001107421": { "2011": { "obs_EconomicCapitalRatio": 4.3489446663070765 }, "2012": { "obs_EconomicCapitalRatio": 5.827030060175055 }, "2018": { "obs_EconomicCapitalRatio": 5.6631567818400965 }, "2020": { "obs_EconomicCapitalRatio": 7.575407591507219 }, "2021": { "obs_EconomicCapitalRatio": 4.171108524583441 }, "2022": { "obs_EconomicCapitalRatio": 2.883405722314086 } }, "0001124105": { "2011": { "obs_EconomicCapitalRatio": 0.20196174709409623 }, "2012": { "obs_EconomicCapitalRatio": 0.2876341525006027 }, "2013": { "obs_EconomicCapitalRatio": 0.33472830653949776 }, "2015": { "obs_EconomicCapitalRatio": 0.07621137264136414 }, "2016": { "obs_EconomicCapitalRatio": 0.039853488863282854 }, "2017": { "obs_EconomicCapitalRatio": 0.3820750886265207 }, "2018": { "obs_EconomicCapitalRatio": 0.2297698596314896 }, "2019": { "obs_EconomicCapitalRatio": 0.2159376702997681 }, "2020": { "obs_EconomicCapitalRatio": 0.41223677548471455 }, "2021": { "obs_EconomicCapitalRatio": 0.143358984955954 }, "2022": { "obs_EconomicCapitalRatio": 0.43278504174366134 } }, "0001124524": { "2011": { "obs_EconomicCapitalRatio": 2.4648333091878083 }, "2012": { "obs_EconomicCapitalRatio": 1.8593608580180503 }, "2013": { "obs_EconomicCapitalRatio": 7.3656864720939925 }, "2014": { "obs_EconomicCapitalRatio": 8.359677065323194 }, "2015": { "obs_EconomicCapitalRatio": 5.583052291948538 }, "2017": { "obs_EconomicCapitalRatio": 19.729762301247288 }, "2018": { "obs_EconomicCapitalRatio": 7.676546478299643 }, "2020": { "obs_EconomicCapitalRatio": 5.19008689022509 }, "2021": { "obs_EconomicCapitalRatio": 3.4190316765012354 }, "2022": { "obs_EconomicCapitalRatio": 1.09260354339657 }, "2023": { "obs_EconomicCapitalRatio": 1.0997798689853466 } }, "0001130166": { "2011": { "obs_EconomicCapitalRatio": 0.0 }, "2012": { "obs_EconomicCapitalRatio": 0.0 }, "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 } }, "0001133416": { "2011": { "obs_EconomicCapitalRatio": 16.88270157281871 }, "2012": { "obs_EconomicCapitalRatio": 5.842248119350461 }, "2013": { "obs_EconomicCapitalRatio": 22.267375550627374 }, "2018": { "obs_EconomicCapitalRatio": 27.945147556095687 }, "2019": { "obs_EconomicCapitalRatio": 6.382354795772914 }, "2020": { "obs_EconomicCapitalRatio": 7.956581110405078 }, "2021": { "obs_EconomicCapitalRatio": 3.287870628790478 }, "2022": { "obs_EconomicCapitalRatio": 1.8599439115005227 }, "2023": { "obs_EconomicCapitalRatio": 1.7657258004588605 }, "2025": { "obs_EconomicCapitalRatio": 3.119665476127909 } }, "0001133818": { "2011": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 1.8441117010428738 }, "2019": { "obs_EconomicCapitalRatio": 1.9003845840591052 }, "2020": { "obs_EconomicCapitalRatio": 1.8771993245543837 }, "2021": { "obs_EconomicCapitalRatio": 2.175547460076075 }, "2022": { "obs_EconomicCapitalRatio": 1.254415758667267 }, "2023": { "obs_EconomicCapitalRatio": 1.9355732103322663 } }, "0001160308": { "2017": { "obs_EconomicCapitalRatio": 4.745640338481788 }, "2018": { "obs_EconomicCapitalRatio": 2.608425955539138 }, "2019": { "obs_EconomicCapitalRatio": 0.8425161535078196 }, "2020": { "obs_EconomicCapitalRatio": 1.0736826396507102 }, "2021": { "obs_EconomicCapitalRatio": 1.3531258013583032 }, "2022": { "obs_EconomicCapitalRatio": 1.9983725428604209 } }, "0001174940": { "2011": { "obs_EconomicCapitalRatio": 0.0 }, "2012": { "obs_EconomicCapitalRatio": 0.0 }, "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2021": { "obs_EconomicCapitalRatio": 6.639869177624493 }, "2022": { "obs_EconomicCapitalRatio": 3.4580165138523955 }, "2023": { "obs_EconomicCapitalRatio": 4.027329150416326 }, "2024": { "obs_EconomicCapitalRatio": 2.8724066451160235 }, "2025": { "obs_EconomicCapitalRatio": 0.5801836078992786 } }, "0001175680": { "2012": { "obs_EconomicCapitalRatio": 11.990129245785083 }, "2013": { "obs_EconomicCapitalRatio": 12.895495155433496 }, "2018": { "obs_EconomicCapitalRatio": 12.37742571335845 }, "2019": { "obs_EconomicCapitalRatio": 10.798161833204716 }, "2020": { "obs_EconomicCapitalRatio": 60.212585469417306 }, "2021": { "obs_EconomicCapitalRatio": 4.985942038812679 }, "2022": { "obs_EconomicCapitalRatio": 2.6172100457911642 }, "2023": { "obs_EconomicCapitalRatio": 3.114671171984183 } }, "0001226616": { "2011": { "obs_EconomicCapitalRatio": 1.537941564786132 }, "2012": { "obs_EconomicCapitalRatio": 2.3546405810486153 }, "2013": { "obs_EconomicCapitalRatio": 2.8607221186039924 }, "2014": { "obs_EconomicCapitalRatio": 4.577912758120495 }, "2015": { "obs_EconomicCapitalRatio": 4.904665514441517 }, "2016": { "obs_EconomicCapitalRatio": 10.416358307263954 }, "2017": { "obs_EconomicCapitalRatio": 10.052119682955091 }, "2018": { "obs_EconomicCapitalRatio": 8.212750684667608 }, "2019": { "obs_EconomicCapitalRatio": 7.170880167965075 }, "2020": { "obs_EconomicCapitalRatio": 6.36238702776273 }, "2021": { "obs_EconomicCapitalRatio": 2.9543530255773915 }, "2022": { "obs_EconomicCapitalRatio": 2.575833676860721 } }, "0001228627": { "2011": { "obs_EconomicCapitalRatio": 4.8858943708985025 }, "2012": { "obs_EconomicCapitalRatio": 2.6145991303811 }, "2013": { "obs_EconomicCapitalRatio": 5.051688102935165 }, "2014": { "obs_EconomicCapitalRatio": 6.044271975481872 }, "2015": { "obs_EconomicCapitalRatio": 4.276801962477386 }, "2016": { "obs_EconomicCapitalRatio": 2.731363504841381 }, "2017": { "obs_EconomicCapitalRatio": 3.285683833578194 }, "2018": { "obs_EconomicCapitalRatio": 3.49693809277238 }, "2019": { "obs_EconomicCapitalRatio": 0.9733713874489118 }, "2021": { "obs_EconomicCapitalRatio": 4.329166205231533 }, "2022": { "obs_EconomicCapitalRatio": 2.1231238489802973 }, "2023": { "obs_EconomicCapitalRatio": 2.1080021065509533 } }, "0001232524": { "2011": { "obs_EconomicCapitalRatio": 10.532355239038857 }, "2013": { "obs_EconomicCapitalRatio": 5.889833169313314 }, "2014": { "obs_EconomicCapitalRatio": 5.64349843494089 }, "2015": { "obs_EconomicCapitalRatio": 4.871215974868773 }, "2016": { "obs_EconomicCapitalRatio": 2.5562075124184336 }, "2017": { "obs_EconomicCapitalRatio": 2.9738332853576335 }, "2018": { "obs_EconomicCapitalRatio": 2.6756193268421327 }, "2019": { "obs_EconomicCapitalRatio": 2.9055945060951887 }, "2020": { "obs_EconomicCapitalRatio": 2.4278244366726334 }, "2021": { "obs_EconomicCapitalRatio": 1.1999951953961885 }, "2022": { "obs_EconomicCapitalRatio": 1.6900419826766677 }, "2023": { "obs_EconomicCapitalRatio": 1.1819590371878657 }, "2024": { "obs_EconomicCapitalRatio": 1.1400872089425345 }, "2025": { "obs_EconomicCapitalRatio": 1.4846995550060347 } }, "0001262104": { "2011": { "obs_EconomicCapitalRatio": 2.976131474060693 }, "2012": { "obs_EconomicCapitalRatio": 29.84004095620544 }, "2013": { "obs_EconomicCapitalRatio": 7.194268741361899 }, "2016": { "obs_EconomicCapitalRatio": 1.5454523453078879 }, "2017": { "obs_EconomicCapitalRatio": 1.9367829777284602 }, "2018": { "obs_EconomicCapitalRatio": 1.450311890880624 }, "2019": { "obs_EconomicCapitalRatio": 1.9689337997298595 }, "2020": { "obs_EconomicCapitalRatio": 1.4548882386917967 }, "2021": { "obs_EconomicCapitalRatio": 1.4860588196065856 }, "2022": { "obs_EconomicCapitalRatio": 0.17066667598512655 } }, "0001279704": { "2011": { "obs_EconomicCapitalRatio": 0.0 }, "2012": { "obs_EconomicCapitalRatio": 0.0 }, "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.7802934836126804 }, "2019": { "obs_EconomicCapitalRatio": 2.409518801482663 }, "2020": { "obs_EconomicCapitalRatio": 1.6673740926374905 }, "2021": { "obs_EconomicCapitalRatio": 1.8215826030676574 }, "2022": { "obs_EconomicCapitalRatio": 1.0140222570705515 } }, "0001285819": { "2011": { "obs_EconomicCapitalRatio": 3.9008953991679225 }, "2012": { "obs_EconomicCapitalRatio": 8.856529930836997 }, "2013": { "obs_EconomicCapitalRatio": 23.416633068756767 }, "2014": { "obs_EconomicCapitalRatio": 52.38187959476351 }, "2015": { "obs_EconomicCapitalRatio": 17.417008725890156 }, "2016": { "obs_EconomicCapitalRatio": 10.493546623850774 }, "2017": { "obs_EconomicCapitalRatio": 13.17928717267996 }, "2018": { "obs_EconomicCapitalRatio": 8.556002006090099 }, "2019": { "obs_EconomicCapitalRatio": 7.515377707617327 }, "2020": { "obs_EconomicCapitalRatio": 8.340041355471396 }, "2021": { "obs_EconomicCapitalRatio": 1.9397706515990498 }, "2022": { "obs_EconomicCapitalRatio": 0.383787450562039 }, "2023": { "obs_EconomicCapitalRatio": 0.9380626426710665 }, "2024": { "obs_EconomicCapitalRatio": 3.267956572971576 }, "2025": { "obs_EconomicCapitalRatio": 4.383705131472446 } }, "0001326190": { "2017": { "obs_EconomicCapitalRatio": 0.6508211474874072 }, "2018": { "obs_EconomicCapitalRatio": 0.5494527370680612 }, "2019": { "obs_EconomicCapitalRatio": 0.8698678361974307 }, "2020": { "obs_EconomicCapitalRatio": 2.992421119800507 }, "2021": { "obs_EconomicCapitalRatio": 3.0562409786664384 }, "2022": { "obs_EconomicCapitalRatio": 6.357729243605622 }, "2023": { "obs_EconomicCapitalRatio": 4.155348811357878 } }, "0001347178": { "2011": { "obs_EconomicCapitalRatio": 0.7547629174581635 }, "2012": { "obs_EconomicCapitalRatio": 0.8349347296948693 }, "2013": { "obs_EconomicCapitalRatio": 3.200328803096651 }, "2014": { "obs_EconomicCapitalRatio": 5.1801032398517055 }, "2015": { "obs_EconomicCapitalRatio": 2.784492138224985 }, "2016": { "obs_EconomicCapitalRatio": 4.859040274237193 }, "2017": { "obs_EconomicCapitalRatio": 4.847027555030574 }, "2018": { "obs_EconomicCapitalRatio": 6.838860800683274 }, "2019": { "obs_EconomicCapitalRatio": 3.2008903413809926 }, "2020": { "obs_EconomicCapitalRatio": 2.368962168982374 }, "2021": { "obs_EconomicCapitalRatio": 2.7331520944826213 }, "2022": { "obs_EconomicCapitalRatio": 1.0969963189923904 }, "2023": { "obs_EconomicCapitalRatio": 0.6082415452655552 }, "2024": { "obs_EconomicCapitalRatio": 0.7203169054780709 }, "2025": { "obs_EconomicCapitalRatio": 1.2660125487260627 } }, "0001348362": { "2021": { "obs_EconomicCapitalRatio": 3.688977745827279 }, "2022": { "obs_EconomicCapitalRatio": 3.6289445963532447 }, "2023": { "obs_EconomicCapitalRatio": 7.572181575460779 }, "2024": { "obs_EconomicCapitalRatio": 7.638141696833459 }, "2025": { "obs_EconomicCapitalRatio": 4.640465465175871 } }, "0001355790": { "2011": { "obs_EconomicCapitalRatio": 9.179995649598776 }, "2012": { "obs_EconomicCapitalRatio": 4.978283029972212 }, "2013": { "obs_EconomicCapitalRatio": 4.670844633739837 }, "2014": { "obs_EconomicCapitalRatio": 2.3489847354135502 }, "2015": { "obs_EconomicCapitalRatio": 1.3378663555234789 }, "2016": { "obs_EconomicCapitalRatio": 0.7698728160811572 }, "2017": { "obs_EconomicCapitalRatio": 1.1388606479717176 }, "2018": { "obs_EconomicCapitalRatio": 1.5664269146568608 }, "2019": { "obs_EconomicCapitalRatio": 0.630516760385617 }, "2020": { "obs_EconomicCapitalRatio": 0.6396888771805517 }, "2021": { "obs_EconomicCapitalRatio": 0.6840686118043124 }, "2022": { "obs_EconomicCapitalRatio": 0.267067323314091 } }, "0001360214": { "2012": { "obs_EconomicCapitalRatio": 11.271163127854932 }, "2014": { "obs_EconomicCapitalRatio": 11.638297387028627 }, "2015": { "obs_EconomicCapitalRatio": 4.6241476669712975 }, "2016": { "obs_EconomicCapitalRatio": 1.3484853410256559 }, "2017": { "obs_EconomicCapitalRatio": 1.4895887864053496 }, "2018": { "obs_EconomicCapitalRatio": 3.139266496743132 }, "2019": { "obs_EconomicCapitalRatio": 4.022032566775388 }, "2021": { "obs_EconomicCapitalRatio": 2.5406885482118433 }, "2022": { "obs_EconomicCapitalRatio": 2.6086812218171045 }, "2023": { "obs_EconomicCapitalRatio": 1.3459592890349485 }, "2024": { "obs_EconomicCapitalRatio": 3.4220324055830136 }, "2025": { "obs_EconomicCapitalRatio": 4.8861055897922885 } }, "0001367083": { "2011": { "obs_EconomicCapitalRatio": 0.0 }, "2012": { "obs_EconomicCapitalRatio": 0.0 }, "2013": { "obs_EconomicCapitalRatio": 1.994470946458264 }, "2014": { "obs_EconomicCapitalRatio": 0.7868720336054744 }, "2015": { "obs_EconomicCapitalRatio": 1.891607107582308 }, "2016": { "obs_EconomicCapitalRatio": 2.6568269721745104 }, "2017": { "obs_EconomicCapitalRatio": 1.5709904421686274 }, "2018": { "obs_EconomicCapitalRatio": 0.42252706083525265 }, "2019": { "obs_EconomicCapitalRatio": 0.6068179714239148 }, "2020": { "obs_EconomicCapitalRatio": 1.4163627569047794 }, "2021": { "obs_EconomicCapitalRatio": 1.2007561835223088 }, "2022": { "obs_EconomicCapitalRatio": 0.24080595316110787 }, "2023": { "obs_EconomicCapitalRatio": 0.17877829794683045 }, "2024": { "obs_EconomicCapitalRatio": 0.30807278696085183 }, "2025": { "obs_EconomicCapitalRatio": 0.5338305819074114 } }, "0001367644": { "2011": { "obs_EconomicCapitalRatio": 1.7976370649598783 }, "2012": { "obs_EconomicCapitalRatio": 1.6553627727050257 }, "2013": { "obs_EconomicCapitalRatio": 2.2274553933987518 }, "2014": { "obs_EconomicCapitalRatio": 1.5230589567105508 }, "2015": { "obs_EconomicCapitalRatio": 2.1371256774520164 }, "2016": { "obs_EconomicCapitalRatio": 2.0215611137578677 }, "2017": { "obs_EconomicCapitalRatio": 3.1513393230994735 }, "2019": { "obs_EconomicCapitalRatio": 1.5667597014802146 }, "2020": { "obs_EconomicCapitalRatio": 2.302469812906637 }, "2021": { "obs_EconomicCapitalRatio": 1.1285330392970574 }, "2022": { "obs_EconomicCapitalRatio": 0.22635234499274465 }, "2023": { "obs_EconomicCapitalRatio": 0.08309536561881938 }, "2024": { "obs_EconomicCapitalRatio": 0.39093964867994657 }, "2025": { "obs_EconomicCapitalRatio": 0.6154566792280605 } }, "0001369568": { "2011": { "obs_EconomicCapitalRatio": 6.3889201791876715 }, "2012": { "obs_EconomicCapitalRatio": 1.6500315683457198 }, "2013": { "obs_EconomicCapitalRatio": 7.24899447590868 }, "2014": { "obs_EconomicCapitalRatio": 7.717318407302692 }, "2015": { "obs_EconomicCapitalRatio": 6.397961577879862 }, "2016": { "obs_EconomicCapitalRatio": 4.096110143541204 }, "2017": { "obs_EconomicCapitalRatio": 7.592382758094557 }, "2018": { "obs_EconomicCapitalRatio": 5.934355974386351 }, "2019": { "obs_EconomicCapitalRatio": 5.80155007335537 }, "2020": { "obs_EconomicCapitalRatio": 3.295770377836332 }, "2021": { "obs_EconomicCapitalRatio": 5.317984424463229 }, "2022": { "obs_EconomicCapitalRatio": 8.584912933619535 }, "2023": { "obs_EconomicCapitalRatio": 6.301951486531034 } }, "0001379006": { "2012": { "obs_EconomicCapitalRatio": 8.82692233269271 }, "2014": { "obs_EconomicCapitalRatio": 5.005091122551198 }, "2015": { "obs_EconomicCapitalRatio": 2.279453044698694 }, "2016": { "obs_EconomicCapitalRatio": 2.6540924954040306 }, "2017": { "obs_EconomicCapitalRatio": 3.610151360278 }, "2018": { "obs_EconomicCapitalRatio": 1.999905258053884 }, "2019": { "obs_EconomicCapitalRatio": 1.2415729695877673 }, "2020": { "obs_EconomicCapitalRatio": 2.8594669245643027 }, "2021": { "obs_EconomicCapitalRatio": 2.974100414432412 }, "2022": { "obs_EconomicCapitalRatio": 1.1703385171652987 } }, "0001385818": { "2011": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.47539841134977767 }, "2019": { "obs_EconomicCapitalRatio": 0.6184507895794792 }, "2020": { "obs_EconomicCapitalRatio": 7.419178312245873 }, "2021": { "obs_EconomicCapitalRatio": 0.21444895471445116 }, "2022": { "obs_EconomicCapitalRatio": 0.10542865791319143 }, "2023": { "obs_EconomicCapitalRatio": 0.13920572699943723 }, "2024": { "obs_EconomicCapitalRatio": 0.08701631303291904 } }, "0001390478": { "2011": { "obs_EconomicCapitalRatio": 0.0 }, "2012": { "obs_EconomicCapitalRatio": 0.0 }, "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 13.057185525906862 }, "2017": { "obs_EconomicCapitalRatio": 0.5909151161860207 }, "2018": { "obs_EconomicCapitalRatio": 1.957224034983383 }, "2019": { "obs_EconomicCapitalRatio": 1.4332895378611077 }, "2021": { "obs_EconomicCapitalRatio": 5.6975438796109055 }, "2022": { "obs_EconomicCapitalRatio": 2.5238461075906766 }, "2023": { "obs_EconomicCapitalRatio": 3.471029264381213 }, "2024": { "obs_EconomicCapitalRatio": 4.405008459786115 } }, "0001401667": { "2012": { "obs_EconomicCapitalRatio": 6.208129575901305 }, "2013": { "obs_EconomicCapitalRatio": 47.28546182478878 }, "2016": { "obs_EconomicCapitalRatio": 8.166416840300958 }, "2017": { "obs_EconomicCapitalRatio": 26.524215277890093 }, "2018": { "obs_EconomicCapitalRatio": 3.3687600343432424 }, "2019": { "obs_EconomicCapitalRatio": 1.515901568624176 }, "2020": { "obs_EconomicCapitalRatio": 1.793524192155767 }, "2022": { "obs_EconomicCapitalRatio": 0.9862356814586613 }, "2023": { "obs_EconomicCapitalRatio": 0.9476593306311685 }, "2024": { "obs_EconomicCapitalRatio": 0.8715847856281287 }, "2025": { "obs_EconomicCapitalRatio": 1.9772070498623269 } }, "0001410098": { "2011": { "obs_EconomicCapitalRatio": 1.707348625435781 }, "2012": { "obs_EconomicCapitalRatio": 5.495184693083727 }, "2013": { "obs_EconomicCapitalRatio": 3.5549801222373585 }, "2014": { "obs_EconomicCapitalRatio": 10.54156882709548 }, "2015": { "obs_EconomicCapitalRatio": 3.5823663057939346 }, "2016": { "obs_EconomicCapitalRatio": 5.255700805598911 }, "2017": { "obs_EconomicCapitalRatio": 3.8414521129507024 }, "2018": { "obs_EconomicCapitalRatio": 8.20786823667722 }, "2022": { "obs_EconomicCapitalRatio": 4.731337422878887 } }, "0001427925": { "2011": { "obs_EconomicCapitalRatio": 1.3034921695309352 }, "2012": { "obs_EconomicCapitalRatio": 1.8794397350645533 }, "2013": { "obs_EconomicCapitalRatio": 6.190613990895643 }, "2014": { "obs_EconomicCapitalRatio": 4.632558275150405 }, "2015": { "obs_EconomicCapitalRatio": 1.6283040693257576 }, "2020": { "obs_EconomicCapitalRatio": 1.2009877482213018 }, "2021": { "obs_EconomicCapitalRatio": 0.6909657662137705 }, "2022": { "obs_EconomicCapitalRatio": 0.43682041596359344 }, "2023": { "obs_EconomicCapitalRatio": 0.98467364218298 }, "2024": { "obs_EconomicCapitalRatio": 0.7297125653194421 }, "2025": { "obs_EconomicCapitalRatio": 2.4292445713278736 } }, "0001429260": { "2011": { "obs_EconomicCapitalRatio": 3.253092521290889 }, "2015": { "obs_EconomicCapitalRatio": 1.6662457324617772 }, "2016": { "obs_EconomicCapitalRatio": 0.8588979539480799 }, "2018": { "obs_EconomicCapitalRatio": 0.35840342417624116 }, "2019": { "obs_EconomicCapitalRatio": 0.9183721904509325 } }, "0001520262": { "2011": { "obs_EconomicCapitalRatio": 8.732023309477322 }, "2012": { "obs_EconomicCapitalRatio": 2.517461855559167 }, "2021": { "obs_EconomicCapitalRatio": 2.592124046221965 }, "2022": { "obs_EconomicCapitalRatio": 2.9128639481286616 } }, "0000034956": { "2012": { "obs_EconomicCapitalRatio": 0.0 }, "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.3540114054548826 }, "2019": { "obs_EconomicCapitalRatio": 2.8899991460190257 }, "2020": { "obs_EconomicCapitalRatio": 4.897165306601755 }, "2022": { "obs_EconomicCapitalRatio": 3.2820129462831895 } }, "0001010086": { "2012": { "obs_EconomicCapitalRatio": 0.9648025582518476 }, "2013": { "obs_EconomicCapitalRatio": 0.6122333166847467 }, "2014": { "obs_EconomicCapitalRatio": 0.17171419351669243 }, "2015": { "obs_EconomicCapitalRatio": 0.0432894554129469 }, "2016": { "obs_EconomicCapitalRatio": 0.3312190917217559 }, "2017": { "obs_EconomicCapitalRatio": 0.8228692095294068 }, "2018": { "obs_EconomicCapitalRatio": 2.367189708200457 }, "2019": { "obs_EconomicCapitalRatio": 1.6709424646890423 }, "2020": { "obs_EconomicCapitalRatio": 4.320985928424905 }, "2021": { "obs_EconomicCapitalRatio": 2.8752768361840704 }, "2022": { "obs_EconomicCapitalRatio": 3.4587745773706 }, "2023": { "obs_EconomicCapitalRatio": 1.9068535975232734 }, "2024": { "obs_EconomicCapitalRatio": 2.5027926004205803 }, "2025": { "obs_EconomicCapitalRatio": 3.3031185345796064 } }, "0001053369": { "2012": { "obs_EconomicCapitalRatio": 1.6726245064737015 }, "2013": { "obs_EconomicCapitalRatio": 3.942127979494112 }, "2014": { "obs_EconomicCapitalRatio": 2.3327765420151856 }, "2015": { "obs_EconomicCapitalRatio": 10.622213853856026 }, "2019": { "obs_EconomicCapitalRatio": 4.007498141213826 }, "2021": { "obs_EconomicCapitalRatio": 1.6749061695400072 }, "2022": { "obs_EconomicCapitalRatio": 1.3496143238340297 }, "2023": { "obs_EconomicCapitalRatio": 5.373588498873877 }, "2024": { "obs_EconomicCapitalRatio": 10.709577886668663 }, "2025": { "obs_EconomicCapitalRatio": 7.561446798527235 } }, "0001072379": { "2012": { "obs_EconomicCapitalRatio": 4.228018601326807 }, "2013": { "obs_EconomicCapitalRatio": 7.2865613000880245 }, "2014": { "obs_EconomicCapitalRatio": 4.52993998077677 }, "2015": { "obs_EconomicCapitalRatio": 4.527295199401648 }, "2016": { "obs_EconomicCapitalRatio": 0.6543832260773149 }, "2017": { "obs_EconomicCapitalRatio": 1.0230629448163566 }, "2018": { "obs_EconomicCapitalRatio": 2.3408783084374467 }, "2019": { "obs_EconomicCapitalRatio": 4.249206486316114 }, "2020": { "obs_EconomicCapitalRatio": 5.050165155650398 }, "2022": { "obs_EconomicCapitalRatio": 10.296921656988848 }, "2023": { "obs_EconomicCapitalRatio": 16.389711808491185 } }, "0001106644": { "2012": { "obs_EconomicCapitalRatio": 0.10529819253310034 }, "2017": { "obs_EconomicCapitalRatio": 0.20418745392206505 }, "2018": { "obs_EconomicCapitalRatio": 0.30945320350833017 }, "2019": { "obs_EconomicCapitalRatio": 0.5937127287741156 }, "2020": { "obs_EconomicCapitalRatio": 1.145776768270793 }, "2021": { "obs_EconomicCapitalRatio": 1.0364130811908552 }, "2022": { "obs_EconomicCapitalRatio": 0.39625593318918223 }, "2023": { "obs_EconomicCapitalRatio": 0.29740034984607266 } }, "0001335105": { "2012": { "obs_EconomicCapitalRatio": 49.54886091585484 }, "2013": { "obs_EconomicCapitalRatio": 73.73107600728025 }, "2014": { "obs_EconomicCapitalRatio": 184.6777060447673 }, "2015": { "obs_EconomicCapitalRatio": 227.5628680751955 }, "2016": { "obs_EconomicCapitalRatio": 123.34925799596552 }, "2017": { "obs_EconomicCapitalRatio": 59.98915919863948 }, "2018": { "obs_EconomicCapitalRatio": 143.21102280858813 }, "2019": { "obs_EconomicCapitalRatio": 193.5388975202505 }, "2020": { "obs_EconomicCapitalRatio": 85.08478882834855 }, "2021": { "obs_EconomicCapitalRatio": 6.317707417866715 }, "2022": { "obs_EconomicCapitalRatio": 2.82344689908857 }, "2023": { "obs_EconomicCapitalRatio": 2.1556305622560687 }, "2024": { "obs_EconomicCapitalRatio": 6.146495357589595 }, "2025": { "obs_EconomicCapitalRatio": 3.1498425897523785 } }, "0001356576": { "2012": { "obs_EconomicCapitalRatio": 2.695540367680527 }, "2013": { "obs_EconomicCapitalRatio": 2.6819507906417344 }, "2014": { "obs_EconomicCapitalRatio": 3.6192991362911293 }, "2015": { "obs_EconomicCapitalRatio": 5.316418467284552 }, "2016": { "obs_EconomicCapitalRatio": 5.88475069658678 }, "2017": { "obs_EconomicCapitalRatio": 6.845847663884459 }, "2018": { "obs_EconomicCapitalRatio": 2.2751603686509516 }, "2019": { "obs_EconomicCapitalRatio": 1.4335697423386706 }, "2020": { "obs_EconomicCapitalRatio": 1.166670190388528 }, "2021": { "obs_EconomicCapitalRatio": 1.2466838685294064 }, "2022": { "obs_EconomicCapitalRatio": 1.5813024649466632 }, "2024": { "obs_EconomicCapitalRatio": 2.335857420368807 }, "2025": { "obs_EconomicCapitalRatio": 3.1951230806398243 } }, "0001388320": { "2012": { "obs_EconomicCapitalRatio": 3.1758383030536113 }, "2013": { "obs_EconomicCapitalRatio": 20.019256940326006 }, "2014": { "obs_EconomicCapitalRatio": 21.102887995768853 }, "2015": { "obs_EconomicCapitalRatio": 6.972635870887473 }, "2016": { "obs_EconomicCapitalRatio": 3.96230988267313 }, "2017": { "obs_EconomicCapitalRatio": 4.591006599702462 }, "2018": { "obs_EconomicCapitalRatio": 4.370547084943421 }, "2019": { "obs_EconomicCapitalRatio": 3.906735389662115 }, "2020": { "obs_EconomicCapitalRatio": 4.214246383862464 }, "2021": { "obs_EconomicCapitalRatio": 3.2352607848056922 }, "2022": { "obs_EconomicCapitalRatio": 3.2565770272742274 }, "2023": { "obs_EconomicCapitalRatio": 2.1343787594410806 } }, "0001389545": { "2012": { "obs_EconomicCapitalRatio": 0.0 }, "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 0.0 }, "2020": { "obs_EconomicCapitalRatio": 0.0 }, "2021": { "obs_EconomicCapitalRatio": 0.0 }, "2022": { "obs_EconomicCapitalRatio": 5.799501346685527 }, "2023": { "obs_EconomicCapitalRatio": 0.14129171741239246 }, "2024": { "obs_EconomicCapitalRatio": 0.5000556342652639 }, "2025": { "obs_EconomicCapitalRatio": 29.918924920830538 } }, "0001396814": { "2012": { "obs_EconomicCapitalRatio": 6.812999715393255 }, "2013": { "obs_EconomicCapitalRatio": 12.636013346815789 }, "2018": { "obs_EconomicCapitalRatio": 3.3327445733519814 }, "2019": { "obs_EconomicCapitalRatio": 2.9220177647014838 }, "2020": { "obs_EconomicCapitalRatio": 2.6584057140847492 }, "2021": { "obs_EconomicCapitalRatio": 1.5788473346705905 } }, "0001420720": { "2012": { "obs_EconomicCapitalRatio": 0.0 }, "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.34077731721950805 }, "2019": { "obs_EconomicCapitalRatio": 0.26100959550370434 }, "2020": { "obs_EconomicCapitalRatio": 3.164789801549658 }, "2021": { "obs_EconomicCapitalRatio": 1.4815209121315438 }, "2022": { "obs_EconomicCapitalRatio": 0.057123507229856735 } }, "0001445815": { "2012": { "obs_EconomicCapitalRatio": 0.0 }, "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.08307183763266385 }, "2018": { "obs_EconomicCapitalRatio": 311.14325814608617 }, "2019": { "obs_EconomicCapitalRatio": 39.30893470756033 }, "2020": { "obs_EconomicCapitalRatio": 17.983410572796405 }, "2022": { "obs_EconomicCapitalRatio": 24.0879966140076 }, "2024": { "obs_EconomicCapitalRatio": 7.4472678808704975 }, "2025": { "obs_EconomicCapitalRatio": 3.879519452350511 } }, "0001530746": { "2012": { "obs_EconomicCapitalRatio": 48.743731158522266 }, "2015": { "obs_EconomicCapitalRatio": 2.874689942555272 }, "2020": { "obs_EconomicCapitalRatio": 5.888234447141673 }, "2021": { "obs_EconomicCapitalRatio": 0.22244353315329501 } }, "0001533040": { "2012": { "obs_EconomicCapitalRatio": 0.0 }, "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.0 }, "2022": { "obs_EconomicCapitalRatio": 0.6486316593055985 }, "2023": { "obs_EconomicCapitalRatio": 0.3373636555128727 }, "2024": { "obs_EconomicCapitalRatio": 0.6281623329011384 }, "2025": { "obs_EconomicCapitalRatio": 0.9997190225657764 } }, "0001538495": { "2014": { "obs_EconomicCapitalRatio": 90.5824484998404 }, "2018": { "obs_EconomicCapitalRatio": 97.152601082712 }, "2019": { "obs_EconomicCapitalRatio": 8.080338857180678 }, "2023": { "obs_EconomicCapitalRatio": 8.712763067559049 }, "2024": { "obs_EconomicCapitalRatio": 13.4928062961499 }, "2025": { "obs_EconomicCapitalRatio": 7.536035522691852 } }, "0001544227": { "2012": { "obs_EconomicCapitalRatio": 0.0 }, "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 5.756485829560471 } }, "0000818033": { "2013": { "obs_EconomicCapitalRatio": 3.2901186557493314 }, "2014": { "obs_EconomicCapitalRatio": 6.2947477925451345 }, "2016": { "obs_EconomicCapitalRatio": 6.69787657841924 }, "2017": { "obs_EconomicCapitalRatio": 5.773831569020795 }, "2018": { "obs_EconomicCapitalRatio": 6.710899739303245 }, "2019": { "obs_EconomicCapitalRatio": 7.210154006316952 }, "2020": { "obs_EconomicCapitalRatio": 7.984729054440954 }, "2021": { "obs_EconomicCapitalRatio": 3.7120049615170845 }, "2022": { "obs_EconomicCapitalRatio": 1.227031168154277 } }, "0000822370": { "2013": { "obs_EconomicCapitalRatio": 16.953206263457304 }, "2014": { "obs_EconomicCapitalRatio": 12.503291998490209 }, "2015": { "obs_EconomicCapitalRatio": 0.9501448579961315 }, "2016": { "obs_EconomicCapitalRatio": 13.956093492017365 }, "2017": { "obs_EconomicCapitalRatio": 3.983601278513772 }, "2018": { "obs_EconomicCapitalRatio": 1.715303466761049 }, "2021": { "obs_EconomicCapitalRatio": 1.1111050021413131 }, "2022": { "obs_EconomicCapitalRatio": 0.25056198404886904 } }, "0000887151": { "2016": { "obs_EconomicCapitalRatio": 3.851922974427995 }, "2017": { "obs_EconomicCapitalRatio": 3.076097907239819 } }, "0001069899": { "2014": { "obs_EconomicCapitalRatio": 0.8935879204520644 }, "2015": { "obs_EconomicCapitalRatio": 0.9508600960375623 }, "2016": { "obs_EconomicCapitalRatio": 0.793610361831243 }, "2017": { "obs_EconomicCapitalRatio": 1.016798789211543 }, "2018": { "obs_EconomicCapitalRatio": 0.9354751915827592 }, "2019": { "obs_EconomicCapitalRatio": 0.6931133060887299 }, "2020": { "obs_EconomicCapitalRatio": 0.49350298466545506 }, "2021": { "obs_EconomicCapitalRatio": 0.5200930672010649 }, "2022": { "obs_EconomicCapitalRatio": 0.313936991934562 } }, "0001104506": { "2013": { "obs_EconomicCapitalRatio": 6.239386499572907 }, "2014": { "obs_EconomicCapitalRatio": 5.559776850126781 } }, "0001125345": { "2013": { "obs_EconomicCapitalRatio": 7.803881980904605 }, "2014": { "obs_EconomicCapitalRatio": 8.424909912013891 }, "2015": { "obs_EconomicCapitalRatio": 5.284021545136552 }, "2016": { "obs_EconomicCapitalRatio": 3.9013252707834996 }, "2017": { "obs_EconomicCapitalRatio": 3.1599055119679273 }, "2018": { "obs_EconomicCapitalRatio": 2.527222996513196 }, "2019": { "obs_EconomicCapitalRatio": 2.6990521646869077 }, "2020": { "obs_EconomicCapitalRatio": 5.983826636156595 }, "2021": { "obs_EconomicCapitalRatio": 4.738597933159698 }, "2022": { "obs_EconomicCapitalRatio": 1.7374711486845418 }, "2023": { "obs_EconomicCapitalRatio": 2.7508258106149883 }, "2024": { "obs_EconomicCapitalRatio": 0.9955773842653965 }, "2025": { "obs_EconomicCapitalRatio": 0.44188357025285224 } }, "0001130598": { "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.8760307150595883 } }, "0001176309": { "2013": { "obs_EconomicCapitalRatio": 18.96374780999439 }, "2015": { "obs_EconomicCapitalRatio": 6.853734582183693 }, "2016": { "obs_EconomicCapitalRatio": 2.526336074927299 }, "2017": { "obs_EconomicCapitalRatio": 4.125791873249401 }, "2018": { "obs_EconomicCapitalRatio": 1.7197718408127676 }, "2019": { "obs_EconomicCapitalRatio": 3.430129084485662 }, "2020": { "obs_EconomicCapitalRatio": 3.471973647944272 }, "2021": { "obs_EconomicCapitalRatio": 7.578119224307776 }, "2023": { "obs_EconomicCapitalRatio": 0.6042175137645596 }, "2024": { "obs_EconomicCapitalRatio": 1.0805057222764693 } }, "0001177648": { "2013": { "obs_EconomicCapitalRatio": 8.112576671408831 }, "2014": { "obs_EconomicCapitalRatio": 11.458921414358276 }, "2015": { "obs_EconomicCapitalRatio": 4.739370496323121 }, "2016": { "obs_EconomicCapitalRatio": 4.347583184663215 }, "2017": { "obs_EconomicCapitalRatio": 6.320430181270734 }, "2018": { "obs_EconomicCapitalRatio": 6.28232019258115 }, "2019": { "obs_EconomicCapitalRatio": 4.868766833283514 }, "2020": { "obs_EconomicCapitalRatio": 3.31097125848491 }, "2021": { "obs_EconomicCapitalRatio": 6.40068695232658 }, "2022": { "obs_EconomicCapitalRatio": 4.51700389556921 }, "2023": { "obs_EconomicCapitalRatio": 0.5518999495160052 } }, "0001295947": { "2013": { "obs_EconomicCapitalRatio": 1.234083101191435 }, "2017": { "obs_EconomicCapitalRatio": 0.6751705902222275 }, "2018": { "obs_EconomicCapitalRatio": 0.5002811341605694 }, "2019": { "obs_EconomicCapitalRatio": 0.702931364694115 }, "2020": { "obs_EconomicCapitalRatio": 0.5977205081707389 }, "2021": { "obs_EconomicCapitalRatio": 1.12929687903751 }, "2022": { "obs_EconomicCapitalRatio": 1.0708172655863475 }, "2023": { "obs_EconomicCapitalRatio": 1.1593510793678938 }, "2024": { "obs_EconomicCapitalRatio": 1.5607829762146974 } }, "0001422142": { "2018": { "obs_EconomicCapitalRatio": 2.0166717971745087 }, "2019": { "obs_EconomicCapitalRatio": 1.0673470561314449 }, "2020": { "obs_EconomicCapitalRatio": 2.074347492998886 }, "2021": { "obs_EconomicCapitalRatio": 5.79141032727474 }, "2022": { "obs_EconomicCapitalRatio": 2.893564453874418 }, "2023": { "obs_EconomicCapitalRatio": 0.6359938686600423 }, "2024": { "obs_EconomicCapitalRatio": 1.6662710669263088 } }, "0001422143": { "2015": { "obs_EconomicCapitalRatio": 3.369248096829516 }, "2016": { "obs_EconomicCapitalRatio": 3.1625897198124835 }, "2017": { "obs_EconomicCapitalRatio": 8.25384480595116 }, "2018": { "obs_EconomicCapitalRatio": 4.985778240350756 }, "2019": { "obs_EconomicCapitalRatio": 4.867052264367894 }, "2020": { "obs_EconomicCapitalRatio": 5.976791842622965 }, "2021": { "obs_EconomicCapitalRatio": 3.5394127480171993 }, "2022": { "obs_EconomicCapitalRatio": 3.261053122473768 } }, "0001430306": { "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 0.0 }, "2020": { "obs_EconomicCapitalRatio": 0.0 }, "2021": { "obs_EconomicCapitalRatio": 0.0 }, "2022": { "obs_EconomicCapitalRatio": 0.0 }, "2023": { "obs_EconomicCapitalRatio": 0.0 }, "2024": { "obs_EconomicCapitalRatio": 0.7326351572316913 }, "2025": { "obs_EconomicCapitalRatio": 1.2786182495279823 } }, "0001434868": { "2013": { "obs_EconomicCapitalRatio": 4.990914676628872 }, "2014": { "obs_EconomicCapitalRatio": 9.726111733017273 }, "2015": { "obs_EconomicCapitalRatio": 3.3754092489620873 }, "2016": { "obs_EconomicCapitalRatio": 2.2034935943965324 }, "2017": { "obs_EconomicCapitalRatio": 10.321430770156113 }, "2018": { "obs_EconomicCapitalRatio": 11.344584986079722 }, "2019": { "obs_EconomicCapitalRatio": 7.5531542464423955 }, "2020": { "obs_EconomicCapitalRatio": 1.9574243547929262 }, "2021": { "obs_EconomicCapitalRatio": 0.30890702629983063 }, "2022": { "obs_EconomicCapitalRatio": 1.0976268299515959 }, "2023": { "obs_EconomicCapitalRatio": 0.6167576764568707 }, "2024": { "obs_EconomicCapitalRatio": 0.8127698162651695 }, "2025": { "obs_EconomicCapitalRatio": 1.505606914542882 } }, "0001438533": { "2013": { "obs_EconomicCapitalRatio": 4.338907006980449 }, "2014": { "obs_EconomicCapitalRatio": 2.2438108045252743 }, "2015": { "obs_EconomicCapitalRatio": 1.9909044593386087 }, "2016": { "obs_EconomicCapitalRatio": 1.9465652604480188 }, "2017": { "obs_EconomicCapitalRatio": 2.3240419148596247 }, "2018": { "obs_EconomicCapitalRatio": 1.6932986955759188 }, "2019": { "obs_EconomicCapitalRatio": 1.2469359762444685 }, "2020": { "obs_EconomicCapitalRatio": 2.7955623418513964 }, "2021": { "obs_EconomicCapitalRatio": 2.987538852042171 }, "2022": { "obs_EconomicCapitalRatio": 1.990765953595929 }, "2023": { "obs_EconomicCapitalRatio": 0.966461297382591 }, "2024": { "obs_EconomicCapitalRatio": 2.3819207475662103 }, "2025": { "obs_EconomicCapitalRatio": 6.058174443400131 } }, "0001439222": { "2013": { "obs_EconomicCapitalRatio": 6.010792545649196 }, "2014": { "obs_EconomicCapitalRatio": 14.427215733512456 }, "2015": { "obs_EconomicCapitalRatio": 10.152840121937325 }, "2016": { "obs_EconomicCapitalRatio": 5.1377806433858195 }, "2017": { "obs_EconomicCapitalRatio": 6.359322116960603 }, "2018": { "obs_EconomicCapitalRatio": 5.099084201225455 }, "2019": { "obs_EconomicCapitalRatio": 4.9771337691935384 }, "2020": { "obs_EconomicCapitalRatio": 4.619781227945105 }, "2021": { "obs_EconomicCapitalRatio": 2.3379954495073885 }, "2022": { "obs_EconomicCapitalRatio": 2.240306141532274 }, "2023": { "obs_EconomicCapitalRatio": 2.421286069721265 }, "2024": { "obs_EconomicCapitalRatio": 2.226980796611712 }, "2025": { "obs_EconomicCapitalRatio": 2.1892605948265986 } }, "0001447028": { "2014": { "obs_EconomicCapitalRatio": 4.137390561672009 }, "2015": { "obs_EconomicCapitalRatio": 0.5718949329772033 }, "2016": { "obs_EconomicCapitalRatio": 0.7939316007515166 }, "2017": { "obs_EconomicCapitalRatio": 1.8297281847793387 }, "2018": { "obs_EconomicCapitalRatio": 1.6735901287268171 }, "2021": { "obs_EconomicCapitalRatio": 4.5460396854681004 }, "2022": { "obs_EconomicCapitalRatio": 2.950860947004616 }, "2023": { "obs_EconomicCapitalRatio": 4.256969558004361 }, "2024": { "obs_EconomicCapitalRatio": 7.315003596033688 } }, "0001488039": { "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 1.464336515563814 }, "2019": { "obs_EconomicCapitalRatio": 1.8789726658392594 }, "2020": { "obs_EconomicCapitalRatio": 0.31720077467551944 }, "2021": { "obs_EconomicCapitalRatio": 3.084746010229382 }, "2022": { "obs_EconomicCapitalRatio": 1.1138704020398191 } }, "0001498382": { "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 3.577001255121189 }, "2021": { "obs_EconomicCapitalRatio": 6.072430958497425 }, "2022": { "obs_EconomicCapitalRatio": 68.63174459169403 } }, "0001503802": { "2014": { "obs_EconomicCapitalRatio": 10.568267673318969 }, "2015": { "obs_EconomicCapitalRatio": 4.234783843903932 }, "2017": { "obs_EconomicCapitalRatio": 3.9041353963426646 }, "2018": { "obs_EconomicCapitalRatio": 2.2353114096595594 }, "2019": { "obs_EconomicCapitalRatio": 4.452252617312478 }, "2020": { "obs_EconomicCapitalRatio": 4.039306074089596 }, "2021": { "obs_EconomicCapitalRatio": 1.4804850726715195 }, "2022": { "obs_EconomicCapitalRatio": 0.6665063990066935 } }, "0001509261": { "2013": { "obs_EconomicCapitalRatio": 5.086219265656686 }, "2014": { "obs_EconomicCapitalRatio": 6.0707381417572925 }, "2015": { "obs_EconomicCapitalRatio": 4.985934370337063 }, "2016": { "obs_EconomicCapitalRatio": 6.283976228503316 }, "2017": { "obs_EconomicCapitalRatio": 6.795295310951352 }, "2018": { "obs_EconomicCapitalRatio": 1.3518936383405822 }, "2019": { "obs_EconomicCapitalRatio": 3.0683180651136253 }, "2020": { "obs_EconomicCapitalRatio": 16.80130407778926 }, "2021": { "obs_EconomicCapitalRatio": 2.4576320665776623 }, "2022": { "obs_EconomicCapitalRatio": 0.9410206800819028 } }, "0001510964": { "2013": { "obs_EconomicCapitalRatio": 14.68082349336576 }, "2014": { "obs_EconomicCapitalRatio": 7.935457650084689 }, "2015": { "obs_EconomicCapitalRatio": 0.40491650603475937 }, "2016": { "obs_EconomicCapitalRatio": 1.4697979619780515 }, "2017": { "obs_EconomicCapitalRatio": 2.555887871177016 }, "2018": { "obs_EconomicCapitalRatio": 18.640806572937688 }, "2019": { "obs_EconomicCapitalRatio": 2.5922748033763816 }, "2020": { "obs_EconomicCapitalRatio": 1.9188970641079883 }, "2021": { "obs_EconomicCapitalRatio": 0.7811896639092076 }, "2022": { "obs_EconomicCapitalRatio": 0.34310972374923965 } }, "0001516551": { "2015": { "obs_EconomicCapitalRatio": 4.119831509212193 }, "2016": { "obs_EconomicCapitalRatio": 7.634612941564023 }, "2017": { "obs_EconomicCapitalRatio": 4.691264869308869 }, "2018": { "obs_EconomicCapitalRatio": 5.017589306013457 }, "2019": { "obs_EconomicCapitalRatio": 14.945189639139171 }, "2020": { "obs_EconomicCapitalRatio": 4.395640268516184 }, "2021": { "obs_EconomicCapitalRatio": 3.8168424336686164 }, "2022": { "obs_EconomicCapitalRatio": 1.1601060857746122 }, "2023": { "obs_EconomicCapitalRatio": 2.7796492108229773 }, "2024": { "obs_EconomicCapitalRatio": 2.1016027261151256 }, "2025": { "obs_EconomicCapitalRatio": 1.4748690162029767 } }, "0001534525": { "2017": { "obs_EconomicCapitalRatio": 1.4490394659367776 }, "2018": { "obs_EconomicCapitalRatio": 1.7484343180061497 }, "2019": { "obs_EconomicCapitalRatio": 0.6382098530180732 }, "2020": { "obs_EconomicCapitalRatio": 1.7628676846384046 }, "2021": { "obs_EconomicCapitalRatio": 1.7651874702486943 }, "2022": { "obs_EconomicCapitalRatio": 0.543535154049098 }, "2023": { "obs_EconomicCapitalRatio": 0.9367081985114467 }, "2024": { "obs_EconomicCapitalRatio": 1.6132142321110672 }, "2025": { "obs_EconomicCapitalRatio": 1.0385019129814923 } }, "0001535955": { "2013": { "obs_EconomicCapitalRatio": 3.80951395842458 }, "2014": { "obs_EconomicCapitalRatio": 4.484665187952989 }, "2015": { "obs_EconomicCapitalRatio": 9.666698677538678 }, "2016": { "obs_EconomicCapitalRatio": 4.874530917876101 }, "2017": { "obs_EconomicCapitalRatio": 4.6990766813576395 }, "2018": { "obs_EconomicCapitalRatio": 1.7078513542217602 }, "2019": { "obs_EconomicCapitalRatio": 0.5361184010136972 }, "2020": { "obs_EconomicCapitalRatio": 5.216460021131948 }, "2021": { "obs_EconomicCapitalRatio": 3.08629287481249 }, "2022": { "obs_EconomicCapitalRatio": 1.8362438163077024 }, "2023": { "obs_EconomicCapitalRatio": 1.214237420839552 }, "2024": { "obs_EconomicCapitalRatio": 2.1281845992346944 }, "2025": { "obs_EconomicCapitalRatio": 2.6318924774286794 } }, "0001551152": { "2013": { "obs_EconomicCapitalRatio": 2.830790180578059 }, "2014": { "obs_EconomicCapitalRatio": 3.433454015057143 }, "2015": { "obs_EconomicCapitalRatio": 1.9423485332421722 }, "2016": { "obs_EconomicCapitalRatio": 1.7976357034299837 }, "2017": { "obs_EconomicCapitalRatio": 2.4973235713716044 }, "2018": { "obs_EconomicCapitalRatio": 2.4285136647028804 }, "2019": { "obs_EconomicCapitalRatio": 1.9353808052892818 }, "2020": { "obs_EconomicCapitalRatio": 1.6600659528716244 }, "2021": { "obs_EconomicCapitalRatio": 2.207745471098879 }, "2022": { "obs_EconomicCapitalRatio": 3.004369768582203 }, "2023": { "obs_EconomicCapitalRatio": 2.896346731964981 }, "2024": { "obs_EconomicCapitalRatio": 3.4184774378859855 }, "2025": { "obs_EconomicCapitalRatio": 4.486019242804715 } }, "0001559053": { "2013": { "obs_EconomicCapitalRatio": 6.274475527995295 }, "2014": { "obs_EconomicCapitalRatio": 3.555240237199364 }, "2015": { "obs_EconomicCapitalRatio": 10.781347415563726 }, "2016": { "obs_EconomicCapitalRatio": 6.262097250121002 }, "2017": { "obs_EconomicCapitalRatio": 4.853544935160512 }, "2018": { "obs_EconomicCapitalRatio": 1.203722221822252 }, "2019": { "obs_EconomicCapitalRatio": 2.234599621041635 }, "2020": { "obs_EconomicCapitalRatio": 2.1603142399661874 }, "2024": { "obs_EconomicCapitalRatio": 2.690037933050509 }, "2025": { "obs_EconomicCapitalRatio": 2.7366970621221456 } }, "0001580149": { "2020": { "obs_EconomicCapitalRatio": 16.645305521172176 }, "2022": { "obs_EconomicCapitalRatio": 11.007711429755684 }, "2023": { "obs_EconomicCapitalRatio": 1.7609395614375387 }, "2024": { "obs_EconomicCapitalRatio": 2.1427383390745054 } }, "0001585364": { "2014": { "obs_EconomicCapitalRatio": 1.797467911617485 }, "2016": { "obs_EconomicCapitalRatio": 0.8588285460560211 }, "2017": { "obs_EconomicCapitalRatio": 1.1182437890174832 }, "2018": { "obs_EconomicCapitalRatio": 0.5289068467907572 }, "2019": { "obs_EconomicCapitalRatio": 0.6971525678852332 }, "2020": { "obs_EconomicCapitalRatio": 0.5723944883354882 }, "2021": { "obs_EconomicCapitalRatio": 0.5576594937896573 }, "2022": { "obs_EconomicCapitalRatio": 0.4367027339465495 }, "2023": { "obs_EconomicCapitalRatio": 0.4500543240745834 }, "2024": { "obs_EconomicCapitalRatio": 0.43153707026666605 }, "2025": { "obs_EconomicCapitalRatio": 0.25459107099964257 } }, "0000894158": { "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.45840814733792534 }, "2019": { "obs_EconomicCapitalRatio": 0.7458799373449941 }, "2020": { "obs_EconomicCapitalRatio": 1.2450476388168137 }, "2021": { "obs_EconomicCapitalRatio": 1.104415694485011 }, "2022": { "obs_EconomicCapitalRatio": 0.158159831871509 }, "2023": { "obs_EconomicCapitalRatio": 0.2288718953647814 } }, "0001005286": { "2014": { "obs_EconomicCapitalRatio": 1.7964608968568716 }, "2015": { "obs_EconomicCapitalRatio": 1.3881882041224352 }, "2016": { "obs_EconomicCapitalRatio": 1.6000760916448888 }, "2017": { "obs_EconomicCapitalRatio": 1.3934041904536012 }, "2018": { "obs_EconomicCapitalRatio": 1.274525956308206 }, "2019": { "obs_EconomicCapitalRatio": 0.8782635756660979 }, "2020": { "obs_EconomicCapitalRatio": 0.7241950199416594 }, "2021": { "obs_EconomicCapitalRatio": 0.8085732734578128 }, "2023": { "obs_EconomicCapitalRatio": 0.7946687239882525 } }, "0001081938": { "2014": { "obs_EconomicCapitalRatio": 24.798158649712516 }, "2018": { "obs_EconomicCapitalRatio": 3.0340184485227577 }, "2019": { "obs_EconomicCapitalRatio": 4.094288661085645 }, "2020": { "obs_EconomicCapitalRatio": 1.400630499064566 }, "2022": { "obs_EconomicCapitalRatio": 0.22856186348027485 }, "2023": { "obs_EconomicCapitalRatio": 0.02085915706496507 }, "2024": { "obs_EconomicCapitalRatio": 0.274704453126574 }, "2025": { "obs_EconomicCapitalRatio": 0.15591606480719788 } }, "0001157601": { "2014": { "obs_EconomicCapitalRatio": 4.341188952805879 }, "2018": { "obs_EconomicCapitalRatio": 6.488683448986104 }, "2019": { "obs_EconomicCapitalRatio": 6.067750596961241 }, "2020": { "obs_EconomicCapitalRatio": 10.865689025506962 }, "2021": { "obs_EconomicCapitalRatio": 8.130161003271429 }, "2022": { "obs_EconomicCapitalRatio": 17.64314754873853 }, "2023": { "obs_EconomicCapitalRatio": 10.491030513883619 }, "2024": { "obs_EconomicCapitalRatio": 10.157226400900424 }, "2025": { "obs_EconomicCapitalRatio": 13.989437963906283 } }, "0001178253": { "2014": { "obs_EconomicCapitalRatio": 3.6521598876967274 }, "2015": { "obs_EconomicCapitalRatio": 2.8445582088352213 }, "2017": { "obs_EconomicCapitalRatio": 1.8020299925753376 }, "2018": { "obs_EconomicCapitalRatio": 0.5211327320508553 }, "2019": { "obs_EconomicCapitalRatio": 0.8852073910277948 }, "2020": { "obs_EconomicCapitalRatio": 0.8514995515209948 }, "2021": { "obs_EconomicCapitalRatio": 1.6132436985084486 }, "2022": { "obs_EconomicCapitalRatio": 0.5986303702132718 } }, "0001253689": { "2022": { "obs_EconomicCapitalRatio": 3.563091100578236 }, "2023": { "obs_EconomicCapitalRatio": 5.536842666003607 } }, "0001297184": { "2014": { "obs_EconomicCapitalRatio": 2.1269462487249093 }, "2015": { "obs_EconomicCapitalRatio": 2.65513432698816 }, "2016": { "obs_EconomicCapitalRatio": 3.5203039587929785 }, "2017": { "obs_EconomicCapitalRatio": 3.1242555268336623 }, "2018": { "obs_EconomicCapitalRatio": 2.7752269134021916 }, "2019": { "obs_EconomicCapitalRatio": 2.4411844945872296 }, "2020": { "obs_EconomicCapitalRatio": 2.217148801257373 }, "2021": { "obs_EconomicCapitalRatio": 2.4283466270366865 }, "2022": { "obs_EconomicCapitalRatio": 2.8741219144747516 }, "2023": { "obs_EconomicCapitalRatio": 2.4367223036504586 } }, "0001343009": { "2014": { "obs_EconomicCapitalRatio": 11.135576808625036 }, "2015": { "obs_EconomicCapitalRatio": 29.204850072482998 }, "2017": { "obs_EconomicCapitalRatio": 57.14357766254051 }, "2018": { "obs_EconomicCapitalRatio": 21.073064451886307 }, "2019": { "obs_EconomicCapitalRatio": 1.6521169122003325 }, "2020": { "obs_EconomicCapitalRatio": 25.04805838183159 }, "2021": { "obs_EconomicCapitalRatio": 5.575010777304091 }, "2022": { "obs_EconomicCapitalRatio": 2.222389581523738 }, "2023": { "obs_EconomicCapitalRatio": 0.25153193883875463 } }, "0001393434": { "2014": { "obs_EconomicCapitalRatio": 9.723762656180517 }, "2015": { "obs_EconomicCapitalRatio": 3.6396014649500734 }, "2016": { "obs_EconomicCapitalRatio": 4.245367407321326 }, "2017": { "obs_EconomicCapitalRatio": 3.1586602946560784 }, "2018": { "obs_EconomicCapitalRatio": 3.098624810304815 }, "2019": { "obs_EconomicCapitalRatio": 2.3784652282637255 }, "2020": { "obs_EconomicCapitalRatio": 6.806910043019627 }, "2021": { "obs_EconomicCapitalRatio": 3.3165392530152924 }, "2022": { "obs_EconomicCapitalRatio": 1.6004878747764422 }, "2023": { "obs_EconomicCapitalRatio": 1.5903378431512945 } }, "0001401914": { "2014": { "obs_EconomicCapitalRatio": 3.9749108988053177 }, "2015": { "obs_EconomicCapitalRatio": 1.7793294237143362 }, "2016": { "obs_EconomicCapitalRatio": 0.647193872144733 }, "2021": { "obs_EconomicCapitalRatio": 4.188590883783982 }, "2022": { "obs_EconomicCapitalRatio": 1.899653309523115 }, "2023": { "obs_EconomicCapitalRatio": 1.3773038942544311 }, "2024": { "obs_EconomicCapitalRatio": 1.1054306529956048 } }, "0001404281": { "2014": { "obs_EconomicCapitalRatio": 5.641429299848193 }, "2021": { "obs_EconomicCapitalRatio": 0.7230097507704459 }, "2022": { "obs_EconomicCapitalRatio": 0.6498330155428738 } }, "0001404644": { "2014": { "obs_EconomicCapitalRatio": 3.112438741240614 }, "2015": { "obs_EconomicCapitalRatio": 3.66314659749228 }, "2016": { "obs_EconomicCapitalRatio": 4.666188054215424 }, "2017": { "obs_EconomicCapitalRatio": 4.472501841321298 }, "2018": { "obs_EconomicCapitalRatio": 1.2201436186914152 }, "2022": { "obs_EconomicCapitalRatio": 0.2718573870509964 }, "2023": { "obs_EconomicCapitalRatio": 1.1061815689134848 }, "2024": { "obs_EconomicCapitalRatio": 1.861957314482675 } }, "0001437402": { "2014": { "obs_EconomicCapitalRatio": 4.926661749470438 }, "2015": { "obs_EconomicCapitalRatio": 7.937166009598443 }, "2016": { "obs_EconomicCapitalRatio": 5.864265172195904 }, "2017": { "obs_EconomicCapitalRatio": 3.5416783481777787 }, "2018": { "obs_EconomicCapitalRatio": 0.8694093294722323 }, "2019": { "obs_EconomicCapitalRatio": 2.97619547684202 }, "2020": { "obs_EconomicCapitalRatio": 4.502454051781784 }, "2021": { "obs_EconomicCapitalRatio": 1.167873651644269 }, "2022": { "obs_EconomicCapitalRatio": 3.1398158634339004 }, "2023": { "obs_EconomicCapitalRatio": 6.850181889159298 }, "2024": { "obs_EconomicCapitalRatio": 3.222650149881341 }, "2025": { "obs_EconomicCapitalRatio": 3.367464199027977 } }, "0001485003": { "2023": { "obs_EconomicCapitalRatio": 1.5632126082991586 }, "2024": { "obs_EconomicCapitalRatio": 0.4148454443859101 } }, "0001517022": { "2014": { "obs_EconomicCapitalRatio": 4.010819223234276 }, "2015": { "obs_EconomicCapitalRatio": 4.8237243575533135 }, "2016": { "obs_EconomicCapitalRatio": 1.4730434380249977 }, "2017": { "obs_EconomicCapitalRatio": 2.3876562009982942 }, "2018": { "obs_EconomicCapitalRatio": 0.48055421021598477 }, "2019": { "obs_EconomicCapitalRatio": 1.3494051436213654 }, "2020": { "obs_EconomicCapitalRatio": 0.8291826353614926 }, "2021": { "obs_EconomicCapitalRatio": 0.870633819197869 }, "2022": { "obs_EconomicCapitalRatio": 0.2233559190516168 }, "2023": { "obs_EconomicCapitalRatio": 0.875991209192467 }, "2024": { "obs_EconomicCapitalRatio": 1.6501753585300492 }, "2025": { "obs_EconomicCapitalRatio": 1.219065982409421 } }, "0001517681": { "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 } }, "0001527728": { "2018": { "obs_EconomicCapitalRatio": 2.302516553080004 }, "2019": { "obs_EconomicCapitalRatio": 2.3775735808175726 }, "2023": { "obs_EconomicCapitalRatio": 6.055969830162965 }, "2024": { "obs_EconomicCapitalRatio": 1.6861727041832997 } }, "0001540159": { "2015": { "obs_EconomicCapitalRatio": 8.276585544563552 }, "2016": { "obs_EconomicCapitalRatio": 2.6501242318372156 }, "2017": { "obs_EconomicCapitalRatio": 1.9270691516342444 }, "2018": { "obs_EconomicCapitalRatio": 0.7880523009856242 }, "2020": { "obs_EconomicCapitalRatio": 8.152620731319265 }, "2022": { "obs_EconomicCapitalRatio": 5.054299772437978 }, "2023": { "obs_EconomicCapitalRatio": 2.854481801541483 }, "2024": { "obs_EconomicCapitalRatio": 2.1800251672491813 }, "2025": { "obs_EconomicCapitalRatio": 1.6714362166326928 } }, "0001574235": { "2014": { "obs_EconomicCapitalRatio": 2.0469770380681473 }, "2015": { "obs_EconomicCapitalRatio": 2.207632602380119 }, "2016": { "obs_EconomicCapitalRatio": 0.7181712517809893 }, "2017": { "obs_EconomicCapitalRatio": 2.8167511874971356 }, "2018": { "obs_EconomicCapitalRatio": 1.626270015339166 }, "2019": { "obs_EconomicCapitalRatio": 0.5494034407077054 }, "2020": { "obs_EconomicCapitalRatio": 1.5457787375224854 }, "2021": { "obs_EconomicCapitalRatio": 0.6892383766578533 }, "2022": { "obs_EconomicCapitalRatio": 0.49146228292780314 }, "2023": { "obs_EconomicCapitalRatio": 0.28093937465011043 }, "2024": { "obs_EconomicCapitalRatio": 4.120047303893817 }, "2025": { "obs_EconomicCapitalRatio": 3.8419290070237064 } }, "0001582313": { "2014": { "obs_EconomicCapitalRatio": 4.392368429265987 }, "2015": { "obs_EconomicCapitalRatio": 3.476660776453972 }, "2016": { "obs_EconomicCapitalRatio": 4.103680140318783 }, "2017": { "obs_EconomicCapitalRatio": 1.614193722770627 }, "2018": { "obs_EconomicCapitalRatio": 2.093243843844552 }, "2019": { "obs_EconomicCapitalRatio": 3.3904067163153058 }, "2020": { "obs_EconomicCapitalRatio": 4.973343390727814 }, "2021": { "obs_EconomicCapitalRatio": 5.3605927874064205 }, "2022": { "obs_EconomicCapitalRatio": 6.135998550200953 } }, "0001582554": { "2014": { "obs_EconomicCapitalRatio": 6.583806821973907 }, "2015": { "obs_EconomicCapitalRatio": 8.203102613253769 }, "2016": { "obs_EconomicCapitalRatio": 12.462807120338587 }, "2017": { "obs_EconomicCapitalRatio": 14.12256248864945 }, "2018": { "obs_EconomicCapitalRatio": 5.7222806221190705 }, "2019": { "obs_EconomicCapitalRatio": 12.112346070508153 }, "2020": { "obs_EconomicCapitalRatio": 5.299472496229888 }, "2021": { "obs_EconomicCapitalRatio": 6.349425394200524 }, "2022": { "obs_EconomicCapitalRatio": 4.169448789703781 }, "2023": { "obs_EconomicCapitalRatio": 3.1366592849168913 }, "2024": { "obs_EconomicCapitalRatio": 0.3033443877558794 }, "2025": { "obs_EconomicCapitalRatio": 0.9102057238354853 } }, "0001583107": { "2014": { "obs_EconomicCapitalRatio": 2.524510289086943 }, "2015": { "obs_EconomicCapitalRatio": 3.5502715758954673 }, "2016": { "obs_EconomicCapitalRatio": 4.769352639402022 }, "2017": { "obs_EconomicCapitalRatio": 5.97018939026352 }, "2018": { "obs_EconomicCapitalRatio": 4.009561421194865 }, "2019": { "obs_EconomicCapitalRatio": 5.525429130789294 }, "2020": { "obs_EconomicCapitalRatio": 3.9967540930032373 }, "2021": { "obs_EconomicCapitalRatio": 3.6474585228242065 }, "2022": { "obs_EconomicCapitalRatio": 2.371147972942393 }, "2023": { "obs_EconomicCapitalRatio": 2.7435188030991986 } }, "0001583648": { "2015": { "obs_EconomicCapitalRatio": 4.7747987863209085 }, "2016": { "obs_EconomicCapitalRatio": 2.596238426600483 }, "2017": { "obs_EconomicCapitalRatio": 2.7677828179053505 }, "2018": { "obs_EconomicCapitalRatio": 1.141407671889934 }, "2019": { "obs_EconomicCapitalRatio": 1.5409437503001444 }, "2020": { "obs_EconomicCapitalRatio": 1.6540422363874783 }, "2021": { "obs_EconomicCapitalRatio": 1.8727478616863706 }, "2022": { "obs_EconomicCapitalRatio": 0.8323592340556023 }, "2023": { "obs_EconomicCapitalRatio": 0.6057469211723506 } }, "0000014272": { "2015": { "obs_EconomicCapitalRatio": 3.2475450415220855 }, "2016": { "obs_EconomicCapitalRatio": 2.7259590116089485 }, "2017": { "obs_EconomicCapitalRatio": 2.650646716670952 }, "2018": { "obs_EconomicCapitalRatio": 2.199930130401309 }, "2020": { "obs_EconomicCapitalRatio": 1.114835636149512 }, "2021": { "obs_EconomicCapitalRatio": 1.2419398460280224 }, "2022": { "obs_EconomicCapitalRatio": 1.612627956472529 }, "2023": { "obs_EconomicCapitalRatio": 1.138243408987469 }, "2024": { "obs_EconomicCapitalRatio": 1.2721676304709277 }, "2025": { "obs_EconomicCapitalRatio": 1.321169806314478 } }, "0000873303": { "2015": { "obs_EconomicCapitalRatio": 9.668485604102845 }, "2016": { "obs_EconomicCapitalRatio": 6.233662004332542 }, "2017": { "obs_EconomicCapitalRatio": 3.924175866378392 }, "2018": { "obs_EconomicCapitalRatio": 6.339103672060055 }, "2019": { "obs_EconomicCapitalRatio": 6.823271045904484 }, "2020": { "obs_EconomicCapitalRatio": 5.29119921898451 }, "2021": { "obs_EconomicCapitalRatio": 2.9435836473847226 }, "2022": { "obs_EconomicCapitalRatio": 3.8077405647956177 } }, "0001128189": { "2016": { "obs_EconomicCapitalRatio": 42.5561641662153 }, "2017": { "obs_EconomicCapitalRatio": 44.12701545013146 }, "2018": { "obs_EconomicCapitalRatio": 100.30969158981598 }, "2019": { "obs_EconomicCapitalRatio": 88.26242021178395 }, "2020": { "obs_EconomicCapitalRatio": 104.06358738597007 }, "2021": { "obs_EconomicCapitalRatio": 89.94199206829096 }, "2022": { "obs_EconomicCapitalRatio": 41.60826773992075 }, "2023": { "obs_EconomicCapitalRatio": 22.90371520612683 }, "2024": { "obs_EconomicCapitalRatio": 12.311765432860431 } }, "0001267565": { "2015": { "obs_EconomicCapitalRatio": 9.545499460498341 }, "2016": { "obs_EconomicCapitalRatio": 4.83483609366986 }, "2017": { "obs_EconomicCapitalRatio": 7.157401045644926 }, "2018": { "obs_EconomicCapitalRatio": 2.1923205454261003 }, "2019": { "obs_EconomicCapitalRatio": 2.5638217711610176 }, "2020": { "obs_EconomicCapitalRatio": 1.1945982442476681 }, "2021": { "obs_EconomicCapitalRatio": 1.1275846582888194 }, "2022": { "obs_EconomicCapitalRatio": 0.7166745350456436 }, "2023": { "obs_EconomicCapitalRatio": 0.9397213313234996 }, "2025": { "obs_EconomicCapitalRatio": 1.0262046808470957 } }, "0001281895": { "2015": { "obs_EconomicCapitalRatio": 5.0364370997148225 }, "2016": { "obs_EconomicCapitalRatio": 1.9822646801810113 }, "2017": { "obs_EconomicCapitalRatio": 0.8946573077218604 }, "2018": { "obs_EconomicCapitalRatio": 3.5163891482923164 }, "2019": { "obs_EconomicCapitalRatio": 5.289572624031411 }, "2020": { "obs_EconomicCapitalRatio": 9.152568054550002 }, "2021": { "obs_EconomicCapitalRatio": 5.464254934454973 }, "2022": { "obs_EconomicCapitalRatio": 4.816510052502813 } }, "0001326732": { "2015": { "obs_EconomicCapitalRatio": 4.7370337142113 }, "2016": { "obs_EconomicCapitalRatio": 3.9967030445270955 }, "2017": { "obs_EconomicCapitalRatio": 4.202511162476909 }, "2018": { "obs_EconomicCapitalRatio": 6.073969875839424 }, "2019": { "obs_EconomicCapitalRatio": 5.83986745888784 }, "2020": { "obs_EconomicCapitalRatio": 6.222607779114316 }, "2021": { "obs_EconomicCapitalRatio": 4.9964835227058515 }, "2022": { "obs_EconomicCapitalRatio": 3.2034867036915506 }, "2023": { "obs_EconomicCapitalRatio": 2.070616845257262 }, "2024": { "obs_EconomicCapitalRatio": 2.7552069968217667 }, "2025": { "obs_EconomicCapitalRatio": 1.9795640740863942 } }, "0001348911": { "2015": { "obs_EconomicCapitalRatio": 0.20211091249350502 }, "2016": { "obs_EconomicCapitalRatio": 12.845502948864823 }, "2017": { "obs_EconomicCapitalRatio": 5.386046168520068 }, "2019": { "obs_EconomicCapitalRatio": 4.363753356040546 }, "2020": { "obs_EconomicCapitalRatio": 6.251934538262092 }, "2021": { "obs_EconomicCapitalRatio": 2.3451793339305693 }, "2022": { "obs_EconomicCapitalRatio": 1.2250090948446972 } }, "0001372514": { "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 4.8687372773255175 }, "2020": { "obs_EconomicCapitalRatio": 2.1345849403381534 }, "2021": { "obs_EconomicCapitalRatio": 0.8948813852784885 }, "2022": { "obs_EconomicCapitalRatio": 0.24485864375810124 }, "2023": { "obs_EconomicCapitalRatio": 0.3888692783137503 }, "2024": { "obs_EconomicCapitalRatio": 0.4182487345061539 } }, "0001374690": { "2015": { "obs_EconomicCapitalRatio": 20.943435399614355 }, "2016": { "obs_EconomicCapitalRatio": 15.15781782827369 }, "2017": { "obs_EconomicCapitalRatio": 20.69114475239754 }, "2018": { "obs_EconomicCapitalRatio": 29.417509168744573 }, "2019": { "obs_EconomicCapitalRatio": 8.48372085170697 }, "2020": { "obs_EconomicCapitalRatio": 5.486558924421429 }, "2021": { "obs_EconomicCapitalRatio": 4.021593630675525 }, "2022": { "obs_EconomicCapitalRatio": 2.6954254166627156 } }, "0001434647": { "2015": { "obs_EconomicCapitalRatio": 4.4921423898171 }, "2016": { "obs_EconomicCapitalRatio": 0.5165262290733772 }, "2017": { "obs_EconomicCapitalRatio": 0.6848099016426473 }, "2018": { "obs_EconomicCapitalRatio": 0.865624026468524 }, "2019": { "obs_EconomicCapitalRatio": 0.24683179633840263 }, "2020": { "obs_EconomicCapitalRatio": 24.491947700213355 }, "2023": { "obs_EconomicCapitalRatio": 1.2615329818804297 }, "2024": { "obs_EconomicCapitalRatio": 2.8610987447081255 }, "2025": { "obs_EconomicCapitalRatio": 2.3330351772908413 } }, "0001460702": { "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 0.0 }, "2021": { "obs_EconomicCapitalRatio": 2.2107914692835418 }, "2022": { "obs_EconomicCapitalRatio": 3.7082246599908757 }, "2023": { "obs_EconomicCapitalRatio": 0.9723846982305767 }, "2024": { "obs_EconomicCapitalRatio": 0.8966105358545655 }, "2025": { "obs_EconomicCapitalRatio": 0.7992021507471163 } }, "0001501989": { "2015": { "obs_EconomicCapitalRatio": 5.593684092339584 }, "2016": { "obs_EconomicCapitalRatio": 2.619381599651744 }, "2017": { "obs_EconomicCapitalRatio": 2.3376888954500075 }, "2018": { "obs_EconomicCapitalRatio": 1.6725413392645991 }, "2019": { "obs_EconomicCapitalRatio": 1.2386537359077794 }, "2020": { "obs_EconomicCapitalRatio": 1.036637404678561 }, "2021": { "obs_EconomicCapitalRatio": 0.9597362946003473 }, "2022": { "obs_EconomicCapitalRatio": 0.3339390654966768 } }, "0001506251": { "2015": { "obs_EconomicCapitalRatio": 68.18891485061765 }, "2016": { "obs_EconomicCapitalRatio": 2.7992844910974117 }, "2017": { "obs_EconomicCapitalRatio": 2.685011457384177 }, "2018": { "obs_EconomicCapitalRatio": 1.0813813832971078 }, "2020": { "obs_EconomicCapitalRatio": 2.2591166917938206 }, "2023": { "obs_EconomicCapitalRatio": 2.159536016547452 }, "2024": { "obs_EconomicCapitalRatio": 6.035944830417154 } }, "0001526119": { "2015": { "obs_EconomicCapitalRatio": 1.10776532837638 }, "2017": { "obs_EconomicCapitalRatio": 2.0776084538190913 }, "2018": { "obs_EconomicCapitalRatio": 1.1626992843450203 }, "2019": { "obs_EconomicCapitalRatio": 0.7040930043916058 }, "2020": { "obs_EconomicCapitalRatio": 3.968963717126026 }, "2021": { "obs_EconomicCapitalRatio": 6.306571084828538 }, "2022": { "obs_EconomicCapitalRatio": 1.0850427238616216 }, "2023": { "obs_EconomicCapitalRatio": 1.839270489546306 } }, "0001527599": { "2015": { "obs_EconomicCapitalRatio": 42.38419100270754 }, "2016": { "obs_EconomicCapitalRatio": 15.55508778937919 }, "2017": { "obs_EconomicCapitalRatio": 42.78514884794768 }, "2018": { "obs_EconomicCapitalRatio": 34.08047468923924 }, "2019": { "obs_EconomicCapitalRatio": 10.248352718914434 }, "2020": { "obs_EconomicCapitalRatio": 13.415002946338147 }, "2021": { "obs_EconomicCapitalRatio": 24.718119187681346 }, "2022": { "obs_EconomicCapitalRatio": 10.796971933946313 } }, "0001541157": { "2015": { "obs_EconomicCapitalRatio": 333.2338112169181 }, "2025": { "obs_EconomicCapitalRatio": 557.3736464203313 } }, "0001553643": { "2015": { "obs_EconomicCapitalRatio": 1.7338821891929213 }, "2016": { "obs_EconomicCapitalRatio": 1.1816013242874706 }, "2017": { "obs_EconomicCapitalRatio": 4.599958387137025 }, "2018": { "obs_EconomicCapitalRatio": 5.631594568993065 }, "2020": { "obs_EconomicCapitalRatio": 8.070490617556281 }, "2021": { "obs_EconomicCapitalRatio": 3.189405967515967 }, "2023": { "obs_EconomicCapitalRatio": 1.648304465498439 } }, "0001557746": { "2016": { "obs_EconomicCapitalRatio": 6.604216738408072 }, "2017": { "obs_EconomicCapitalRatio": 5.6131375883934025 }, "2018": { "obs_EconomicCapitalRatio": 1.7019790590737285 }, "2019": { "obs_EconomicCapitalRatio": 1.212098674624993 }, "2020": { "obs_EconomicCapitalRatio": 5.435226457505301 }, "2021": { "obs_EconomicCapitalRatio": 5.8301042520779305 }, "2022": { "obs_EconomicCapitalRatio": 6.499861999475928 }, "2023": { "obs_EconomicCapitalRatio": 0.6170529806766536 } }, "0001569340": { "2015": { "obs_EconomicCapitalRatio": 9.116142223062687 }, "2020": { "obs_EconomicCapitalRatio": 11.37309540355387 } }, "0001585608": { "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 } }, "0001595097": { "2015": { "obs_EconomicCapitalRatio": 7.150216686101165 }, "2016": { "obs_EconomicCapitalRatio": 28.092542245692012 }, "2017": { "obs_EconomicCapitalRatio": 10.055725124496933 }, "2018": { "obs_EconomicCapitalRatio": 9.993523112769557 }, "2019": { "obs_EconomicCapitalRatio": 7.498768621961081 }, "2020": { "obs_EconomicCapitalRatio": 1.4308728416796583 }, "2021": { "obs_EconomicCapitalRatio": 1.104648603895476 }, "2022": { "obs_EconomicCapitalRatio": 0.27635414874298914 } }, "0001598646": { "2015": { "obs_EconomicCapitalRatio": 2.634548670759021 }, "2016": { "obs_EconomicCapitalRatio": 5.485442013339983 }, "2017": { "obs_EconomicCapitalRatio": 1.9859162487009006 }, "2018": { "obs_EconomicCapitalRatio": 2.747774885570393 }, "2019": { "obs_EconomicCapitalRatio": 4.208753853253404 }, "2020": { "obs_EconomicCapitalRatio": 3.3886058732353694 }, "2021": { "obs_EconomicCapitalRatio": 0.5251543288767053 }, "2022": { "obs_EconomicCapitalRatio": 0.2067192346550029 } }, "0001607678": { "2015": { "obs_EconomicCapitalRatio": 1.9834389723963093 }, "2016": { "obs_EconomicCapitalRatio": 2.0814310306844765 }, "2017": { "obs_EconomicCapitalRatio": 7.592782060667528 }, "2018": { "obs_EconomicCapitalRatio": 3.5884317978740667 }, "2019": { "obs_EconomicCapitalRatio": 4.005092177058184 }, "2020": { "obs_EconomicCapitalRatio": 3.3915361928929455 }, "2021": { "obs_EconomicCapitalRatio": 3.468945823287514 }, "2022": { "obs_EconomicCapitalRatio": 6.479499566971428 } }, "0001609809": { "2015": { "obs_EconomicCapitalRatio": 12.371324494321517 }, "2016": { "obs_EconomicCapitalRatio": 1.9421880149134538 }, "2017": { "obs_EconomicCapitalRatio": 2.5908631473715626 }, "2018": { "obs_EconomicCapitalRatio": 1.384064290835004 }, "2019": { "obs_EconomicCapitalRatio": 1.8615650337156782 }, "2020": { "obs_EconomicCapitalRatio": 8.781524800983108 }, "2021": { "obs_EconomicCapitalRatio": 2.7321700147524 }, "2022": { "obs_EconomicCapitalRatio": 1.9955432209497879 } }, "0001618835": { "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 27.260771879425697 }, "2021": { "obs_EconomicCapitalRatio": 1.304128340362082 }, "2022": { "obs_EconomicCapitalRatio": 0.14293480962284852 }, "2023": { "obs_EconomicCapitalRatio": 0.01667205175592019 }, "2024": { "obs_EconomicCapitalRatio": 0.015834009366340877 }, "2025": { "obs_EconomicCapitalRatio": 0.023036945432258746 } }, "0001621221": { "2019": { "obs_EconomicCapitalRatio": 2.4753873505624306 }, "2020": { "obs_EconomicCapitalRatio": 4.264908581177564 }, "2021": { "obs_EconomicCapitalRatio": 4.02697447143019 }, "2023": { "obs_EconomicCapitalRatio": 0.6054883871847317 }, "2024": { "obs_EconomicCapitalRatio": 0.9901373189844184 }, "2025": { "obs_EconomicCapitalRatio": 0.9241621649519836 } }, "0001631574": { "2015": { "obs_EconomicCapitalRatio": 4.069113217531914 }, "2016": { "obs_EconomicCapitalRatio": 7.185150465314827 }, "2017": { "obs_EconomicCapitalRatio": 9.051139386919285 }, "2018": { "obs_EconomicCapitalRatio": 4.859865684220317 }, "2019": { "obs_EconomicCapitalRatio": 2.1475345165686233 }, "2020": { "obs_EconomicCapitalRatio": 1.769382687303525 }, "2021": { "obs_EconomicCapitalRatio": 1.0659833362894395 }, "2022": { "obs_EconomicCapitalRatio": 3.2970693329247367 } }, "0001641489": { "2015": { "obs_EconomicCapitalRatio": 1.2552103799603973 }, "2016": { "obs_EconomicCapitalRatio": 1.3459374903125807 }, "2017": { "obs_EconomicCapitalRatio": 1.1345479524457975 }, "2018": { "obs_EconomicCapitalRatio": 1.2383672431029904 }, "2019": { "obs_EconomicCapitalRatio": 4.491518150513322 }, "2020": { "obs_EconomicCapitalRatio": 7.976879057591623 }, "2021": { "obs_EconomicCapitalRatio": 3.9162067227323436 }, "2022": { "obs_EconomicCapitalRatio": 1.826215242233967 }, "2023": { "obs_EconomicCapitalRatio": 35.7174631241012 }, "2024": { "obs_EconomicCapitalRatio": 1.1686335633140843 }, "2025": { "obs_EconomicCapitalRatio": 2.5435087644018997 } }, "0000812306": { "2017": { "obs_EconomicCapitalRatio": 0.7679844265560579 }, "2018": { "obs_EconomicCapitalRatio": 1.3238043750261224 }, "2019": { "obs_EconomicCapitalRatio": 1.553680659218853 }, "2020": { "obs_EconomicCapitalRatio": 3.951228396195592 }, "2021": { "obs_EconomicCapitalRatio": 1.0293958339533176 }, "2022": { "obs_EconomicCapitalRatio": 0.9173385873482564 }, "2023": { "obs_EconomicCapitalRatio": 0.6230011525278941 } }, "0001014763": { "2021": { "obs_EconomicCapitalRatio": 3.2970328242500426 }, "2022": { "obs_EconomicCapitalRatio": 0.6373987318483224 }, "2023": { "obs_EconomicCapitalRatio": 2.2353109180655855 }, "2024": { "obs_EconomicCapitalRatio": 0.2989579783403101 }, "2025": { "obs_EconomicCapitalRatio": 0.5564579677349022 } }, "0001395937": { "2016": { "obs_EconomicCapitalRatio": 2.0274181405815592 }, "2017": { "obs_EconomicCapitalRatio": 2.3708227426577966 }, "2018": { "obs_EconomicCapitalRatio": 1.7735484369185335 }, "2019": { "obs_EconomicCapitalRatio": 5.012956899172152 }, "2020": { "obs_EconomicCapitalRatio": 5.657839182322721 }, "2021": { "obs_EconomicCapitalRatio": 4.338131466604313 }, "2022": { "obs_EconomicCapitalRatio": 5.533006676662477 } }, "0001539029": { "2016": { "obs_EconomicCapitalRatio": 3.8001069543615715 }, "2017": { "obs_EconomicCapitalRatio": 5.511027749062352 }, "2018": { "obs_EconomicCapitalRatio": 1.0708192486420613 }, "2019": { "obs_EconomicCapitalRatio": 5.457817849157306 }, "2020": { "obs_EconomicCapitalRatio": 6.830495344600248 } }, "0001555280": { "2016": { "obs_EconomicCapitalRatio": 3.5294023070229286 }, "2017": { "obs_EconomicCapitalRatio": 4.26721278609896 }, "2019": { "obs_EconomicCapitalRatio": 5.830222610803596 }, "2020": { "obs_EconomicCapitalRatio": 6.2465194766286976 }, "2021": { "obs_EconomicCapitalRatio": 9.433935491487597 }, "2022": { "obs_EconomicCapitalRatio": 5.098553510112966 }, "2023": { "obs_EconomicCapitalRatio": 7.413320323582953 }, "2024": { "obs_EconomicCapitalRatio": 6.132488673752045 }, "2025": { "obs_EconomicCapitalRatio": 3.9456146954632536 } }, "0001579428": { "2016": { "obs_EconomicCapitalRatio": 4.731285154323032 }, "2017": { "obs_EconomicCapitalRatio": 4.395347931767885 }, "2018": { "obs_EconomicCapitalRatio": 4.458882968102999 }, "2019": { "obs_EconomicCapitalRatio": 26.65313506898581 }, "2022": { "obs_EconomicCapitalRatio": 11.82261524078376 } }, "0001583771": { "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 1.4764049161692996 }, "2020": { "obs_EconomicCapitalRatio": 0.6820121179955333 }, "2021": { "obs_EconomicCapitalRatio": 1.6165558445799055 }, "2022": { "obs_EconomicCapitalRatio": 0.6594129903533573 }, "2023": { "obs_EconomicCapitalRatio": 0.9993418815360613 }, "2024": { "obs_EconomicCapitalRatio": 1.36001469804817 }, "2025": { "obs_EconomicCapitalRatio": 0.43504776570784937 } }, "0001590560": { "2017": { "obs_EconomicCapitalRatio": 3.443816673125471 }, "2018": { "obs_EconomicCapitalRatio": 5.436808380747137 }, "2019": { "obs_EconomicCapitalRatio": 10.904943748745998 }, "2020": { "obs_EconomicCapitalRatio": 7.792438910067191 }, "2021": { "obs_EconomicCapitalRatio": 1.9302182695305188 }, "2022": { "obs_EconomicCapitalRatio": 2.290830914690775 }, "2023": { "obs_EconomicCapitalRatio": 0.4456950008088053 } }, "0001626878": { "2016": { "obs_EconomicCapitalRatio": 7.28422372646887 }, "2017": { "obs_EconomicCapitalRatio": 3.755245458715203 }, "2019": { "obs_EconomicCapitalRatio": 1.5759474094123005 }, "2020": { "obs_EconomicCapitalRatio": 2.345949117862805 }, "2021": { "obs_EconomicCapitalRatio": 2.433294962975098 }, "2022": { "obs_EconomicCapitalRatio": 0.7500901950035245 }, "2023": { "obs_EconomicCapitalRatio": 1.0375765523682057 }, "2025": { "obs_EconomicCapitalRatio": 0.9328657551171378 } }, "0001626971": { "2016": { "obs_EconomicCapitalRatio": 4.277405407531264 }, "2017": { "obs_EconomicCapitalRatio": 4.149375012876857 }, "2019": { "obs_EconomicCapitalRatio": 2.6843077546283682 }, "2020": { "obs_EconomicCapitalRatio": 2.241320520434651 }, "2021": { "obs_EconomicCapitalRatio": 1.9728459381286443 }, "2022": { "obs_EconomicCapitalRatio": 0.9395855641792878 }, "2023": { "obs_EconomicCapitalRatio": 3.1431390679772337 } }, "0001636282": { "2016": { "obs_EconomicCapitalRatio": 1.911949666807195 }, "2017": { "obs_EconomicCapitalRatio": 2.7490583145413074 }, "2018": { "obs_EconomicCapitalRatio": 4.003210640999432 }, "2019": { "obs_EconomicCapitalRatio": 4.235264567342523 }, "2020": { "obs_EconomicCapitalRatio": 4.34926970229657 }, "2021": { "obs_EconomicCapitalRatio": 3.0591140227060354 }, "2022": { "obs_EconomicCapitalRatio": 0.480811302312216 }, "2023": { "obs_EconomicCapitalRatio": 0.3451585198947146 }, "2024": { "obs_EconomicCapitalRatio": 3.4522188932719113 }, "2025": { "obs_EconomicCapitalRatio": 6.1043163744290645 } }, "0001638287": { "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 0.0 }, "2020": { "obs_EconomicCapitalRatio": 0.0 }, "2021": { "obs_EconomicCapitalRatio": 0.0 }, "2023": { "obs_EconomicCapitalRatio": 9.290038100241892 } }, "0001651308": { "2016": { "obs_EconomicCapitalRatio": 55.07257988517769 }, "2017": { "obs_EconomicCapitalRatio": 80.78994328623331 }, "2018": { "obs_EconomicCapitalRatio": 75.19069906966709 }, "2019": { "obs_EconomicCapitalRatio": 117.56902263238351 }, "2020": { "obs_EconomicCapitalRatio": 83.7077839131438 }, "2021": { "obs_EconomicCapitalRatio": 60.09190503077995 }, "2022": { "obs_EconomicCapitalRatio": 70.79176203538113 }, "2023": { "obs_EconomicCapitalRatio": 60.354771279349215 }, "2024": { "obs_EconomicCapitalRatio": 58.74717564636796 }, "2025": { "obs_EconomicCapitalRatio": 74.46961209797139 } }, "0001659617": { "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 0.0 }, "2020": { "obs_EconomicCapitalRatio": 0.0 }, "2021": { "obs_EconomicCapitalRatio": 1.402227694170675 }, "2022": { "obs_EconomicCapitalRatio": 1.2594041493424097 }, "2023": { "obs_EconomicCapitalRatio": 0.909656247498064 }, "2025": { "obs_EconomicCapitalRatio": 13.456130084491564 } }, "0001680048": { "2017": { "obs_EconomicCapitalRatio": 0.2596643535753641 }, "2018": { "obs_EconomicCapitalRatio": 0.07895219091057175 }, "2019": { "obs_EconomicCapitalRatio": 0.0501303238990739 }, "2020": { "obs_EconomicCapitalRatio": 0.03952130469039673 }, "2021": { "obs_EconomicCapitalRatio": 0.016593300619834713 }, "2022": { "obs_EconomicCapitalRatio": 0.003244066029327926 }, "2023": { "obs_EconomicCapitalRatio": 0.06359334012047171 } }, "0000109657": { "2020": { "obs_EconomicCapitalRatio": 1.6846332758244982 }, "2022": { "obs_EconomicCapitalRatio": 3.276889997621411 }, "2023": { "obs_EconomicCapitalRatio": 1.0101946437098341 }, "2024": { "obs_EconomicCapitalRatio": 1.2853889944280936 }, "2025": { "obs_EconomicCapitalRatio": 1.622201918946696 } }, "0001173313": { "2017": { "obs_EconomicCapitalRatio": 133.7703825988571 }, "2019": { "obs_EconomicCapitalRatio": 14.62906593991791 }, "2020": { "obs_EconomicCapitalRatio": 10.431590816230356 }, "2021": { "obs_EconomicCapitalRatio": 11.24254806221214 }, "2022": { "obs_EconomicCapitalRatio": 2.569020672124645 }, "2023": { "obs_EconomicCapitalRatio": 0.8218812740633279 } }, "0001370053": { "2017": { "obs_EconomicCapitalRatio": 13.167988751469355 }, "2018": { "obs_EconomicCapitalRatio": 6.2142651603584 }, "2019": { "obs_EconomicCapitalRatio": 1.921164157298367 }, "2020": { "obs_EconomicCapitalRatio": 2.81203464508538 }, "2021": { "obs_EconomicCapitalRatio": 2.991710648767185 }, "2022": { "obs_EconomicCapitalRatio": 2.6017630895148307 }, "2023": { "obs_EconomicCapitalRatio": 2.2108411190227493 }, "2024": { "obs_EconomicCapitalRatio": 1.6017455543069687 } }, "0001377121": { "2017": { "obs_EconomicCapitalRatio": 3.914023929056892 }, "2018": { "obs_EconomicCapitalRatio": 1.9371601789637214 }, "2019": { "obs_EconomicCapitalRatio": 1.6918961236380876 }, "2020": { "obs_EconomicCapitalRatio": 4.6012149122973 }, "2021": { "obs_EconomicCapitalRatio": 8.232979661392296 }, "2022": { "obs_EconomicCapitalRatio": 3.4935072045172726 }, "2023": { "obs_EconomicCapitalRatio": 6.698251527915118 } }, "0001411685": { "2017": { "obs_EconomicCapitalRatio": 3.827433625855536 }, "2018": { "obs_EconomicCapitalRatio": 5.7207627820698495 }, "2019": { "obs_EconomicCapitalRatio": 3.0027583042272052 }, "2020": { "obs_EconomicCapitalRatio": 11.917054122105522 }, "2021": { "obs_EconomicCapitalRatio": 6.12552075504253 }, "2022": { "obs_EconomicCapitalRatio": 0.4842481960234831 }, "2023": { "obs_EconomicCapitalRatio": 9.274635539846695 }, "2024": { "obs_EconomicCapitalRatio": 1.0717075833225695 } }, "0001412486": { "2017": { "obs_EconomicCapitalRatio": 2.460451307469997 }, "2018": { "obs_EconomicCapitalRatio": 2.5120455856560415 } }, "0001420565": { "2017": { "obs_EconomicCapitalRatio": 5.1023289307496595 }, "2018": { "obs_EconomicCapitalRatio": 0.5726969681607266 }, "2019": { "obs_EconomicCapitalRatio": 0.8727951563208037 }, "2020": { "obs_EconomicCapitalRatio": 4.163633669590643 }, "2021": { "obs_EconomicCapitalRatio": 1.850461391873863 }, "2022": { "obs_EconomicCapitalRatio": 16.418427885256513 } }, "0001509745": { "2017": { "obs_EconomicCapitalRatio": 2.4505707185375876 }, "2018": { "obs_EconomicCapitalRatio": 2.369922122381597 }, "2019": { "obs_EconomicCapitalRatio": 2.8635571965108215 }, "2020": { "obs_EconomicCapitalRatio": 4.25639470917342 }, "2021": { "obs_EconomicCapitalRatio": 4.100610570922096 }, "2022": { "obs_EconomicCapitalRatio": 1.0865248758170611 }, "2023": { "obs_EconomicCapitalRatio": 1.9134670273083285 } }, "0001514946": { "2017": { "obs_EconomicCapitalRatio": 73.39159388942399 }, "2018": { "obs_EconomicCapitalRatio": 7.96001803039942 }, "2022": { "obs_EconomicCapitalRatio": 0.7094745888114613 }, "2023": { "obs_EconomicCapitalRatio": 0.5978697836515268 } }, "0001528172": { "2017": { "obs_EconomicCapitalRatio": 0.019099386123103267 }, "2018": { "obs_EconomicCapitalRatio": 0.8283695524372952 }, "2019": { "obs_EconomicCapitalRatio": 142.77801500563763 }, "2020": { "obs_EconomicCapitalRatio": 0.05812407823255177 }, "2021": { "obs_EconomicCapitalRatio": 0.11790771971716654 } }, "0001534120": { "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 0.0 }, "2020": { "obs_EconomicCapitalRatio": 0.0 }, "2021": { "obs_EconomicCapitalRatio": 0.0 }, "2022": { "obs_EconomicCapitalRatio": 1.1778632103795506 }, "2023": { "obs_EconomicCapitalRatio": 131.79765640599854 }, "2024": { "obs_EconomicCapitalRatio": 1.1101645179123487 } }, "0001566044": { "2018": { "obs_EconomicCapitalRatio": 1.317547784011202 }, "2019": { "obs_EconomicCapitalRatio": 2.6616596600295654 }, "2020": { "obs_EconomicCapitalRatio": 3.9600248195471717 }, "2021": { "obs_EconomicCapitalRatio": 1.3698621993549591 }, "2022": { "obs_EconomicCapitalRatio": 0.32575957408979317 }, "2023": { "obs_EconomicCapitalRatio": 0.6649149421403918 }, "2024": { "obs_EconomicCapitalRatio": 1.012622254166815 }, "2025": { "obs_EconomicCapitalRatio": 0.909971665771834 } }, "0001589150": { "2017": { "obs_EconomicCapitalRatio": 1.5939039321287882 }, "2021": { "obs_EconomicCapitalRatio": 5.815418147348666 }, "2022": { "obs_EconomicCapitalRatio": 3.3803374988335997 }, "2023": { "obs_EconomicCapitalRatio": 0.9680986000563736 } }, "0001595248": { "2018": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 0.0 }, "2020": { "obs_EconomicCapitalRatio": 0.0 }, "2021": { "obs_EconomicCapitalRatio": 0.0 }, "2022": { "obs_EconomicCapitalRatio": 0.0 }, "2023": { "obs_EconomicCapitalRatio": 0.0 }, "2024": { "obs_EconomicCapitalRatio": 2.2975715784653983 }, "2025": { "obs_EconomicCapitalRatio": 0.6890334170541527 } }, "0001615219": { "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 0.0 }, "2020": { "obs_EconomicCapitalRatio": 0.0 }, "2021": { "obs_EconomicCapitalRatio": 0.0 }, "2022": { "obs_EconomicCapitalRatio": 0.4266213271995585 }, "2023": { "obs_EconomicCapitalRatio": 0.8817239426328813 }, "2024": { "obs_EconomicCapitalRatio": 1.0538230226625522 } }, "0001645469": { "2019": { "obs_EconomicCapitalRatio": 25.93457561963354 }, "2020": { "obs_EconomicCapitalRatio": 7.94561875748812 }, "2021": { "obs_EconomicCapitalRatio": 3.8337806849507885 }, "2022": { "obs_EconomicCapitalRatio": 3.7394488995043447 }, "2023": { "obs_EconomicCapitalRatio": 1.237974920283715 }, "2024": { "obs_EconomicCapitalRatio": 3.90769690668125 }, "2025": { "obs_EconomicCapitalRatio": 6.343918823471869 } }, "0001671584": { "2017": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 0.0 }, "2020": { "obs_EconomicCapitalRatio": 0.0 }, "2021": { "obs_EconomicCapitalRatio": 0.0 }, "2022": { "obs_EconomicCapitalRatio": 0.0 } }, "0001682639": { "2018": { "obs_EconomicCapitalRatio": 2.2837564752113586 }, "2019": { "obs_EconomicCapitalRatio": 7.0391953952305535 }, "2020": { "obs_EconomicCapitalRatio": 5.154502189305028 }, "2021": { "obs_EconomicCapitalRatio": 5.026111355492541 }, "2022": { "obs_EconomicCapitalRatio": 2.5051335831758266 }, "2023": { "obs_EconomicCapitalRatio": 3.079128218817466 } }, "0001698530": { "2018": { "obs_EconomicCapitalRatio": 8.357163676148797 }, "2019": { "obs_EconomicCapitalRatio": 2.9887187823059307 }, "2020": { "obs_EconomicCapitalRatio": 2.483895035470864 }, "2021": { "obs_EconomicCapitalRatio": 0.3380830254064559 }, "2022": { "obs_EconomicCapitalRatio": 0.36138827407151963 }, "2023": { "obs_EconomicCapitalRatio": 0.5142840533526112 }, "2024": { "obs_EconomicCapitalRatio": 3.239869857320238 } }, "0001701108": { "2017": { "obs_EconomicCapitalRatio": 3.249938964861851 }, "2018": { "obs_EconomicCapitalRatio": 1.533993943015218 }, "2019": { "obs_EconomicCapitalRatio": 2.918587726691467 }, "2020": { "obs_EconomicCapitalRatio": 6.327245808454878 }, "2021": { "obs_EconomicCapitalRatio": 3.5665420006235404 }, "2022": { "obs_EconomicCapitalRatio": 0.9629564817040931 } }, "0000818686": { "2018": { "obs_EconomicCapitalRatio": 0.32514906136361227 }, "2019": { "obs_EconomicCapitalRatio": 0.2178319843684473 }, "2020": { "obs_EconomicCapitalRatio": 0.23675779404262848 }, "2021": { "obs_EconomicCapitalRatio": 0.21886047552551496 }, "2022": { "obs_EconomicCapitalRatio": 0.25601351138535516 }, "2023": { "obs_EconomicCapitalRatio": 0.2979363623480095 }, "2024": { "obs_EconomicCapitalRatio": 0.6887107587567836 } }, "0001205922": { "2018": { "obs_EconomicCapitalRatio": 3.558545253032523 }, "2019": { "obs_EconomicCapitalRatio": 14.107889173710923 }, "2020": { "obs_EconomicCapitalRatio": 3.848820391735063 }, "2021": { "obs_EconomicCapitalRatio": 6.534633254036944 }, "2022": { "obs_EconomicCapitalRatio": 5.585500529255729 } }, "0001398733": { "2018": { "obs_EconomicCapitalRatio": 2.0335208694788927 }, "2019": { "obs_EconomicCapitalRatio": 1.6769019425473788 }, "2020": { "obs_EconomicCapitalRatio": 2.480994835552515 }, "2021": { "obs_EconomicCapitalRatio": 1.556911477192337 }, "2022": { "obs_EconomicCapitalRatio": 0.41985375789917745 }, "2023": { "obs_EconomicCapitalRatio": 1.2066939811949051 }, "2024": { "obs_EconomicCapitalRatio": 2.4787610336985555 }, "2025": { "obs_EconomicCapitalRatio": 4.105635682704048 } }, "0001401040": { "2019": { "obs_EconomicCapitalRatio": 9.581231195149424 }, "2020": { "obs_EconomicCapitalRatio": 11.44489460295306 }, "2021": { "obs_EconomicCapitalRatio": 3.9817759093568927 }, "2023": { "obs_EconomicCapitalRatio": 3.74479963887114 }, "2024": { "obs_EconomicCapitalRatio": 8.787097452657084 }, "2025": { "obs_EconomicCapitalRatio": 12.966407842541559 } }, "0001426800": { "2018": { "obs_EconomicCapitalRatio": 3.2715032567189795 }, "2019": { "obs_EconomicCapitalRatio": 2.656833630410397 }, "2020": { "obs_EconomicCapitalRatio": 1.2260807054391023 }, "2021": { "obs_EconomicCapitalRatio": 1.012923367531431 }, "2022": { "obs_EconomicCapitalRatio": 1.0245394097639269 } }, "0001513525": { "2018": { "obs_EconomicCapitalRatio": 15.29204527391044 }, "2019": { "obs_EconomicCapitalRatio": 7.422992112609702 }, "2020": { "obs_EconomicCapitalRatio": 9.195160674374737 }, "2023": { "obs_EconomicCapitalRatio": 0.8112821129859077 } }, "0001570562": { "2018": { "obs_EconomicCapitalRatio": 2.4644934958280946 }, "2019": { "obs_EconomicCapitalRatio": 1.6526450097941916 }, "2020": { "obs_EconomicCapitalRatio": 0.504423451769479 }, "2021": { "obs_EconomicCapitalRatio": 1.6900619644881842 }, "2022": { "obs_EconomicCapitalRatio": 2.3100849590901413 }, "2023": { "obs_EconomicCapitalRatio": 2.8583602912038395 }, "2024": { "obs_EconomicCapitalRatio": 3.0213055263832986 }, "2025": { "obs_EconomicCapitalRatio": 1.8769865134086707 } }, "0001604191": { "2018": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 0.0 }, "2020": { "obs_EconomicCapitalRatio": 0.0 }, "2021": { "obs_EconomicCapitalRatio": 0.0 }, "2022": { "obs_EconomicCapitalRatio": 0.6221840865782279 }, "2023": { "obs_EconomicCapitalRatio": 10.104779725932428 } }, "0001622229": { "2019": { "obs_EconomicCapitalRatio": 0.653173704312413 }, "2020": { "obs_EconomicCapitalRatio": 1.041837424690067 }, "2021": { "obs_EconomicCapitalRatio": 2.68914694631765 }, "2022": { "obs_EconomicCapitalRatio": 4.443547993300266 } }, "0001655759": { "2018": { "obs_EconomicCapitalRatio": 3.2808490818527978 }, "2019": { "obs_EconomicCapitalRatio": 7.486499358429144 }, "2020": { "obs_EconomicCapitalRatio": 8.251738168682177 }, "2021": { "obs_EconomicCapitalRatio": 3.5375048165770537 }, "2022": { "obs_EconomicCapitalRatio": 1.833701160049044 }, "2023": { "obs_EconomicCapitalRatio": 2.188090869424132 }, "2024": { "obs_EconomicCapitalRatio": 1.599250605197483 }, "2025": { "obs_EconomicCapitalRatio": 1.5230753357527844 } }, "0001659323": { "2018": { "obs_EconomicCapitalRatio": 1.2956470910456483 }, "2019": { "obs_EconomicCapitalRatio": 0.9991685577319022 }, "2020": { "obs_EconomicCapitalRatio": 0.7321175401737595 }, "2021": { "obs_EconomicCapitalRatio": 1.2505648158055298 }, "2022": { "obs_EconomicCapitalRatio": 0.19588772714124267 } }, "0001661181": { "2019": { "obs_EconomicCapitalRatio": 2.4337172392910094 }, "2020": { "obs_EconomicCapitalRatio": 3.178293633366289 }, "2021": { "obs_EconomicCapitalRatio": 3.7505662449012793 }, "2022": { "obs_EconomicCapitalRatio": 1.067092580296219 } }, "0001661998": { "2018": { "obs_EconomicCapitalRatio": 5.061694686560405 }, "2019": { "obs_EconomicCapitalRatio": 5.264587553460372 }, "2020": { "obs_EconomicCapitalRatio": 3.3929572131000203 }, "2021": { "obs_EconomicCapitalRatio": 1.8249824165964792 }, "2022": { "obs_EconomicCapitalRatio": 0.5213274307293991 } }, "0001668243": { "2019": { "obs_EconomicCapitalRatio": 6.351614519380273 }, "2020": { "obs_EconomicCapitalRatio": 5.627440820998476 }, "2021": { "obs_EconomicCapitalRatio": 1.8434655464148624 }, "2022": { "obs_EconomicCapitalRatio": 1.0245192387938165 }, "2023": { "obs_EconomicCapitalRatio": 2.1951516473304666 }, "2024": { "obs_EconomicCapitalRatio": 1.5615001591597384 }, "2025": { "obs_EconomicCapitalRatio": 4.298345678378464 } }, "0001708599": { "2020": { "obs_EconomicCapitalRatio": 9.389529401288595 }, "2022": { "obs_EconomicCapitalRatio": 1.7540810203784016 }, "2023": { "obs_EconomicCapitalRatio": 1.5714257944094645 }, "2024": { "obs_EconomicCapitalRatio": 7.338972673386068 } }, "0001711786": { "2019": { "obs_EconomicCapitalRatio": 31.04911251583365 }, "2021": { "obs_EconomicCapitalRatio": 2.852022738805497 }, "2022": { "obs_EconomicCapitalRatio": 1.0174342861200536 }, "2023": { "obs_EconomicCapitalRatio": 1.083925115542916 } }, "0001720893": { "2018": { "obs_EconomicCapitalRatio": 2.031438132927808 }, "2019": { "obs_EconomicCapitalRatio": 7.684337873792798 }, "2020": { "obs_EconomicCapitalRatio": 10.558813026558067 }, "2021": { "obs_EconomicCapitalRatio": 4.729842390339243 }, "2022": { "obs_EconomicCapitalRatio": 3.5299603687448617 }, "2023": { "obs_EconomicCapitalRatio": 0.8587140121727126 } }, "0001723128": { "2018": { "obs_EconomicCapitalRatio": 0.415203533677114 }, "2019": { "obs_EconomicCapitalRatio": 0.18065044713560116 }, "2020": { "obs_EconomicCapitalRatio": 0.1718239942463209 }, "2021": { "obs_EconomicCapitalRatio": 0.19469925420081194 }, "2022": { "obs_EconomicCapitalRatio": 0.08732183232289117 }, "2023": { "obs_EconomicCapitalRatio": 0.5032006156988483 }, "2024": { "obs_EconomicCapitalRatio": 0.6880617097541213 }, "2025": { "obs_EconomicCapitalRatio": 1.0974009973927321 } }, "0001724521": { "2018": { "obs_EconomicCapitalRatio": 3.008208356388294 }, "2019": { "obs_EconomicCapitalRatio": 3.7292180755241033 }, "2020": { "obs_EconomicCapitalRatio": 3.8563550492511514 }, "2021": { "obs_EconomicCapitalRatio": 2.512052521732088 }, "2022": { "obs_EconomicCapitalRatio": 1.9429558255953299 }, "2023": { "obs_EconomicCapitalRatio": 2.1356368645167483 }, "2024": { "obs_EconomicCapitalRatio": 2.0590112050369846 }, "2025": { "obs_EconomicCapitalRatio": 3.641939566168213 } }, "0001730430": { "2018": { "obs_EconomicCapitalRatio": 1.8816380603461278 }, "2019": { "obs_EconomicCapitalRatio": 1.660159439750396 }, "2020": { "obs_EconomicCapitalRatio": 3.045260196566863 }, "2021": { "obs_EconomicCapitalRatio": 3.055856469183665 }, "2022": { "obs_EconomicCapitalRatio": 2.032152591371752 }, "2023": { "obs_EconomicCapitalRatio": 2.091221132933098 } }, "0001739104": { "2018": { "obs_EconomicCapitalRatio": 1.7973732754806913 }, "2019": { "obs_EconomicCapitalRatio": 1.7481325752317818 }, "2020": { "obs_EconomicCapitalRatio": 1.0662567361290218 }, "2021": { "obs_EconomicCapitalRatio": 1.0621834473295215 }, "2022": { "obs_EconomicCapitalRatio": 0.4773477266025837 }, "2023": { "obs_EconomicCapitalRatio": 0.6392950171837957 }, "2024": { "obs_EconomicCapitalRatio": 0.613419169390112 }, "2025": { "obs_EconomicCapitalRatio": 1.100692110544838 } }, "0001746466": { "2018": { "obs_EconomicCapitalRatio": 4.161873700106537 }, "2019": { "obs_EconomicCapitalRatio": 2.1735982867865347 }, "2020": { "obs_EconomicCapitalRatio": 2.357638972989078 }, "2021": { "obs_EconomicCapitalRatio": 2.3162186799119553 }, "2022": { "obs_EconomicCapitalRatio": 0.5143186328567134 } }, "0001534248": { "2020": { "obs_EconomicCapitalRatio": 19.16575959466217 }, "2021": { "obs_EconomicCapitalRatio": 2.3500071338810997 }, "2022": { "obs_EconomicCapitalRatio": 20.54831421144658 } }, "0001622244": { "2019": { "obs_EconomicCapitalRatio": 59.08664512486836 }, "2020": { "obs_EconomicCapitalRatio": 3.315685453794312 }, "2021": { "obs_EconomicCapitalRatio": 2.3576372934404723 }, "2022": { "obs_EconomicCapitalRatio": 1.4501694306847879 } }, "0001623526": { "2019": { "obs_EconomicCapitalRatio": 7.74739908520579 }, "2020": { "obs_EconomicCapitalRatio": 12.964685852432778 }, "2021": { "obs_EconomicCapitalRatio": 6.1805890569330995 }, "2022": { "obs_EconomicCapitalRatio": 2.0107832271209825 } }, "0001649904": { "2019": { "obs_EconomicCapitalRatio": 6.079937722420159 }, "2021": { "obs_EconomicCapitalRatio": 3.0156025697181783 }, "2022": { "obs_EconomicCapitalRatio": 6.556528414134431 }, "2025": { "obs_EconomicCapitalRatio": 21.653552672060908 } }, "0001661059": { "2019": { "obs_EconomicCapitalRatio": 6.661137772072324 }, "2020": { "obs_EconomicCapitalRatio": 1.8583391549245685 }, "2021": { "obs_EconomicCapitalRatio": 1.3036217049364485 }, "2022": { "obs_EconomicCapitalRatio": 0.3444290342244711 }, "2023": { "obs_EconomicCapitalRatio": 0.44731514854614707 } }, "0001680581": { "2019": { "obs_EconomicCapitalRatio": 5.7808098137940505 }, "2020": { "obs_EconomicCapitalRatio": 4.260748062645979 }, "2021": { "obs_EconomicCapitalRatio": 5.545902455372892 }, "2022": { "obs_EconomicCapitalRatio": 2.5634132861588323 } }, "0001690585": { "2019": { "obs_EconomicCapitalRatio": 102.2366531448102 }, "2020": { "obs_EconomicCapitalRatio": 67.62029350291377 }, "2021": { "obs_EconomicCapitalRatio": 43.073906165303356 }, "2022": { "obs_EconomicCapitalRatio": 3.8790288898853373 } }, "0001703647": { "2019": { "obs_EconomicCapitalRatio": 3.9689334067178352 }, "2020": { "obs_EconomicCapitalRatio": 6.751884175181702 }, "2021": { "obs_EconomicCapitalRatio": 1.5606886586463908 }, "2022": { "obs_EconomicCapitalRatio": 0.964573573675129 } }, "0001710340": { "2019": { "obs_EconomicCapitalRatio": 10.551165338630362 }, "2020": { "obs_EconomicCapitalRatio": 11.152305168792797 }, "2021": { "obs_EconomicCapitalRatio": 5.580918001036222 }, "2022": { "obs_EconomicCapitalRatio": 4.076857430236477 }, "2023": { "obs_EconomicCapitalRatio": 4.8694454718614555 }, "2024": { "obs_EconomicCapitalRatio": 5.113958645322763 }, "2025": { "obs_EconomicCapitalRatio": 5.65958338479525 } }, "0001743881": { "2019": { "obs_EconomicCapitalRatio": 11.817891342219891 }, "2020": { "obs_EconomicCapitalRatio": 12.923862718869536 }, "2021": { "obs_EconomicCapitalRatio": 2.80267550168653 }, "2022": { "obs_EconomicCapitalRatio": 0.9685514686017004 }, "2025": { "obs_EconomicCapitalRatio": 7.423081982971124 } }, "0001755237": { "2019": { "obs_EconomicCapitalRatio": 0.6467154509978333 }, "2020": { "obs_EconomicCapitalRatio": 1.6091658350418265 }, "2021": { "obs_EconomicCapitalRatio": 2.1222352909850035 }, "2022": { "obs_EconomicCapitalRatio": 1.8967159585278592 } }, "0001759425": { "2019": { "obs_EconomicCapitalRatio": 6.740158002097331 }, "2020": { "obs_EconomicCapitalRatio": 3.0273910929081205 }, "2021": { "obs_EconomicCapitalRatio": 2.050862904586447 }, "2022": { "obs_EconomicCapitalRatio": 2.387721311230474 }, "2024": { "obs_EconomicCapitalRatio": 3.573666967858353 }, "2025": { "obs_EconomicCapitalRatio": 5.932467369373917 } }, "0001761612": { "2019": { "obs_EconomicCapitalRatio": 2.487174279392095 }, "2020": { "obs_EconomicCapitalRatio": 3.602705733294328 }, "2021": { "obs_EconomicCapitalRatio": 5.652923697425659 }, "2022": { "obs_EconomicCapitalRatio": 3.2433037923492805 } }, "0001768224": { "2019": { "obs_EconomicCapitalRatio": 2.494416324374605 }, "2020": { "obs_EconomicCapitalRatio": 8.691195070865797 }, "2021": { "obs_EconomicCapitalRatio": 3.784184735102964 }, "2022": { "obs_EconomicCapitalRatio": 1.4539389804718246 } }, "0001781983": { "2019": { "obs_EconomicCapitalRatio": 11.417820453559177 }, "2020": { "obs_EconomicCapitalRatio": 9.845984775457229 }, "2021": { "obs_EconomicCapitalRatio": 2.165256182243437 }, "2022": { "obs_EconomicCapitalRatio": 1.0867464139946783 }, "2023": { "obs_EconomicCapitalRatio": 1.0559407672736314 } }, "0001783183": { "2019": { "obs_EconomicCapitalRatio": 4.508790694494323 }, "2020": { "obs_EconomicCapitalRatio": 5.193042395538745 }, "2021": { "obs_EconomicCapitalRatio": 3.9761973177993113 }, "2022": { "obs_EconomicCapitalRatio": 2.265079167617603 } }, "0001808898": { "2020": { "obs_EconomicCapitalRatio": 2.1143833140342334 }, "2021": { "obs_EconomicCapitalRatio": 1.9672621564562023 }, "2022": { "obs_EconomicCapitalRatio": 1.0124988074946555 }, "2023": { "obs_EconomicCapitalRatio": 1.9162068530827412 } }, "0000921299": { "2020": { "obs_EconomicCapitalRatio": 6.037695737495577 }, "2021": { "obs_EconomicCapitalRatio": 2.0679100904341126 }, "2022": { "obs_EconomicCapitalRatio": 2.3772951556496356 } }, "0001444192": { "2020": { "obs_EconomicCapitalRatio": 1.8212668931042104 }, "2021": { "obs_EconomicCapitalRatio": 1.601910280914289 } }, "0001453687": { "2020": { "obs_EconomicCapitalRatio": 1.885318991628831 }, "2021": { "obs_EconomicCapitalRatio": 2.583586463141516 }, "2022": { "obs_EconomicCapitalRatio": 1.37528869806314 }, "2023": { "obs_EconomicCapitalRatio": 0.2969628497898465 }, "2024": { "obs_EconomicCapitalRatio": 1.0950299982334744 }, "2025": { "obs_EconomicCapitalRatio": 0.4954362901108546 } }, "0001468639": { "2020": { "obs_EconomicCapitalRatio": 41.71486278196386 }, "2021": { "obs_EconomicCapitalRatio": 91.93342781717148 }, "2022": { "obs_EconomicCapitalRatio": 58.302482661739276 } }, "0001472012": { "2020": { "obs_EconomicCapitalRatio": 4.454862991960487 }, "2021": { "obs_EconomicCapitalRatio": 5.523992589733809 }, "2022": { "obs_EconomicCapitalRatio": 2.422759521127661 }, "2023": { "obs_EconomicCapitalRatio": 4.280267182756013 }, "2024": { "obs_EconomicCapitalRatio": 4.585594760034545 } }, "0001477845": { "2020": { "obs_EconomicCapitalRatio": 10.403516812427029 }, "2021": { "obs_EconomicCapitalRatio": 6.81015427205511 }, "2022": { "obs_EconomicCapitalRatio": 4.367600605808978 }, "2023": { "obs_EconomicCapitalRatio": 9.447126381813128 } }, "0001549595": { "2020": { "obs_EconomicCapitalRatio": 6.056262987617507 }, "2021": { "obs_EconomicCapitalRatio": 4.328866026019691 }, "2022": { "obs_EconomicCapitalRatio": 1.9390477295987234 }, "2023": { "obs_EconomicCapitalRatio": 1.8453547894611453 }, "2024": { "obs_EconomicCapitalRatio": 3.4698470832360737 }, "2025": { "obs_EconomicCapitalRatio": 3.516804360887202 } }, "0001571934": { "2020": { "obs_EconomicCapitalRatio": 1.9367055523471661 }, "2021": { "obs_EconomicCapitalRatio": 3.0562030121239125 }, "2022": { "obs_EconomicCapitalRatio": 0.3571391225015261 }, "2023": { "obs_EconomicCapitalRatio": 0.3055024340497261 } }, "0001593899": { "2020": { "obs_EconomicCapitalRatio": 4.982388173173559 }, "2021": { "obs_EconomicCapitalRatio": 1.7889261352116168 }, "2022": { "obs_EconomicCapitalRatio": 1.1023371148257655 } }, "0001599298": { "2020": { "obs_EconomicCapitalRatio": 7.253437136286895 }, "2021": { "obs_EconomicCapitalRatio": 3.630304594545802 }, "2022": { "obs_EconomicCapitalRatio": 1.3285352790419083 }, "2023": { "obs_EconomicCapitalRatio": 11.018534843177335 }, "2024": { "obs_EconomicCapitalRatio": 55.96920150546034 }, "2025": { "obs_EconomicCapitalRatio": 31.41912147041661 } }, "0001600620": { "2021": { "obs_EconomicCapitalRatio": 9.703248034518616 }, "2022": { "obs_EconomicCapitalRatio": 2.374302612487517 }, "2023": { "obs_EconomicCapitalRatio": 3.7093327061713572 }, "2024": { "obs_EconomicCapitalRatio": 3.588324024493516 }, "2025": { "obs_EconomicCapitalRatio": 4.595182884458584 } }, "0001636651": { "2020": { "obs_EconomicCapitalRatio": 3.065681924492594 }, "2021": { "obs_EconomicCapitalRatio": 2.117481637967616 }, "2022": { "obs_EconomicCapitalRatio": 1.3598528063187154 }, "2023": { "obs_EconomicCapitalRatio": 2.4106470615597217 }, "2024": { "obs_EconomicCapitalRatio": 1.2035985474563016 } }, "0001664710": { "2020": { "obs_EconomicCapitalRatio": 11.15743911511553 }, "2021": { "obs_EconomicCapitalRatio": 9.823255567688177 }, "2022": { "obs_EconomicCapitalRatio": 7.868704196501648 }, "2023": { "obs_EconomicCapitalRatio": 5.476382983993136 }, "2024": { "obs_EconomicCapitalRatio": 2.0694873777143337 }, "2025": { "obs_EconomicCapitalRatio": 3.3872065454063467 } }, "0001672619": { "2020": { "obs_EconomicCapitalRatio": 32.27703889816523 }, "2021": { "obs_EconomicCapitalRatio": 4.815995993435351 } }, "0001676725": { "2020": { "obs_EconomicCapitalRatio": 1.910906464785605 }, "2021": { "obs_EconomicCapitalRatio": 3.888299033936247 }, "2022": { "obs_EconomicCapitalRatio": 3.8187736139631454 } }, "0001677077": { "2021": { "obs_EconomicCapitalRatio": 134.03651058526592 }, "2022": { "obs_EconomicCapitalRatio": 10.957841768849988 }, "2023": { "obs_EconomicCapitalRatio": 1.445083947343951 }, "2024": { "obs_EconomicCapitalRatio": 3.3768356960216277 } }, "0001678660": { "2020": { "obs_EconomicCapitalRatio": 29.852580691842824 }, "2021": { "obs_EconomicCapitalRatio": 3.7897608225132036 }, "2022": { "obs_EconomicCapitalRatio": 1.9743198737884817 } }, "0001680367": { "2020": { "obs_EconomicCapitalRatio": 11.337515983150187 }, "2021": { "obs_EconomicCapitalRatio": 2.2396700444705333 }, "2022": { "obs_EconomicCapitalRatio": 0.8695375359442132 }, "2023": { "obs_EconomicCapitalRatio": 3.2164383492063244 }, "2025": { "obs_EconomicCapitalRatio": 4.095392329748731 } }, "0001695473": { "2020": { "obs_EconomicCapitalRatio": 4.669797408223305 }, "2021": { "obs_EconomicCapitalRatio": 4.255756953222455 }, "2022": { "obs_EconomicCapitalRatio": 0.9977644045203846 }, "2023": { "obs_EconomicCapitalRatio": 1.937291648646682 }, "2024": { "obs_EconomicCapitalRatio": 1.1364421533009899 } }, "0001699382": { "2020": { "obs_EconomicCapitalRatio": 12.848011118817782 }, "2021": { "obs_EconomicCapitalRatio": 5.929521083876715 }, "2022": { "obs_EconomicCapitalRatio": 2.715854942883037 } }, "0001720580": { "2020": { "obs_EconomicCapitalRatio": 2.81568620431054 }, "2021": { "obs_EconomicCapitalRatio": 2.6874207501034557 }, "2022": { "obs_EconomicCapitalRatio": 1.8902049958954465 } }, "0001725160": { "2020": { "obs_EconomicCapitalRatio": 10.979229591790343 }, "2021": { "obs_EconomicCapitalRatio": 13.702353859771764 }, "2022": { "obs_EconomicCapitalRatio": 3.3174172620290943 }, "2023": { "obs_EconomicCapitalRatio": 3.089962409485199 }, "2024": { "obs_EconomicCapitalRatio": 0.8290663394065225 } }, "0001726711": { "2020": { "obs_EconomicCapitalRatio": 0.0 }, "2021": { "obs_EconomicCapitalRatio": 0.0 }, "2023": { "obs_EconomicCapitalRatio": 0.0 } }, "0001728328": { "2020": { "obs_EconomicCapitalRatio": 4.577471381356152 }, "2021": { "obs_EconomicCapitalRatio": 3.271531063244177 }, "2022": { "obs_EconomicCapitalRatio": 0.17978140318971794 }, "2023": { "obs_EconomicCapitalRatio": 0.23825555809900759 }, "2024": { "obs_EconomicCapitalRatio": 3.88013069052814 } }, "0001742927": { "2020": { "obs_EconomicCapitalRatio": 7.287951365168326 }, "2022": { "obs_EconomicCapitalRatio": 5.5409080631952605 }, "2023": { "obs_EconomicCapitalRatio": 4.613513866544896 }, "2024": { "obs_EconomicCapitalRatio": 3.7878517832107255 }, "2025": { "obs_EconomicCapitalRatio": 3.1156774432362093 } }, "0001746473": { "2020": { "obs_EconomicCapitalRatio": 5.857802788342808 }, "2021": { "obs_EconomicCapitalRatio": 4.3773197207660886 }, "2022": { "obs_EconomicCapitalRatio": 4.726552714214153 }, "2023": { "obs_EconomicCapitalRatio": 3.7010006534345026 }, "2024": { "obs_EconomicCapitalRatio": 3.333291209670626 }, "2025": { "obs_EconomicCapitalRatio": 0.5568651663918129 } }, "0001763950": { "2020": { "obs_EconomicCapitalRatio": 11.355252435808278 }, "2021": { "obs_EconomicCapitalRatio": 2.1722035078289954 }, "2022": { "obs_EconomicCapitalRatio": 1.9693754788301854 }, "2023": { "obs_EconomicCapitalRatio": 1.9424356466155677 }, "2024": { "obs_EconomicCapitalRatio": 2.3113357750235837 }, "2025": { "obs_EconomicCapitalRatio": 4.7509364652543695 } }, "0001787306": { "2020": { "obs_EconomicCapitalRatio": 7.791943253314391 }, "2021": { "obs_EconomicCapitalRatio": 3.910142729960259 }, "2022": { "obs_EconomicCapitalRatio": 2.524778961577347 }, "2023": { "obs_EconomicCapitalRatio": 0.8833479379113233 }, "2024": { "obs_EconomicCapitalRatio": 6.317635141059226 }, "2025": { "obs_EconomicCapitalRatio": 10.417323618496392 } }, "0001787400": { "2020": { "obs_EconomicCapitalRatio": 12.296919314685818 }, "2021": { "obs_EconomicCapitalRatio": 3.3411289373909545 }, "2022": { "obs_EconomicCapitalRatio": 0.9793904296250519 } }, "0001792044": { "2020": { "obs_EconomicCapitalRatio": 2.8519194602188337e-08 }, "2021": { "obs_EconomicCapitalRatio": 0.3023160057060142 }, "2022": { "obs_EconomicCapitalRatio": 0.2882186828643058 }, "2023": { "obs_EconomicCapitalRatio": 0.3069370365291023 }, "2024": { "obs_EconomicCapitalRatio": 0.4330347985069521 }, "2025": { "obs_EconomicCapitalRatio": 0.46088319499372177 } }, "0001799788": { "2020": { "obs_EconomicCapitalRatio": 30.42976875216127 }, "2021": { "obs_EconomicCapitalRatio": 24.51891800687105 }, "2022": { "obs_EconomicCapitalRatio": 26.799867229313154 }, "2023": { "obs_EconomicCapitalRatio": 37.84356462519523 }, "2024": { "obs_EconomicCapitalRatio": 56.6613741545884 }, "2025": { "obs_EconomicCapitalRatio": 36.68280029973951 } }, "0001802665": { "2020": { "obs_EconomicCapitalRatio": 5.468950647202746 }, "2021": { "obs_EconomicCapitalRatio": 7.357291711352325 }, "2022": { "obs_EconomicCapitalRatio": 6.968809248214065 }, "2023": { "obs_EconomicCapitalRatio": 3.318508034292695 } }, "0001802768": { "2020": { "obs_EconomicCapitalRatio": 1.5083605602075743 }, "2021": { "obs_EconomicCapitalRatio": 1.2404006192636492 }, "2022": { "obs_EconomicCapitalRatio": 1.3215216000222363 }, "2023": { "obs_EconomicCapitalRatio": 1.0095920224940342 }, "2024": { "obs_EconomicCapitalRatio": 0.8300691833941843 }, "2025": { "obs_EconomicCapitalRatio": 1.1156824324208434 } }, "0001810182": { "2020": { "obs_EconomicCapitalRatio": 14.62861782260423 }, "2021": { "obs_EconomicCapitalRatio": 4.550269504823056 }, "2022": { "obs_EconomicCapitalRatio": 2.487207345201067 } }, "0001818794": { "2020": { "obs_EconomicCapitalRatio": 5.4526504778285885 }, "2021": { "obs_EconomicCapitalRatio": 2.641862011132604 }, "2022": { "obs_EconomicCapitalRatio": 3.6937309216583993 } }, "0001819576": { "2021": { "obs_EconomicCapitalRatio": 3.8709267163294454 }, "2022": { "obs_EconomicCapitalRatio": 4.761078308530657 }, "2023": { "obs_EconomicCapitalRatio": 7.8453765509689095 } }, "0001822462": { "2020": { "obs_EconomicCapitalRatio": 4.751909233181428 }, "2021": { "obs_EconomicCapitalRatio": 1.6675293224063918 }, "2022": { "obs_EconomicCapitalRatio": 0.6272968813672785 }, "2023": { "obs_EconomicCapitalRatio": 0.8280520764862019 }, "2024": { "obs_EconomicCapitalRatio": 0.8980197292338962 } }, "0001280776": { "2021": { "obs_EconomicCapitalRatio": 3.3340617426522416 }, "2022": { "obs_EconomicCapitalRatio": 0.7059338103397217 }, "2023": { "obs_EconomicCapitalRatio": 1.666027643790281 }, "2024": { "obs_EconomicCapitalRatio": 2.945386156378902 }, "2025": { "obs_EconomicCapitalRatio": 2.5033241416493146 } }, "0001419041": { "2021": { "obs_EconomicCapitalRatio": 1.4209741119297001 }, "2022": { "obs_EconomicCapitalRatio": 0.9297002390649902 } }, "0001452804": { "2022": { "obs_EconomicCapitalRatio": 3168.512429183764 } }, "0001490978": { "2025": { "obs_EconomicCapitalRatio": 2.117089071809597 } }, "0001574094": { "2021": { "obs_EconomicCapitalRatio": 5.150953517551173 }, "2022": { "obs_EconomicCapitalRatio": 4.409128500339078 }, "2023": { "obs_EconomicCapitalRatio": 3.3439971517133937 }, "2024": { "obs_EconomicCapitalRatio": 5.205257127532486 } }, "0001601485": { "2021": { "obs_EconomicCapitalRatio": 1.415639197764491 }, "2022": { "obs_EconomicCapitalRatio": 0.8165700887487293 }, "2023": { "obs_EconomicCapitalRatio": 2.5601919164746474 }, "2024": { "obs_EconomicCapitalRatio": 1.6178696291329993 }, "2025": { "obs_EconomicCapitalRatio": 5.583320492672247 } }, "0001637715": { "2021": { "obs_EconomicCapitalRatio": 2.6119057182116054 }, "2022": { "obs_EconomicCapitalRatio": 0.9188554177683708 } }, "0001641281": { "2021": { "obs_EconomicCapitalRatio": 0.9512093355759328 }, "2022": { "obs_EconomicCapitalRatio": 0.3446517584862095 } }, "0001645460": { "2021": { "obs_EconomicCapitalRatio": 7.119845614894133 }, "2022": { "obs_EconomicCapitalRatio": 1.6334346042316759 } }, "0001660334": { "2021": { "obs_EconomicCapitalRatio": 3.9992043021661643 }, "2022": { "obs_EconomicCapitalRatio": 4.416390192021974 }, "2025": { "obs_EconomicCapitalRatio": 2.233302684760354 } }, "0001671858": { "2021": { "obs_EconomicCapitalRatio": 1.3161514949634543 }, "2022": { "obs_EconomicCapitalRatio": 2.0094306464423357 } }, "0001683553": { "2021": { "obs_EconomicCapitalRatio": 0.0 }, "2022": { "obs_EconomicCapitalRatio": 0.0 } }, "0001684144": { "2021": { "obs_EconomicCapitalRatio": 2.325411279249918 }, "2022": { "obs_EconomicCapitalRatio": 1.1047721659202565 }, "2023": { "obs_EconomicCapitalRatio": 1.5634931168213562 } }, "0001689375": { "2021": { "obs_EconomicCapitalRatio": 3.4050607267756394 }, "2022": { "obs_EconomicCapitalRatio": 3.277871231738275 }, "2023": { "obs_EconomicCapitalRatio": 1.4420649053685184 }, "2024": { "obs_EconomicCapitalRatio": 2.091201556950649 }, "2025": { "obs_EconomicCapitalRatio": 1.8060770649526663 } }, "0001689548": { "2021": { "obs_EconomicCapitalRatio": 5.257153136894679 }, "2022": { "obs_EconomicCapitalRatio": 1.4008110546579007 }, "2023": { "obs_EconomicCapitalRatio": 48.6720633206395 }, "2024": { "obs_EconomicCapitalRatio": 5.492877727846892 }, "2025": { "obs_EconomicCapitalRatio": 13.798237590422602 } }, "0001703057": { "2021": { "obs_EconomicCapitalRatio": 5.128698575879268 }, "2022": { "obs_EconomicCapitalRatio": 3.148047741990266 }, "2023": { "obs_EconomicCapitalRatio": 1.8105113718561898 }, "2024": { "obs_EconomicCapitalRatio": 1.023568114995679 }, "2025": { "obs_EconomicCapitalRatio": 1.218246727455875 } }, "0001710072": { "2021": { "obs_EconomicCapitalRatio": 5.066391448451008 }, "2022": { "obs_EconomicCapitalRatio": 2.735818420050592 }, "2023": { "obs_EconomicCapitalRatio": 3.2535404403961716 }, "2024": { "obs_EconomicCapitalRatio": 10.977887819024053 } }, "0001716947": { "2021": { "obs_EconomicCapitalRatio": 0.0 }, "2022": { "obs_EconomicCapitalRatio": 0.28645113019466883 }, "2023": { "obs_EconomicCapitalRatio": 1.1047546706759725 }, "2024": { "obs_EconomicCapitalRatio": 41.079123913525216 }, "2025": { "obs_EconomicCapitalRatio": 0.656978176046888 } }, "0001736243": { "2021": { "obs_EconomicCapitalRatio": 6.565093390600356 }, "2022": { "obs_EconomicCapitalRatio": 7.884893700132662 }, "2023": { "obs_EconomicCapitalRatio": 9.335254148753522 } }, "0001750284": { "2021": { "obs_EconomicCapitalRatio": 2.511734257269554 }, "2022": { "obs_EconomicCapitalRatio": 0.8463406216798857 } }, "0001752828": { "2021": { "obs_EconomicCapitalRatio": 1.6228382618914432 }, "2022": { "obs_EconomicCapitalRatio": 0.5793503252191476 }, "2024": { "obs_EconomicCapitalRatio": 0.3913511061415067 }, "2025": { "obs_EconomicCapitalRatio": 0.2903284139304872 } }, "0001761918": { "2021": { "obs_EconomicCapitalRatio": 6.429819762928459 }, "2022": { "obs_EconomicCapitalRatio": 1.6612816937900394 } }, "0001768446": { "2021": { "obs_EconomicCapitalRatio": 3.163784830589746 }, "2022": { "obs_EconomicCapitalRatio": 1.0700868561112922 } }, "0001782223": { "2021": { "obs_EconomicCapitalRatio": 2.111294265873082 }, "2022": { "obs_EconomicCapitalRatio": 0.3323020132912376 } }, "0001785530": { "2021": { "obs_EconomicCapitalRatio": 3.1720410978971088 }, "2022": { "obs_EconomicCapitalRatio": 0.5601135472074897 }, "2023": { "obs_EconomicCapitalRatio": 0.9462244042196647 }, "2024": { "obs_EconomicCapitalRatio": 0.7704248818211188 } }, "0001790340": { "2021": { "obs_EconomicCapitalRatio": 5.672639281594998 }, "2022": { "obs_EconomicCapitalRatio": 1.708970518177094 }, "2023": { "obs_EconomicCapitalRatio": 3.80062421348927 }, "2024": { "obs_EconomicCapitalRatio": 2.1236015682286755 }, "2025": { "obs_EconomicCapitalRatio": 3.4114869322297863 } }, "0001798749": { "2021": { "obs_EconomicCapitalRatio": 2.7499402452773416 }, "2022": { "obs_EconomicCapitalRatio": 9.087261432076014 }, "2023": { "obs_EconomicCapitalRatio": 7.725094101880131 } }, "0001806952": { "2021": { "obs_EconomicCapitalRatio": 2.7658237776442247 }, "2022": { "obs_EconomicCapitalRatio": 1.4549797893575631 }, "2023": { "obs_EconomicCapitalRatio": 1.2100115484779883 }, "2024": { "obs_EconomicCapitalRatio": 0.5879123817937689 }, "2025": { "obs_EconomicCapitalRatio": 3.361295963504125 } }, "0001807120": { "2021": { "obs_EconomicCapitalRatio": 5.110273773093571 }, "2022": { "obs_EconomicCapitalRatio": 2.9091935322443994 } }, "0001810560": { "2021": { "obs_EconomicCapitalRatio": 0.0 }, "2022": { "obs_EconomicCapitalRatio": 0.0 } }, "0001811063": { "2021": { "obs_EconomicCapitalRatio": 4.4594460489134535 }, "2022": { "obs_EconomicCapitalRatio": 1.156596156073967 } }, "0001815903": { "2021": { "obs_EconomicCapitalRatio": 0.9315853262360096 }, "2022": { "obs_EconomicCapitalRatio": 1.8389462883029757 }, "2023": { "obs_EconomicCapitalRatio": 0.11262634902034269 } }, "0001815974": { "2021": { "obs_EconomicCapitalRatio": 13.860591563674177 }, "2022": { "obs_EconomicCapitalRatio": 8.012390333548375 }, "2023": { "obs_EconomicCapitalRatio": 9.79937517371494 }, "2024": { "obs_EconomicCapitalRatio": 17.533372649206587 } }, "0001816590": { "2022": { "obs_EconomicCapitalRatio": 3.469069793877861 }, "2023": { "obs_EconomicCapitalRatio": 3.181819330791114 }, "2024": { "obs_EconomicCapitalRatio": 1.9976368353893532 } }, "0001816736": { "2021": { "obs_EconomicCapitalRatio": 1.5673969847038716 }, "2022": { "obs_EconomicCapitalRatio": 17.946181285719497 } }, "0001817713": { "2021": { "obs_EconomicCapitalRatio": 4.222290083037995 }, "2022": { "obs_EconomicCapitalRatio": 2.4602137482729134 } }, "0001818844": { "2021": { "obs_EconomicCapitalRatio": 5.108939352094039 }, "2022": { "obs_EconomicCapitalRatio": 0.9600408848841279 }, "2023": { "obs_EconomicCapitalRatio": 5.086933153035263 } }, "0001819133": { "2021": { "obs_EconomicCapitalRatio": 2.9059148447166874 }, "2022": { "obs_EconomicCapitalRatio": 2.1709711795560804 } }, "0001819411": { "2021": { "obs_EconomicCapitalRatio": 3.076434388579569 }, "2022": { "obs_EconomicCapitalRatio": 2.4217228765908048 }, "2023": { "obs_EconomicCapitalRatio": 2.6616627665067916 } }, "0001821825": { "2021": { "obs_EconomicCapitalRatio": 0.9514939785370281 }, "2022": { "obs_EconomicCapitalRatio": 0.9005471267937213 }, "2023": { "obs_EconomicCapitalRatio": 0.2657689617152537 }, "2024": { "obs_EconomicCapitalRatio": 0.2860582314552151 }, "2025": { "obs_EconomicCapitalRatio": 0.14698366747611746 } }, "0001823239": { "2021": { "obs_EconomicCapitalRatio": 3.324821543814707 }, "2022": { "obs_EconomicCapitalRatio": 1.0187043552243467 }, "2023": { "obs_EconomicCapitalRatio": 0.7979658106136953 }, "2024": { "obs_EconomicCapitalRatio": 1.079141954197552 }, "2025": { "obs_EconomicCapitalRatio": 0.82289065119173 } }, "0001824293": { "2021": { "obs_EconomicCapitalRatio": 0.0 }, "2022": { "obs_EconomicCapitalRatio": 0.0 }, "2023": { "obs_EconomicCapitalRatio": 0.0 }, "2024": { "obs_EconomicCapitalRatio": 1.766930002257645 }, "2025": { "obs_EconomicCapitalRatio": 0.18999951389172234 } }, "0001828673": { "2021": { "obs_EconomicCapitalRatio": 3.034524794547648 }, "2022": { "obs_EconomicCapitalRatio": 2.4330632068491176 } }, "0001829635": { "2021": { "obs_EconomicCapitalRatio": 0.0 }, "2022": { "obs_EconomicCapitalRatio": 0.0 }, "2023": { "obs_EconomicCapitalRatio": 0.0 }, "2024": { "obs_EconomicCapitalRatio": 7.880452829308091 } }, "0001829802": { "2021": { "obs_EconomicCapitalRatio": 2.1770565929437673 }, "2022": { "obs_EconomicCapitalRatio": 0.6635101635348523 } }, "0001840233": { "2021": { "obs_EconomicCapitalRatio": 3.411233264533946 }, "2022": { "obs_EconomicCapitalRatio": 0.7416409577746491 }, "2023": { "obs_EconomicCapitalRatio": 0.36062284533159966 } }, "0001840904": { "2021": { "obs_EconomicCapitalRatio": 5.634686356849057 }, "2022": { "obs_EconomicCapitalRatio": 2.701176549058382 } }, "0001857044": { "2021": { "obs_EconomicCapitalRatio": 2.126214716188324 }, "2022": { "obs_EconomicCapitalRatio": 0.8140410650242103 }, "2023": { "obs_EconomicCapitalRatio": 1.748806858580108 }, "2024": { "obs_EconomicCapitalRatio": 1.7037172495363144 }, "2025": { "obs_EconomicCapitalRatio": 0.5309387175287837 } }, "0001858685": { "2021": { "obs_EconomicCapitalRatio": 2.0565299498420657 }, "2022": { "obs_EconomicCapitalRatio": 0.6194003825807052 }, "2023": { "obs_EconomicCapitalRatio": 0.17770193395364212 }, "2024": { "obs_EconomicCapitalRatio": 0.395556793187993 }, "2025": { "obs_EconomicCapitalRatio": 0.3598275158539455 } }, "0001861560": { "2021": { "obs_EconomicCapitalRatio": 5.488287614155773 }, "2022": { "obs_EconomicCapitalRatio": 5.949742697006308 } }, "0001861657": { "2022": { "obs_EconomicCapitalRatio": 1.1921959530489235 }, "2023": { "obs_EconomicCapitalRatio": 1.4108271541154638 }, "2024": { "obs_EconomicCapitalRatio": 1.0148133307016274 } }, "0001863127": { "2021": { "obs_EconomicCapitalRatio": 3.6689204765827528 }, "2022": { "obs_EconomicCapitalRatio": 2.3778352646735605 } }, "0001865494": { "2021": { "obs_EconomicCapitalRatio": 1.984167670127024 }, "2022": { "obs_EconomicCapitalRatio": 0.912960344779015 } }, "0001867096": { "2021": { "obs_EconomicCapitalRatio": 1.1827520422190887 }, "2022": { "obs_EconomicCapitalRatio": 0.5343457845599805 }, "2023": { "obs_EconomicCapitalRatio": 0.8876602074616373 }, "2024": { "obs_EconomicCapitalRatio": 1.5068427753479947 }, "2025": { "obs_EconomicCapitalRatio": 3.213363246006965 } }, "0001873835": { "2022": { "obs_EconomicCapitalRatio": 3.612121626948463 }, "2023": { "obs_EconomicCapitalRatio": 9.546066891374704 }, "2024": { "obs_EconomicCapitalRatio": 3.6907687937165123 }, "2025": { "obs_EconomicCapitalRatio": 3.2771052417139117 } }, "0001231457": { "2023": { "obs_EconomicCapitalRatio": 20.58658297936221 }, "2024": { "obs_EconomicCapitalRatio": 3.8012970654339866 }, "2025": { "obs_EconomicCapitalRatio": 12.487756265058431 } }, "0001575142": { "2023": { "obs_EconomicCapitalRatio": 0.46157616565160214 }, "2024": { "obs_EconomicCapitalRatio": 137.2589511115023 }, "2025": { "obs_EconomicCapitalRatio": 0.20558168607917748 } }, "0001690080": { "2023": { "obs_EconomicCapitalRatio": 0.24947006630043778 } }, "0001704292": { "2025": { "obs_EconomicCapitalRatio": 23.99537244484833 } }, "0001719406": { "2023": { "obs_EconomicCapitalRatio": 2.8107941259243874 }, "2024": { "obs_EconomicCapitalRatio": 1.2123808991964091 }, "2025": { "obs_EconomicCapitalRatio": 3.256314248115792 } }, "0001728117": { "2023": { "obs_EconomicCapitalRatio": 0.7082923364427968 }, "2024": { "obs_EconomicCapitalRatio": 0.6442715394449453 } }, "0001729427": { "2023": { "obs_EconomicCapitalRatio": 0.0 }, "2024": { "obs_EconomicCapitalRatio": 1.3765743708780394 }, "2025": { "obs_EconomicCapitalRatio": 0.6059397013669012 } }, "0001771910": { "2024": { "obs_EconomicCapitalRatio": 0.4591204113571571 }, "2025": { "obs_EconomicCapitalRatio": 1.0509994743294888 } }, "0001834105": { "2024": { "obs_EconomicCapitalRatio": 1.0074543225769161 }, "2025": { "obs_EconomicCapitalRatio": 5.449758180736699 } }, "0001847903": { "2023": { "obs_EconomicCapitalRatio": 3.1551998397667322 }, "2024": { "obs_EconomicCapitalRatio": 5.9799791062469065 } }, "0001860657": { "2023": { "obs_EconomicCapitalRatio": 0.22728545269121814 }, "2024": { "obs_EconomicCapitalRatio": 0.2806654262934393 }, "2025": { "obs_EconomicCapitalRatio": 1.2323411898099832 } }, "0001873875": { "2023": { "obs_EconomicCapitalRatio": 456.5184457750075 }, "2024": { "obs_EconomicCapitalRatio": 2.550487370004812 } }, "0001904286": { "2023": { "obs_EconomicCapitalRatio": 5.895620284301549 }, "2024": { "obs_EconomicCapitalRatio": 9.85535789993241 }, "2025": { "obs_EconomicCapitalRatio": 10.827874200411674 } }, "0001610820": { "2024": { "obs_EconomicCapitalRatio": 3.431083357476488 }, "2025": { "obs_EconomicCapitalRatio": 1.1485388588887744 } }, "0001625297": { "2025": { "obs_EconomicCapitalRatio": 3.599845897191032 } }, "0001677940": { "2025": { "obs_EconomicCapitalRatio": 1.9832255110904602 } }, "0001679628": { "2024": { "obs_EconomicCapitalRatio": 88.34065319613647 }, "2025": { "obs_EconomicCapitalRatio": 5.844019823713041 } } } }